Horizon Technology Finance (HRZN) 10-Q 31 Oct 23 2023 Q3 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	9 Months Ended
	Sep. 30, 2023	Oct. 31, 2023
Document Information [Line Items]
Entity Central Index Key	0001487428
Entity Registrant Name	Horizon Technology Finance Corp
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2023
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2023
Document Transition Report	false
Entity File Number	814-00802
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	27-2114934
Entity Address, Address Line One	312 Farmington Avenue
Entity Address, City or Town	Farmington
Entity Address, State or Province	CT
Entity Address, Postal Zip Code	06032
City Area Code	860
Local Phone Number	676‑8654
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		33,330,529
The 6.25% Notes due 2027 [Member]
Document Information [Line Items]
Title of 12(b) Security	6.25% Notes due 2027
Trading Symbol	HTFC
Security Exchange Name	NYSE
The 4.875% Notes due 2026 [Member]
Document Information [Line Items]
Title of 12(b) Security	4.875% Notes due 2026
Trading Symbol	HTFB
Security Exchange Name	NYSE
Common Stock [Member]
Document Information [Line Items]
Title of 12(b) Security	Common Stock, par value $0.001 per share
Trading Symbol	HRZN
Security Exchange Name	NASDAQ

Consolidated Statements of Asse

Consolidated Statements of Assets and Liabilities (Current Period Unaudited) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Assets
Investments at fair value	$ 729,053	$ 720,026
Cash	34,816	20,612
Investments in money market funds	12,457	7,066
Restricted investments in money market funds	2,838	2,788
Interest receivable	14,135	13,573
Other assets	3,945	2,761
Total assets	797,244	766,826
Liabilities
Borrowings (Note 7)	435,500	434,078
Distributions payable	10,991	9,159
Base management fee payable (Note 3)	1,080	1,065
Incentive fee payable (Note 3)	0	1,392
Other accrued expenses	3,098	2,684
Total liabilities	450,669	448,378
Commitments and contingencies (Notes 3 and 8)
Net assets
Preferred stock, par value $0.001 per share, 1,000,000 shares authorized, zero shares issued and outstanding as of September 30, 2023 and December 31, 2022	0	0
Common stock, par value $0.001 per share, 100,000,000 shares authorized, 33,474,423 and 27,920,838 shares issued and 33,306,958 and 27,753,373 shares outstanding as of September 30, 2023 and December 31, 2022, respectively	35	29
Paid-in capital in excess of par	451,722	385,921
Distributable loss	(105,182)	(67,502)
Total net assets	346,575	318,448
Total liabilities and net assets	$ 797,244	$ 766,826
Net asset value per common share (in dollars per share)	$ 10.41	$ 11.47
Investment, Unaffiliated Issuer [Member]
Assets
Investments at fair value	$ 695,423	$ 720,026
Investment, Affiliated Issuer, Noncontrolled [Member]
Assets
Investments at fair value	20,485	0
Investment, Affiliated Issuer, Controlled [Member]
Assets
Investments at fair value	$ 13,145	$ 0

Consolidated Statements of As_2

Consolidated Statements of Assets and Liabilities (Current Period Unaudited) (Parentheticals) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Investments at cost	$ 754,814	$ 721,248
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	1,000,000	1,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares oustanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	100,000,000	100,000,000
Common stock, shares issued (in shares)	33,474,423	27,920,838
Common stock, shares outstanding (in shares)	33,306,958	27,753,373
Investment, Unaffiliated Issuer [Member]
Investments at cost	$ 700,932	$ 721,248
Investment, Affiliated Issuer, Noncontrolled [Member]
Investments at cost	39,666	0
Investment, Affiliated Issuer, Controlled [Member]
Investments at cost	$ 14,216	$ 0

Consolidated Statements of Oper

Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Investment income
Payment-in-kind interest income	$ 3,900	$ 0	$ 6,088	$ 0
Total investment income	29,138	23,254	85,292	56,046
Expenses
Interest expense	7,107	5,339	21,407	12,987
Base management fee (Note 3)	3,213	2,788	9,621	7,555
Performance based incentive fee (Note 3)	0	2,784	3,094	6,353
Administrative fee (Note 3)	441	412	1,249	1,147
Professional fees	452	314	1,558	1,163
General and administrative	392	381	1,384	1,088
Total expenses	11,605	12,018	38,313	30,293
Net investment income before excise tax	17,533	11,236	46,979	25,753
Provision for excise tax	179	100	542	306
Net investment income	17,354	11,136	46,437	25,447
Net realized and unrealized loss
Net realized gain (loss) on investments	(11,816)	(8,585)	(28,513)	(9,484)
Net unrealized appreciation (depreciation) on investments	(17,518)	3,442	(24,448)	1,169
Net realized and unrealized loss	(29,334)	(5,143)	(52,961)	(8,315)
Net (decrease) increase in net assets resulting from operations	$ (11,980)	$ 5,993	$ (6,524)	$ 17,132
Net investment income per common share (in dollars per share)	$ 0.53	$ 0.43	$ 1.54	$ 1.06
Net (decrease) increase in net assets resulting from operations per common share (in dollars per share)	(0.37)	0.23	(0.22)	0.71
Distributions declared per share (in dollars per share)	$ 0.33	$ 0.30	$ 0.99	$ 0.90
Weighted average shares outstanding (in shares)	32,451,900	25,738,054	30,155,287	23,995,369
Investment, Unaffiliated Issuer [Member]
Investment income
Interest income	$ 23,825	$ 22,745	$ 75,695	$ 54,317
Fee income	124	509	2,255	1,729
Payment-in-kind interest income	3,777	0	5,930	0
Net realized and unrealized loss
Net realized gain (loss) on investments	(11,816)	(8,665)	(28,513)	(8,364)
Net unrealized appreciation (depreciation) on investments	180	3,442	(7,656)	(281)
Investment, Affiliated Issuer, Noncontrolled [Member]
Investment income
Interest income	1,246	0	1,246	0
Net realized and unrealized loss
Net realized gain (loss) on investments	0	30	0	30
Net unrealized appreciation (depreciation) on investments	(19,055)	0	(18,149)	0
Investment, Affiliated Issuer, Controlled [Member]
Investment income
Interest income	8	0	8	0
Payment-in-kind interest income	158	0	158	0
Net realized and unrealized loss
Net realized gain (loss) on investments	0	50	0	(1,150)
Net unrealized appreciation (depreciation) on investments	$ 1,357	$ 0	$ 1,357	$ 1,450

Consolidated Statements of Chan

Consolidated Statements of Changes in Net Assets (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Common Stock Outstanding [Member]
Balance (in shares)	32,096,259	24,857,104	27,753,373	21,217,460
Issuance of common stock, net of offering costs (in shares)	1,186,303	1,523,519	5,490,326	5,141,920
Issuance of common stock under dividend reinvestment plan (in shares)	24,396	13,150	63,259	34,393
Balance (in shares)	33,306,958	26,393,773	33,306,958	26,393,773
Common Stock [Member]
Balance	$ 34	$ 26	$ 29	$ 22
Issuance of common stock, net of offering costs	1	1	6	5
Net investment income, net of excise tax	0	0	0	0
Net realized gain (loss) on investments	0	0	0	0
Net unrealized appreciation (depreciation) on investments	0	0	0	0
Issuance of common stock under dividend reinvestment plan	0	0	0	0
Distributions declared	0	0	0	0
Net realized gain (loss) on investments	0	0	0	0
Balance	35	27	35	27
Additional Paid-in Capital [Member]
Balance	437,561	350,173	385,921	301,359
Issuance of common stock, net of offering costs	13,854	18,995	65,025	67,519
Net investment income, net of excise tax	0	0	0	0
Net realized gain (loss) on investments	0	0	0	0
Net unrealized appreciation (depreciation) on investments	0	0	0	0
Issuance of common stock under dividend reinvestment plan	307	166	776	456
Distributions declared	0	0	0	0
Net realized gain (loss) on investments	0	0	0	0
Balance	451,722	369,334	451,722	369,334
Retained Earnings [Member]
Balance	(82,176)	(59,594)	(67,502)	(56,046)
Issuance of common stock, net of offering costs	0	0	0	0
Net investment income, net of excise tax	17,354	11,136	46,437	25,447
Net realized gain (loss) on investments	(11,816)	(8,585)	(28,513)	(9,484)
Net unrealized appreciation (depreciation) on investments	(17,518)	3,442	(24,448)	1,169
Issuance of common stock under dividend reinvestment plan	0	0	0	0
Distributions declared	(11,026)	(8,073)	(31,156)	(22,760)
Net realized gain (loss) on investments	(11,816)	(8,585)	(28,513)	(9,484)
Balance	(105,182)	(61,674)	(105,182)	(61,674)
Balance	355,419	290,605	318,448	245,335
Issuance of common stock, net of offering costs	13,855	18,996	65,031	67,524
Net investment income, net of excise tax	17,354	11,136	46,437	25,447
Net realized gain (loss) on investments	(11,816)	(8,585)	(28,513)	(9,484)
Net unrealized appreciation (depreciation) on investments	(17,518)	3,442	(24,448)	1,169
Issuance of common stock under dividend reinvestment plan	307	166	776	456
Distributions declared	(11,026)	(8,073)	(31,156)	(22,760)
Net realized gain (loss) on investments	(11,816)	(8,585)	(28,513)	(9,484)
Balance	$ 346,575	$ 307,687	$ 346,575	$ 307,687

Consolidated Statements of Cash

Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Cash flows from operating activities:
Net (decrease) increase in net assets resulting from operations	$ (11,980)	$ 5,993	$ (6,524)	$ 17,132
Adjustments to reconcile net (decrease) increase in net assets resulting from operations to net cash used in operating activities:
Amortization of debt issuance costs	500	400	1,433	1,142
Net realized loss on investments			28,513	9,484
Net unrealized depreciation on investments	17,518	(3,442)	24,448	(1,169)
Purchase of investments			(154,488)	(348,347)
Principal payments received on investments			90,222	114,433
Payment-in-kind interest on investments	(3,900)	0	(6,088)	0
Proceeds from sale of investments			11,063	49,681
Equity received in settlement of fee income			(89)	0
Warrants received in settlement of fee income			(80)	0
Changes in assets and liabilities:
Decrease (increase) in interest receivable			1,491	(2,175)
Increase in end-of-term payments			(1,960)	(3,003)
Decrease in unearned income			(2,621)	(274)
(Increase) decrease in other assets			(837)	115
Increase in other accrued expenses			414	193
Increase in base management fee payable			15	1,164
(Decrease) increase in incentive fee payable			(1,392)	769
Net cash used in operating activities			(16,480)	(160,855)
Cash flows from financing activities:
Proceeds from issuance of 2027 Notes			0	57,500
Proceeds from issuance of common stock, net of offering costs			65,031	67,525
Advances on Credit Facilities			59,250	119,000
Repayment of Credit Facilities			(35,000)	(47,000)
Debt issuance costs			(732)	(2,470)
Distributions paid			(28,548)	(20,752)
Net cash provided by financing activities			36,125	146,762
Net increase (decrease) in cash, cash equivalents and restricted cash			19,645	(14,093)
Cash, cash equivalents and restricted cash:
Beginning of period			30,466	47,281
End of period	50,111	33,188	50,111	33,188
Supplemental disclosure of cash flow information:
Cash paid for interest			19,956	11,543
Supplemental non-cash investing and financing activities:
Warrant investments received and recorded as unearned income			1,870	2,969
Distributions payable	10,991	7,918	10,991	7,918
End-of-term payments receivable			11,743	8,240
Non-cash income			12,861	4,504
Cash	34,816	23,839	34,816	23,839
Investments in money market funds	12,457	7,732	12,457	7,732
Restricted investments in money market funds	2,838	1,617	2,838	1,617
Total cash, cash equivalents and restricted cash	$ 50,111	$ 33,188	50,111	33,188
Asset-backed Notes 2019 [Member]
Cash flows from financing activities:
Repayment of notes			$ (23,876)	$ (27,041)

Consolidated Schedule of Invest

Consolidated Schedule of Investments (Unaudited)	9 Months Ended
	Sep. 30, 2023
Notes to Financial Statements
Schedule of Investments [Text Block]	September 30, 2023 (Dollars in thousands) Portfolio Company (1)(3) Sector Type of Investment (7) Cash Rate (4) Index Margin Floor Ceiling ETP (10) Maturity Date Principal Amount Cost of Investments (6)(9) Fair Value (9) Non-Affiliate Investments — 200.7% Non-Affiliate Debt Investments — 191.4% Non-Affiliate Debt Investments — Life Science — 69.7% Castle Creek Biosciences, Inc. (2)(12) Biotechnology Term Loan 13.25 % Prime 4.75 % 9.55 % 13.50 % 5.50 % May 1, 2026 5,000 4,903 4,903 Term Loan 13.25 % Prime 4.75 % 9.55 % 13.50 % 5.50 % May 1, 2026 5,000 4,975 4,975 Term Loan 13.25 % Prime 4.75 % 9.55 % 13.50 % 5.50 % May 1, 2026 3,000 2,985 2,985 Term Loan 13.25 % Prime 4.75 % 9.55 % 13.50 % 5.50 % May 1, 2026 5,000 4,975 4,975 Term Loan 13.25 % Prime 4.75 % 9.55 % 13.50 % 5.50 % May 1, 2026 5,000 4,975 4,975 Term Loan 13.25 % Prime 4.75 % 9.55 % 13.50 % 5.50 % May 1, 2026 3,000 2,985 2,985 Emalex Biosciences, Inc. (2)(12) Biotechnology Term Loan 13.22 % Prime 4.72 % 9.75 % - 5.00 % June 1, 2024 1,979 1,971 1,971 Term Loan 13.22 % Prime 4.72 % 9.75 % - 5.00 % June 1, 2024 1,979 1,972 1,972 Term Loan 13.22 % Prime 4.72 % 9.75 % - 5.00 % November 1, 2025 5,000 4,943 4,943 Term Loan 13.22 % Prime 4.72 % 9.75 % - 5.00 % May 1, 2026 5,000 4,939 4,939 Greenlight Biosciences, Inc. (2)(12) Biotechnology Term Loan 14.25 % Prime 5.75 % 9.00 % - 3.00 % July 1, 2025 3,500 3,399 3,365 Term Loan 14.25 % Prime 5.75 % 9.00 % - 3.00 % July 1, 2025 1,750 1,699 1,684 KSQ Therapeutics, Inc. (2)(12) Biotechnology Term Loan 13.25 % Prime 4.75 % 8.50 % - 5.50 % May 1, 2027 6,250 6,193 6,193 Term Loan 13.25 % Prime 4.75 % 8.50 % - 5.50 % May 1, 2027 6,250 6,193 6,193 Native Microbials, Inc (2)(12) Biotechnology Term Loan 13.75 % Prime 5.25 % 8.50 % - 5.00 % November 1, 2026 3,750 3,716 3,716 Term Loan 13.75 % Prime 5.25 % 8.50 % - 5.00 % November 1, 2026 2,500 2,478 2,478 PDS Biotechnology Corporation (2)(5)(12) Biotechnology Term Loan 14.25 % Prime 5.75 % 9.75 % - 3.75 % September 1, 2026 10,000 9,898 9,898 Term Loan 14.25 % Prime 5.75 % 9.75 % - 3.75 % September 1, 2026 3,750 3,712 3,712 Term Loan 14.25 % Prime 5.75 % 9.75 % - 3.75 % September 1, 2026 3,750 3,712 3,712 Provivi, Inc. (2)(12) Biotechnology Term Loan 13.86 % Prime 5.36 % 9.50 % - 5.50 % December 1, 2024 4,667 4,594 4,594 Term Loan 13.86 % Prime 5.36 % 9.50 % - 5.50 % December 1, 2024 4,667 4,594 4,594 Term Loan 13.86 % Prime 5.36 % 9.50 % - 5.50 % December 1, 2024 2,333 2,286 2,286 Term Loan 13.86 % Prime 5.36 % 9.50 % - 5.50 % December 1, 2024 2,333 2,286 2,286 Term Loan 13.86 % Prime 5.36 % 9.50 % - 5.50 % December 1, 2024 2,333 2,282 2,282 Term Loan 13.86 % Prime 5.36 % 9.50 % - 5.50 % December 1, 2024 2,333 2,282 2,282 Stealth Biotherapeutics Inc. (2)(12) Biotechnology Term Loan 14.00 % Prime 5.50 % 8.75 % - 6.00 % October 1, 2025 4,500 4,434 4,434 Term Loan 14.00 % Prime 5.50 % 8.75 % - 6.00 % October 1, 2025 2,250 2,217 2,217 Tallac Therapeutics, Inc. (2)(12) Biotechnology Term Loan 12.75 % Prime 4.25 % 12.25 % - 4.00 % August 1, 2027 2,500 2,226 2,226 Term Loan 12.75 % Prime 4.25 % 12.25 % - 4.00 % August 1, 2027 2,500 2,455 2,455 Aerobiotix, LLC (2)(12) Medical Device Term Loan 9.00 % Fixed - - - 18.00 % April 1, 2028 2,500 2,466 2,344 Term Loan 9.00 % Fixed - - - 18.00 % April 1, 2028 2,500 2,466 2,344 Term Loan 9.00 % Fixed - - - 18.00 % June 30, 2024 200 200 190 Candesant Biomedical, Inc. (2)(12) Medical Device Term Loan 12.00 % Prime 3.50 % 11.50 % - 5.00 % September 1, 2027 5,000 4,751 4,751 Term Loan 12.00 % Prime 3.50 % 11.50 % - 5.00 % September 1, 2027 2,500 2,451 2,451 Term Loan 12.00 % Prime 3.50 % 11.50 % - 5.00 % September 1, 2027 2,500 2,451 2,451 Ceribell, Inc. (2)(12) Medical Device Term Loan 12.00 % Prime 3.50 % 8.25 % - 5.50 % October 1, 2024 5,000 4,985 4,985 Term Loan 12.00 % Prime 3.50 % 8.25 % - 5.50 % October 1, 2024 5,000 4,985 4,985 Term Loan 12.00 % Prime 3.50 % 8.25 % - 5.50 % October 1, 2024 2,500 2,488 2,488 Term Loan 12.00 % Prime 3.50 % 8.25 % - 5.50 % October 1, 2024 2,500 2,488 2,488 Cognoa, Inc. (2)(12) Medical Device Term Loan 14.00 % Prime 5.50 % 8.75 % - 6.00 % August 1, 2026 4,722 4,678 4,678 Term Loan 14.00 % Prime 5.50 % 8.75 % - 6.00 % August 1, 2026 2,361 2,339 2,339 Conventus Orthopaedics, Inc. (2)(12) Medical Device Term Loan 13.32 % Prime 4.82 % 9.25 % - 10.36 % July 1, 2025 3,960 3,916 3,916 Term Loan 13.32 % Prime 4.82 % 9.25 % - 10.36 % July 1, 2025 3,960 3,916 3,916 CSA Medical, Inc. (2)(12) Medical Device Term Loan 13.59 % Prime 5.09 % 10.00 % - 5.00 % January 1, 2024 750 739 739 Term Loan 13.59 % Prime 5.09 % 10.00 % - 5.00 % January 1, 2024 50 49 49 Term Loan 13.59 % Prime 5.09 % 10.00 % - 5.00 % March 1, 2024 1,067 1,052 1,052 InfoBionic, Inc. (2)(12) Medical Device Term Loan 14.75 % Prime 6.25 % 9.50 % - 4.00 % October 1, 2024 2,771 2,733 2,733 Term Loan 14.75 % Prime 6.25 % 9.50 % - 4.00 % June 1, 2025 1,000 982 982 Magnolia Medical Technologies, Inc. (2)(12) Medical Device Term Loan 13.50 % Prime 5.00 % 9.75 % - 4.00 % March 1, 2025 5,000 4,960 4,960 Term Loan 13.50 % Prime 5.00 % 9.75 % - 4.00 % March 1, 2025 5,000 4,960 4,960 Term Loan 13.50 % Prime 5.00 % 9.75 % - 4.00 % March 1, 2025 5,000 4,956 4,956 Term Loan 13.50 % Prime 5.00 % 9.75 % - 4.00 % March 1, 2025 5,000 4,956 4,956 Term Loan 13.50 % Prime 5.00 % 9.75 % - 4.00 % January 1, 2027 5,000 4,934 4,934 Term Loan 13.50 % Prime 5.00 % 9.75 % - 4.00 % January 1, 2027 5,000 4,934 4,934 See Notes to Consolidated Financial Statements Consolidated Schedule of Investments (Unaudited) September 30, 2023 (Dollars in thousands) Portfolio Company (1)(3) Sector Type of Investment (7) Cash Rate (4) Index Margin Floor Ceiling ETP (10) Maturity Date Principal Amount Cost of Investments (6)(9) Fair Value (9) Robin Healthcare, Inc. (2)(12)(13) Medical Device Term Loan 14.00 % Prime 5.50 % 10.25 % - 4.00 % November 1, 2026 3,500 3,468 1,749 Term Loan 14.00 % Prime 5.50 % 10.25 % - 4.00 % November 1, 2026 3,500 3,468 1,749 Scientia Vascular, Inc. (2)(12) Medical Device Term Loan 13.25 % Prime 4.75 % 8.50 % - 5.00 % January 1, 2027 3,750 3,663 3,663 Term Loan 13.25 % Prime 4.75 % 8.50 % - 5.00 % January 1, 2027 3,750 3,718 3,718 Term Loan 13.75 % Prime 5.25 % 9.00 % - 5.00 % March 1, 2027 5,000 4,938 4,938 Sonex Health, Inc. (2)(12) Medical Device Term Loan 12.00 % Prime 3.50 % 11.75 % - 8.00 % September 1, 2027 2,500 2,295 2,295 Term Loan 12.00 % Prime 3.50 % 11.75 % - 8.00 % September 1, 2027 2,500 2,471 2,471 Term Loan 12.00 % Prime 3.50 % 11.75 % - 8.00 % September 1, 2027 5,000 4,943 4,943 Term Loan 12.00 % Prime 3.50 % 11.75 % - 8.00 % September 1, 2027 5,000 4,943 4,943 Spineology, Inc. (2)(12) Medical Device Term Loan 15.50 % Prime 7.00 % 10.25 % - 1.00 % October 1, 2025 5,000 4,975 4,975 Term Loan 15.50 % Prime 7.00 % 10.25 % - 1.00 % April 1, 2026 2,500 2,487 2,487 Swift Health Systems Inc. (2)(12) Medical Device Term Loan 13.75 % Prime 5.25 % 9.00 % - 5.00 % July 1, 2027 3,500 3,464 3,464 Term Loan 13.75 % Prime 5.25 % 9.00 % - 5.00 % July 1, 2027 3,500 3,464 3,464 Term Loan 13.75 % Prime 5.25 % 9.00 % - 5.00 % July 1, 2027 3,500 3,453 3,453 Term Loan 13.75 % Prime 5.25 % 9.00 % - 5.00 % July 1, 2027 3,500 3,453 3,453 Total Non-Affiliate Debt Investments — Life Science 245,317 241,576 Non-Affiliate Debt Investments — Sustainability — 23.8% New Aerofarms, Inc. assignee of Aerofarms, Inc. (2)(12)(15) Other Sustainability Term Loan 15.25 % Prime 6.75 % 10.00 % - 4.33 % December 1, 2026 3,750 3,675 3,675 Term Loan 15.25 % Prime 6.75 % 10.00 % - 4.33 % December 1, 2026 3,750 3,675 3,675 Nexii Building Solutions, Inc. (2)(12)(14) Other Sustainability Term Loan 15.50 % (11) Prime 7.00 % 10.25 % - 2.50 % September 1, 2025 8,102 8,009 6,754 Term Loan 15.50 % (11) Prime 7.00 % 10.25 % - 2.50 % September 1, 2025 8,102 8,009 6,754 Term Loan 15.50 % (11) Prime 7.00 % 10.25 % - 2.50 % September 1, 2025 8,102 8,009 6,754 Term Loan 15.50 % (11) Prime 7.00 % 10.25 % - 2.50 % July 1, 2026 5,402 5,332 4,496 Term Loan 15.50 % (11) Prime 7.00 % 10.25 % - 2.50 % July 1, 2026 5,402 5,332 4,496 Term Loan 15.50 % (11) Prime 7.00 % 10.25 % - 2.50 % September 30, 2023 707 707 596 Term Loan 15.50 % (11) Prime 7.00 % 10.25 % - 2.50 % September 30, 2023 564 564 475 Term Loan 15.50 % (11) Prime 7.00 % 10.25 % - 2.50 % September 30, 2023 281 281 237 Term Loan 15.50 % (11) Prime 7.00 % 10.25 % - 2.50 % September 30, 2023 279 279 235 Term Loan 15.50 % (11) Prime 7.00 % 10.25 % - 2.50 % September 30, 2023 167 167 141 Soli Organic, Inc. (2)(12) Other Sustainability Term Loan 15.25 % Prime 6.75 % 10.00 % - 2.75 % April 1, 2026 5,000 4,951 4,951 Term Loan 15.25 % Prime 6.75 % 10.00 % - 2.75 % April 1, 2026 2,500 2,475 2,475 Term Loan 15.25 % Prime 6.75 % 10.00 % - 2.75 % May 1, 2026 5,000 4,948 4,948 Term Loan 15.25 % Prime 6.75 % 10.00 % - 2.75 % May 1, 2026 2,500 2,474 2,474 Term Loan 14.00 % Prime 5.50 % 11.75 % - 2.75 % December 1, 2026 5,000 4,926 4,926 Term Loan 14.00 % Prime 5.50 % 11.75 % - 2.75 % December 1, 2026 2,500 2,463 2,463 Temperpack Technologies, Inc. (2)(12) Other Sustainability Term Loan 15.25 % Prime 6.75 % 10.00 % - 2.50 % April 1, 2028 3,750 3,678 3,678 Term Loan 15.25 % Prime 6.75 % 10.00 % - 2.50 % April 1, 2028 3,750 3,692 3,692 Term Loan 15.25 % Prime 6.75 % 10.00 % - 2.50 % April 1, 2028 7,500 7,374 7,374 Term Loan 15.25 % Prime 6.75 % 10.00 % - 2.50 % April 1, 2028 3,750 3,687 3,687 Term Loan 15.25 % Prime 6.75 % 10.00 % - 2.50 % April 1, 2028 3,750 3,687 3,687 Total Non-Affiliate Debt Investments — Sustainability 88,394 82,643 See Notes to Consolidated Financial Statements Consolidated Schedule of Investments (Unaudited) September 30, 2023 (Dollars in thousands) Portfolio Company (1)(3) Sector Type of Investment (7) Cash Rate (4) Index Margin Floor Ceiling ETP (10) Maturity Date Principal Amount Cost of Investments (6)(9) Fair Value (9) Non-Affiliate Debt Investments — Technology — 80.5% Axiom Space, Inc. (2)(12) Communications Term Loan 14.50 % Prime 6.00 % 9.25 % - 2.50 % June 1, 2026 6,875 6,840 6,840 Term Loan 14.50 % Prime 6.00 % 9.25 % - 2.50 % June 1, 2026 6,875 6,840 6,840 Term Loan 14.50 % Prime 6.00 % 9.25 % - 2.50 % June 1, 2026 6,875 6,840 6,840 CAMP NYC, Inc. (2)(12) Consumer-related Technologies Term Loan 15.75 % Prime 7.25 % 10.50 % - 3.00 % May 1, 2026 3,500 3,470 3,470 Clara Foods Co. (2)(12) Consumer-related Technologies Term Loan 14.25 % Prime 5.75 % 9.00 % - 5.50 % August 1, 2025 1,833 1,821 1,821 Term Loan 14.25 % Prime 5.75 % 9.00 % - 5.50 % August 1, 2025 1,833 1,821 1,821 Divergent Technologies, Inc. (2)(12) Consumer-related Technologies Term Loan 11.25 % Prime 6.00 % 9.50 % 11.25 % 3.00 % July 1, 2027 3,750 3,605 3,605 Term Loan 11.25 % Prime 6.00 % 9.50 % 11.25 % 3.00 % July 1, 2027 1,250 1,241 1,241 Term Loan 11.25 % Prime 6.00 % 9.50 % 11.25 % 3.00 % July 1, 2027 3,750 3,723 3,723 Term Loan 11.25 % Prime 6.00 % 9.50 % 11.25 % 3.00 % July 1, 2027 1,250 1,241 1,241 Term Loan 11.25 % Prime 6.00 % 9.50 % 11.25 % 3.00 % July 1, 2027 3,750 3,723 3,723 Term Loan 11.25 % Prime 6.00 % 9.50 % 11.25 % 3.00 % July 1, 2027 1,250 1,241 1,241 Term Loan 11.25 % Prime 6.00 % 9.50 % 11.25 % 3.00 % January 1, 2028 3,750 3,709 3,709 Term Loan 11.25 % Prime 6.00 % 9.50 % 11.25 % 3.00 % January 1, 2028 3,750 3,703 3,703 Term Loan 11.25 % Prime 6.00 % 9.50 % 11.25 % 3.00 % April 1, 2028 3,750 3,709 3,709 Term Loan 11.25 % Prime 6.00 % 9.50 % 11.25 % 3.00 % July 1, 2028 3,750 3,705 3,705 Term Loan 11.25 % Prime 6.00 % 9.50 % 11.25 % 3.00 % July 1, 2028 3,750 3,705 3,705 Havenly, Inc. (2)(12) Consumer-related Technologies Term Loan 13.50 % Prime 5.00 % 5.00 % - 4.00 % March 1, 2027 2,000 1,335 1,335 Term Loan 13.50 % Prime 5.00 % 5.00 % - 4.00 % March 1, 2027 3,000 2,003 2,003 Term Loan 12.00 % Prime 3.50 % 10.50 % - 7.78 % February 1, 2028 2,813 2,813 2,813 Term Loan 12.00 % Prime 3.50 % 10.50 % - 7.78 % February 1, 2028 2,813 2,813 2,813 Lyrical Foods, Inc. (2)(12) Consumer-related Technologies Term Loan 11.00 % Prime 2.50 % 8.00 % - - September 1, 2027 2,598 2,589 2,351 MyForest Foods Co. (2)(12) Consumer-related Technologies Term Loan 15.25 % Prime 6.75 % 10.00 % - 3.00 % October 1, 2025 4,000 3,975 3,975 Term Loan 15.25 % Prime 6.75 % 10.00 % - 3.00 % October 1, 2025 2,000 1,987 1,987 NextCar Holding Company, Inc. (2)(12) Consumer-related Technologies Term Loan 14.25 % (11) Prime 5.75 % 9.00 % - 5.25 % October 31, 2023 5,547 5,505 4,894 Term Loan 14.25 % (11) Prime 5.75 % 9.00 % - 5.25 % October 31, 2023 2,219 2,204 1,960 Term Loan 14.25 % (11) Prime 5.75 % 9.00 % - 5.25 % October 31, 2023 2,774 2,759 2,453 Term Loan 14.25 % (11) Prime 5.75 % 9.00 % - 5.25 % October 31, 2023 3,328 3,310 2,943 Term Loan 14.25 % (11) Prime 5.75 % 9.00 % - 5.25 % October 31, 2023 2,774 2,747 2,443 Term Loan 14.25 % (11) Prime 5.75 % 9.00 % - 5.25 % October 31, 2023 2,774 2,747 2,443 Term Loan 14.25 % (11) Prime 5.75 % 9.00 % - 5.25 % October 31, 2023 5,547 5,493 4,884 Term Loan 14.25 % (11) Prime 5.75 % 9.00 % - 5.25 % October 31, 2023 2,774 2,746 2,441 Optoro, Inc. (2)(12) Consumer-related Technologies Term Loan 14.75 % Prime 6.25 % 9.50 % - 4.00 % August 1, 2027 2,500 2,408 2,408 Term Loan 14.75 % Prime 6.25 % 9.50 % - 4.00 % July 1, 2028 1,875 1,783 1,783 Primary Kids, Inc. (2)(12) Consumer-related Technologies Term Loan 15.75 % Prime 7.25 % 10.50 % - 3.00 % March 1, 2025 1,700 1,683 1,683 Term Loan 15.75 % Prime 7.25 % 10.50 % - 3.00 % March 1, 2025 1,700 1,683 1,683 Term Loan 15.75 % Prime 7.25 % 10.50 % - 3.00 % September 1, 2025 2,300 2,277 2,277 Unagi, Inc. (2)(12)(13) Consumer-related Technologies Term Loan 16.25 % (11) Prime 7.75 % 11.00 % - - May 1, 2027 1,108 1,086 872 Term Loan 16.25 % (11) Prime 7.75 % 11.00 % - - May 1, 2027 554 543 436 Term Loan 16.25 % (11) Prime 7.75 % 11.00 % - - May 1, 2027 554 543 436 Liqid, Inc. (2)(12) Networking Term Loan 14.75 % Prime 6.25 % 9.50 % - 4.00 % September 1, 2024 1,833 1,807 1,807 Term Loan 14.75 % Prime 6.25 % 9.50 % - 4.00 % September 1, 2024 1,833 1,807 1,807 Term Loan 14.75 % Prime 6.25 % 9.50 % - 4.00 % September 1, 2024 917 903 903 Term Loan 14.75 % Prime 6.25 % 9.50 % - 4.00 % September 1, 2024 917 903 903 Term Loan 14.75 % Prime 6.25 % 9.50 % - 4.00 % September 1, 2024 917 887 887 BriteCore Holdings, Inc. (2)(12) Software Term Loan 14.00 % Prime 5.50 % 14.00 % - 3.00 % October 1, 2028 5,000 4,857 4,857 Term Loan 14.00 % Prime 5.50 % 14.00 % - 3.00 % October 1, 2028 2,500 2,464 2,464 Term Loan 14.00 % Prime 5.50 % 14.00 % - 3.00 % October 1, 2028 2,500 2,464 2,464 Term Loan 14.00 % Prime 5.50 % 14.00 % - 3.00 % October 1, 2028 2,500 2,464 2,464 See Notes to Consolidated Financial Statements Consolidated Schedule of Investments (Unaudited) September 30, 2023 (Dollars in thousands) Portfolio Company (1)(3) Sector Type of Investment (7) Cash Rate (4) Index Margin Floor Ceiling ETP (10) Maturity Date Principal Amount Cost of Investments (6)(9) Fair Value (9) Dropoff, Inc. (2)(12) Software Term Loan 15.00 % (11) Prime 6.50 % 9.75 % - 3.50 % April 1, 2026 6,550 6,432 6,377 Term Loan 15.00 % (11) Prime 6.50 % 9.75 % - 3.50 % April 1, 2026 6,046 5,937 5,886 Term Loan 15.00 % (11) Prime 6.50 % 9.75 % - 3.50 % August 1, 2026 2,519 2,472 2,451 Engage3, LLC (2)(12) Software Term Loan 14.75 % Prime 6.25 % 9.75 % - 4.50 % July 1, 2027 3,750 3,726 3,726 Term Loan 14.75 % Prime 6.25 % 9.75 % - 4.50 % July 1, 2027 3,750 3,726 3,726 Kodiak Robotics, Inc. (2)(12) Software Term Loan 14.00 % Prime 5.50 % 10.25 % - 4.00 % April 1, 2026 10,000 9,877 9,877 Term Loan 14.00 % Prime 5.50 % 10.25 % - 4.00 % April 1, 2026 10,000 9,877 9,877 Term Loan 14.00 % Prime 5.50 % 10.25 % - 4.00 % April 1, 2026 5,000 4,939 4,939 Term Loan 14.00 % Prime 5.50 % 10.25 % - 4.00 % April 1, 2026 5,000 4,939 4,939 Lemongrass Holdings, Inc. (2)(12) Software Term Loan 15.00 % Prime 6.50 % 9.75 % - 2.50 % March 1, 2026 5,000 4,965 4,965 Term Loan 15.00 % Prime 6.50 % 9.75 % - 2.50 % March 1, 2026 2,500 2,483 2,483 Lytics, Inc. (2)(12) Software Term Loan 14.50 % Prime 6.00 % 14.25 % - 4.00 % November 1, 2026 2,500 2,418 2,350 Term Loan 14.50 % Prime 6.00 % 14.25 % - 4.00 % December 1, 2026 1,250 1,236 1,201 Term Loan 14.50 % Prime 6.00 % 14.25 % - 4.00 % April 1, 2027 1,000 993 966 Mirantis, Inc. (2)(12) Software Term Loan 12.00 % Prime 3.50 % 11.75 % - 4.00 % October 1, 2028 5,000 4,774 4,774 Term Loan 12.00 % Prime 3.50 % 11.75 % - 4.00 % October 1, 2028 5,000 4,910 4,910 Term Loan 12.00 % Prime 3.50 % 11.75 % - 4.00 % October 1, 2028 5,000 4,910 4,910 Term Loan 12.00 % Prime 3.50 % 11.75 % - 4.00 % October 1, 2028 5,000 4,910 4,910 Noodle Partners, Inc. (2)(12) Software Term Loan 13.50 % Prime 5.00 % 12.00 % - 3.00 % March 1, 2027 10,000 9,814 9,814 Term Loan 13.50 % Prime 5.00 % 12.00 % - 3.00 % March 1, 2027 5,000 4,938 4,938 Term Loan 13.50 % Prime 5.00 % 12.00 % - 3.00 % March 1, 2027 5,000 4,939 4,939 Reputation Institute, Inc. (2)(12) Software Term Loan 15.75 % Prime 7.25 % 10.50 % - 3.00 % August 1, 2025 3,833 3,785 3,785 Slingshot Aerospace, Inc. (2)(12) Software Term Loan 14.25 % Prime 5.75 % 9.75 % - 5.00 % August 1, 2026 5,000 4,952 4,952 Term Loan 14.25 % Prime 5.75 % 9.75 % - 5.00 % August 1, 2026 5,000 4,952 4,952 Term Loan 14.25 % Prime 5.75 % 9.75 % - 5.00 % August 1, 2026 5,000 4,952 4,952 Term Loan 14.25 % Prime 5.75 % 9.75 % - 5.00 % August 1, 2026 5,000 4,952 4,952 Supply Network Visibility Holdings LLC (2)(12) Software Term Loan 12.75 % Prime 4.25 % 12.00 % - 2.50 % June 1, 2028 2,500 2,457 2,457 Term Loan 12.75 % Prime 4.25 % 12.00 % - 2.50 % June 1, 2028 3,500 3,489 3,489 Term Loan 12.75 % Prime 4.25 % 12.00 % - 2.50 % June 1, 2028 2,500 2,492 2,492 Term Loan 12.75 % Prime 4.25 % 12.00 % - 2.50 % June 1, 2028 1,500 1,495 1,495 Viken Detection Corporation (2)(12) Software Term Loan 12.50 % Prime 4.00 % 11.75 % - 3.50 % June 1, 2027 5,000 4,768 4,768 Term Loan 12.50 % Prime 4.00 % 11.75 % - 3.50 % June 1, 2027 2,500 2,464 2,464 Term Loan 12.50 % Prime 4.00 % 11.75 % - 3.50 % June 1, 2027 2,500 2,464 2,464 Total Non-Affiliate Debt Investments — Technology 282,962 278,989 Non-Affiliate Debt Investments — Healthcare information and services — 17.4% Hound Labs inc. (2) (12) Diagnostics Term Loan 14.50 % Prime 6.00 % 9.25 % - 3.50 % June 1, 2026 2,500 2,481 2,481 Term Loan 14.50 % Prime 6.00 % 9.25 % - 3.50 % June 1, 2026 2,500 2,481 2,481 Term Loan 14.50 % Prime 6.00 % 9.25 % - 3.50 % June 1, 2026 5,000 4,962 4,962 BrightInsight, Inc. (2)(12) Software Term Loan 14.00 % Prime 5.50 % 9.50 % - 3.00 % August 1, 2027 7,000 6,677 6,677 Term Loan 14.00 % Prime 5.50 % 9.50 % - 3.00 % August 1, 2027 3,500 3,459 3,459 Term Loan 14.00 % Prime 5.50 % 9.50 % - 3.00 % August 1, 2027 3,500 3,459 3,459 Term Loan 14.00 % Prime 5.50 % 9.50 % - 3.00 % April 1, 2028 2,750 2,708 2,708 Elligo Health Research, Inc. (2)(12) Software Term Loan 12.00 % Prime 3.50 % 11.75 % - 4.00 % October 1, 2027 10,000 9,647 9,647 Term Loan 12.00 % Prime 3.50 % 11.75 % - 4.00 % October 1, 2027 5,000 4,921 4,921 Term Loan 12.00 % Prime 3.50 % 11.75 % - 4.00 % October 1, 2027 5,000 4,921 4,921 Term Loan 12.00 % Prime 3.50 % 11.75 % - 4.00 % October 1, 2027 5,000 4,921 4,921 SafelyYou, Inc. (2)(12) Software Term Loan 11.75 % Prime 3.25 % 11.00 % - 5.00 % June 1, 2027 5,000 4,642 4,642 Term Loan 11.75 % Prime 3.25 % 11.00 % - 5.00 % June 1, 2027 5,000 4,912 4,912 Total Non-Affiliate Debt Investments — Healthcare information and services 60,191 60,191 Total Non- Affiliate Debt Investments 676,864 663,399 See Notes to Consolidated Financial Statements Consolidated Schedule of Investments (Unaudited) September 30, 2023 (Dollars in thousands) Cost of Fair Portfolio Company (1)(3) Sector Type of Investment (7) Number of Shares Investments (6)(9) Value (9) Non-Affiliate Warrant Investments — 7.6% Non-Affiliate Warrants — Life Science — 2.0% Avalo Therapeutics, Inc. (2)(5)(12) Biotechnology Common Stock Warrant 26,444 311 — Castle Creek Biosciences, Inc. (2)(12) Biotechnology Preferred Stock Warrant 7,404 214 348 Emalex Biosciences, Inc. (2)(12) Biotechnology Preferred Stock Warrant 110,402 176 269 Imunon, Inc. (2)(5)(12) Biotechnology Common Stock Warrant 19,671 65 — KSQ Therapeutics, Inc. (2) (12) Biotechnology Preferred Stock Warrant 48,076 50 60 Mustang Bio, Inc. (2)(5)(12) Biotechnology Common Stock Warrant 16,611 146 — Native Microbials, Inc (2)(12) Biotechnology Preferred Stock Warrant 103,679 64 165 PDS Biotechnology Corporation (2)(5)(12) Biotechnology Common Stock Warrant 299,848 162 667 Provivi, Inc. (2)(12) Biotechnology Preferred Stock Warrant 345,327 487 205 Stealth Biotherapeutics Inc. (2)(12) Biotechnology Common Stock Warrant 318,181 264 127 Tallac Therapeutics, Inc. (2)(12) Biotechnology Preferred Stock Warrant 1,600,002 194 194 vTv Therapeutics Inc. (2)(5)(12) Biotechnology Common Stock Warrant 95,293 44 — Xeris Pharmaceuticals, Inc. (2)(5)(12) Biotechnology Common Stock Warrant 126,000 72 17 AccuVein Inc. (2)(12) Medical Device Common Stock Warrant 1,175 24 — Aerin Medical, Inc. (2)(12) Medical Device Preferred Stock Warrant 1,818,183 66 1,210 Aerobiotix, LLC (2)(12) Medical Device Preferred Stock Warrant 8,800 48 10 Canary Medical Inc. (2)(12) Medical Device Preferred Stock Warrant 12,153 86 1,307 Candesant Biomedical, Inc. (2)(12) Medical Device Preferred Stock Warrant 93,336 152 152 Ceribell, Inc. (2)(12) Medical Device Preferred Stock Warrant 145,483 69 213 Cognoa, Inc. (2)(12) Medical Device Preferred Stock Warrant 4,106,174 148 184 Conventus Orthopaedics, Inc. (2)(12) Medical Device Preferred Stock Warrant 7,972,222 218 236 CSA Medical, Inc. (2)(12) Medical Device Preferred Stock Warrant 1,730,746 172 176 CVRx, Inc. (2)(5)(12) Medical Device Common Stock Warrant 47,410 76 272 Infobionic, Inc. (2)(12) Medical Device Preferred Stock Warrant 317,647 124 59 Magnolia Medical Technologies, Inc. (2)(12) Medical Device Preferred Stock Warrant 809,931 194 395 Meditrina, Inc. (2)(12) Medical Device Preferred Stock Warrant 233,993 83 104 Robin Healthcare, Inc. (2)(12) Medical Device Preferred Stock Warrant 86,066 16 — Scientia Vascular, Inc (2)(12) Medical Device Preferred Stock Warrant 27,036 59 230 Sonex Health, Inc. (2)(12) Medical Device Preferred Stock Warrant 2,637,043 275 304 VERO Biotech LLC (2)(12) Medical Device Preferred Stock Warrant 408 53 1 Swift Health Systems Inc. (2)(12) Medical Device Preferred Stock Warrant 135,484 71 40 Total Non-Affiliate Warrants — Life Science 4,183 6,945 See Notes to Consolidated Financial Statements Consolidated Schedule of Investments (Unaudited) September 30, 2023 (Dollars in thousands) Cost of Fair Portfolio Company (1)(3) Sector Type of Investment (7) Number of Shares Investments (6)(9) Value (9) Non-Affiliate Warrants — Sustainability — 0.2% New Aerofarms, Inc. assignee of Aerofarms, Inc. (2)(12)(15) Other Sustainability Preferred Stock Warrant 400,000 81 81 LiquiGlide, Inc. (2)(12) Other Sustainability Common Stock Warrant 61,359 41 59 Nexii Building Solutions, Inc. (2)(12)(14) Other Sustainability Common Stock Warrant 217,726 490 — Soli Organic, Inc. (2)(12) Other Sustainability Preferred Stock Warrant 681 214 371 Temperpack Technologies, Inc. (2)(12) Other Sustainability Preferred Stock Warrant 46,311 175 322 Total Non-Affiliate Warrants — Sustainability 1,001 833 Non-Affiliate Warrants — Technology — 4.7% Axiom Space, Inc. (2)(12) Communications Common Stock Warrant 1,991 46 69 Intelepeer Holdings, Inc. (2)(12) Communications Preferred Stock Warrant 2,936,535 138 3,283 PebblePost, Inc. (2)(12) Communications Preferred Stock Warrant 598,850 92 139 Alula Holdings, Inc. (2)(12) Consumer-related Technologies Preferred Stock Warrant 20,000 93 — Aterian, Inc. (2)(5)(12) Consumer-related Technologies Common Stock Warrant 76,923 195 — Caastle, Inc. (2)(12) Consumer-related Technologies Preferred Stock Warrant 268,591 68 1,060 CAMP NYC, Inc. (2)(12) Consumer-related Technologies Preferred Stock Warrant 75,997 22 30 Clara Foods Co. (2)(12) Consumer-related Technologies Preferred Stock Warrant 46,745 31 128 CZV, Inc. (2)(12) Consumer-related Technologies Common Stock Warrant 65,569 81 81 Divergent Technologies, Inc. (2)(12) Consumer-related Technologies Preferred Stock Warrant 37,294 92 279 Havenly, Inc. (2)(12) Consumer-related Technologies Common Stock Warrant 1,312,500 2,945 2,676 MyForest Foods Co. (2)(12) Consumer-related Technologies Preferred Stock Warrant 250 29 63 NextCar Holding Company, Inc. (2)(12) Consumer-related Technologies Preferred and Common Stock Warrant 1,237,370 197 — Optoro, Inc. (2)(12) Consumer-related Technologies Preferred Stock Warrant 11,550 182 182 Primary Kids, Inc. (2)(12) Consumer-related Technologies Preferred Stock Warrant 553,778 57 596 Quip NYC Inc. (2)(12) Consumer-related Technologies Preferred Stock Warrant 6,191 325 538 Unagi, Inc. (2)(12) Consumer-related Technologies Preferred Stock Warrant 171,081 32 — Updater, Inc.(2)(12) Consumer-related Technologies Common Stock Warrant 108,333 34 — CPG Beyond, Inc. (2)(12) Data Storage Preferred Stock Warrant 500,000 242 917 Silk, Inc. (2)(12) Data Storage Preferred Stock Warrant 394,110 175 153 Global Worldwide LLC (2)(12) Internet and Media Preferred Stock Warrant 245,810 75 63 Rocket Lawyer Incorporated (2)(12) Internet and Media Preferred Stock Warrant 261,721 92 336 Skillshare, Inc. (2)(12) Internet and Media Preferred Stock Warrant 139,074 162 1,216 Liqid, Inc. (2)(12) Networking Preferred Stock Warrant 344,102 364 251 Halio, Inc. (2)(12) Power Management Preferred Stock Warrant 5,002,574 1,585 2,901 Avalanche Technology, Inc. (2)(12) Semiconductors Preferred and Common Stock Warrant 6,081 56 — BriteCore Holdings, Inc. (2)(12) Software Preferred Stock Warrant 161,215 98 147 Dropoff, Inc. (2)(12) Software Common Stock Warrant 516,732 455 54 Mirantis, Inc. (2)(12) Software Common Stock Warrant 948,275 223 223 E La Carte, Inc. (2)(5)(12) Software Common Stock Warrant 147,361 60 — Everstream Holdings, LLC (2)(12) Software Preferred Stock Warrant 350,000 70 71 Kodiak Robotics, Inc. (2)(12) Software Preferred Stock Warrant 639,918 273 124 Lemongrass Holdings, Inc. (2)(12) Software Preferred Stock Warrant 101,308 32 43 Lotame Solutions, Inc. (2)(12) Software Preferred Stock Warrant 71,305 18 44 Lytics, Inc. (2)(12) Software Preferred Stock Warrant 85,543 43 1 Noodle Partners, Inc. (2)(12) Software Preferred Stock Warrant 84,037 115 79 Reputation Institute, Inc. (2)(12) Software Preferred Stock Warrant 3,731 56 48 Revinate Holdings, Inc. (2)(12) Software Preferred Stock Warrant 682,034 44 103 SIGNiX, Inc. (12) Software Preferred Stock Warrant 186,235 225 — Slingshot Aerospace, Inc. (2)(12) Software Preferred Stock Warrant 309,208 123 135 Supply Network Visibility Holdings LLC (2)(12) Software Preferred Stock Warrant 682 64 146 Topia Mobility, Inc. (2)(12) Software Preferred Stock Warrant 3,049,607 138 — Viken Detection Corporation (2)(12) Software Preferred Stock Warrant 345,443 120 122 xAd, Inc. (2)(12) Software Preferred Stock Warrant 4,343,348 177 12 Total Non-Affiliate Warrants — Technology 9,744 16,313 See Notes to Consolidated Financial Statements Consolidated Schedule of Investments (Unaudited) September 30, 2023 (Dollars in thousands) Cost of Fair Portfolio Company (1)(3) Sector Type of Investment (7) Number of Shares Investments (6)(9) Value (9) Non-Affiliate Warrants — Healthcare information and services — 0.6% Hound Labs, Inc (2) (12) Diagnostics Preferred Stock Warrant 171,370 47 15 Kate Farms, Inc. (2)(12) Other Healthcare Preferred Stock Warrant 82,965 102 1,379 BrightInsight, Inc. (2)(12) Software Preferred Stock Warrant 85,066 167 — Elligo Health Research, Inc. (2)(12) Software Preferred Stock Warrant 652,250 189 191 Medsphere Systems Corporation (2)(12) Software Preferred Stock Warrant 7,097,792 61 346 SafelyYou, Inc. (2)(12) Software Preferred Stock Warrant 150,353 163 167 Total Non-Affiliate Warrants — Healthcare information and services 729 2,098 Total Non-Affiliate Warrants 15,657 26,189 Non-Affiliate Other Investments — Life Science — 0.3% Lumithera, Inc. (12) Medical Device Royalty Agreement 1,200 1,100 ZetrOZ, Inc. (12) Medical Device Royalty Agreement — — Total Non-Affiliate Other Investments 1,200 1,100 Non-Affiliate Equity — 1.4% Cadrenal Therapeutics, Inc. (5) Biotechnology Common Stock 600,000 — 408 Castle Creek Biosciences, Inc. (12) Biotechnology Common Stock 1,162 250 250 Emalex Biosciences, Inc. (12) Biotechnology Common Stock 32,831 355 356 Getaround, Inc. (2)(5) Consumer-related Technologies Common Stock 87,082 253 30 NextCar Holding Company, Inc. (2)(12) Technology Preferred Stock 2,688,971 89 89 SnagAJob.com, Inc. (12) Consumer-related Technologies Common Stock 82,974 9 83 Lumithera, Inc. (12) Medical Device Common Stock 392,651 2,000 1,700 Tigo Energy, Inc. (5) Other Sustainability Common Stock 5,205 111 36 Branded Online, Inc. (2)(5) Software Common Stock 5,398 1,079 3 Decisyon, Inc. (12) Software Preferred Stock 280,000 2,800 1,281 Lotame, Inc. (12) Software Preferred Stock 66,127 4 193 Axiom Space, Inc. (12) Technology Preferred Stock 1,810 261 306 Total Non-Affiliate Equity 7,211 4,735 Total Non-Affiliate Portfolio Investment Assets $ 700,932 $ 695,423 See Notes to Consolidated Financial Statements Consolidated Schedule of Investments (Unaudited) September 30, 2023 (Dollars in thousands) Portfolio Company (1)(3) Sector Type of Investment (7) Cash Rate (4) Index Margin Floor Ceiling ETP (10) Maturity Date Principal Amount Cost of Investments (6)(9) Fair Value (9) Non-Controlled Affiliate Investments — 5.9% Non-Controlled Affiliate Debt Investments — Life Sciences — 3.5% Evelo Biosciences, Inc. (2)(5)(12)(13) Biotechnology Term Loan 12.75 % Prime 4.25 % 11.00 % - 4.25 % January 1, 2028 7,778 7,672 2,666 Term Loan 12.75 % Prime 4.25 % 11.00 % - 4.25 % January 1, 2028 11,667 11,509 3,997 Term Loan 12.75 % Prime 4.25 % 11.00 % - 4.25 % January 1, 2028 4,681 4,618 1,604 Term Loan 12.75 % Prime 4.25 % 11.00 % - 4.25 % January 1, 2028 4,667 4,603 1,597 Term Loan 12.75 % Prime 4.25 % 11.00 % - 4.25 % January 1, 2028 3,111 3,069 1,068 Term Loan 12.75 % Prime 4.25 % 11.00 % - 4.25 % January 1, 2028 3,111 3,069 1,068 Total Non-Controlled Affiliate Debt Investments 34,540 12,000 Cost of Fair Portfolio Company (1)(3) Sector Type of Investment (7) Number of Shares Investments (6)(9) Value (9) Non-controlled Affiliate Equity — Life Sciences — 2.4% Aulea Medical, Inc. (12)(16) Medical Device Common Stock 660,537 — — Evelo Biosciences, Inc. (5) Biotechnology Common Stock 2,164,502 5,000 8,485 Total Non-Controlled Affiliate Equity 5,000 8,485 Non-controlled Affiliate Warrants — Life Sciences — 0.0% Evelo Biosciences, Inc. (2)(5)(12) Biotechnology Common Stock 23,196 126 — Total Non-Controlled Affiliate Warrants 126 — Total Non-Controlled Affiliate Portfolio Investment Assets $ 39,666 $ 20,485 Portfolio Company (1)(3) Sector Type of Investment (7) Cash Rate (4) Index Margin Floor Ceiling ETP (10) Maturity Date Principal Amount Cost of Investments (6)(9) Fair Value (9) Controlled Affiliate Investments — 3.8% Controlled Affiliate Debt Investments — Technology — 1.3% Better Place Forests Co. (12) Consumer-related Technologies Term Loan 12.25 % (11) Prime 3.75 % 12.00 % - 2.78 % August 1, 2029 3,604 3,556 3,006 Term Loan 12.25 % (11) Prime 3.75 % 12.00 % - 2.78 % August 1, 2029 1,719 1,695 1,433 Total Controlled Affiliate Debt Investments 5,251 4,439 Cost of Fair Portfolio Company (1)(3) Sector Type of Investment (7) Number of Shares Investments (6)(9) Value (9) Controlled Affiliate Equity — Technology — 0.7% Better Place Forests Co. (12) Technology Preferred and Common Stock 2,551,596 2,811 2,552 Total Controlled Affiliate Equity 2,811 2,552 Controlled Affiliate Other Investments — Life Sciences — 1.8% HIMV LLC (12)(17) Biotechnology Other Investment 6,154 6,154 Total Controlled Affiliate Equity 6,154 6,154 Total Controlled Affiliate Portfolio Investment Assets $ 14,216 $ 13,145 Total Portfolio Investment Assets — 210.4% $ 754,814 $ 729,053 ( 1 All investments of the Company are in entities which are organized under the laws of the United States and have a principal place of business in the United States, unless otherwise noted. ( 2 Has been pledged as collateral under the revolving credit facility (the “Key Facility”) with KeyBank National Association (“Key”), the Note Funding Agreement (the “NYL Facility”, together with the Key Facility, the "Credit Facilities") with several entities owned or affiliated with New York Life Insurance Company (“NYL Noteholders”), the term debt securitization in connection with which an affiliate of the Company made an offering of $100.0 million in aggregate principal amount of fixed rate asset-backed notes that were issued in conjuncti

Note 1 - Organization

Note 1 - Organization	9 Months Ended
	Sep. 30, 2023
Notes to Financial Statements
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	1. Horizon Technology Finance Corporation (the “Company”) was organized as a Delaware corporation on March 16, 2010 1940 1986, not On October 28, 2010, Horizon Credit II LLC (“Credit II”) was formed as a Delaware limited liability company on June 28, 2011, not The Company formed Horizon Funding 2019‑1 “2019‑1 May 2, 2019 2019‑1 May 15, 2019 “2019‑1 2019‑1 “2019‑1 2019‑1 2019‑1 2019 Horizon Funding I, LLC (“HFI”) was formed as a Delaware limited liability company on May 9, 2018, not April 21, 2020, The Company formed Horizon Funding 2022‑1 “2022‑1 September 30, 2022 2022‑1 October 18, 2022 ( “2022‑1 2022‑1 “2022‑1 2022‑1 2022‑1 2022 The Company has established wholly owned subsidiaries, which are structured as Delaware limited liability companies, either to hold assets of portfolio companies acquired in connection with a foreclosure or bankruptcy or to hold equity in portfolio companies which the Company may The Company, together with its co-lender to IMV, established HIMV LLC, a Delaware limited liability company to purchase and sell the assets of IMV, a borrower of the Company. HIMV LLC is 70% owned by the Company and 30% owned by the co-lender. The Company’s investment strategy is to maximize the investment portfolio’s return by generating current income from the debt investments the Company makes and capital appreciation from the warrants the Company receives when making such debt investments. The Company has entered into an investment management agreement (the “Investment Management Agreement”) with Horizon Technology Finance Management LLC (the “Advisor”) under which the Advisor manages the day-to-day operations of, and provides investment advisory services to, the Company.

Note 2 - Basis of Presentation

Note 2 - Basis of Presentation and Significant Accounting Policies	9 Months Ended
	Sep. 30, 2023
Notes to Financial Statements
Basis of Presentation and Significant Accounting Policies [Text Block]	Note 2. The consolidated financial statements of the Company have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) and pursuant to the requirements for reporting on Form 10‑Q 6 10 X X” 1933, not may December 31, 2022 Principles of consolidation As required under GAAP and Regulation S- X, Assets related to transactions that do not 860, Transfers and Servicing 2019‑1 2022 1 not Use of estimates In preparing the consolidated financial statements in accordance with GAAP, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities, and disclosures of contingent assets and liabilities, as of the date of the balance sheet and income and expenses for the period. Actual results could differ from those estimates. Material estimates that are particularly susceptible to significant change in the near term relate to the valuation of investments. Fair value The Company records all of its investments at fair value in accordance with relevant GAAP, which establishes a framework used to measure fair value and requires disclosures for fair value measurements. The Company has categorized its investments carried at fair value, based on the priority of the valuation technique, into a three 6. not The availability of observable inputs can vary depending on the financial instrument and is affected by a wide variety of factors, including, for example, the type of product, whether the product is new, whether the product is traded on an active exchange or in the secondary market and the current market conditions. To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for financial instruments classified as Level 3. See Note 6 Segments The Company has determined that it has a single reporting segment and operating unit structure. The Company lends to and invests in portfolio companies in various technology, life science, healthcare information and services and sustainability industries. The Company separately evaluates the performance of each of its lending and investment relationships. However, because each of these debt investments and investment relationships has similar business and economic characteristics, they have been aggregated into a single lending and investment segment. Investments Investments are recorded at fair value. Pursuant to the amended SEC Rule 2a 5 1940 July 29, 2022, Interest on debt investments is accrued and included in income based on contractual rates applied to principal amounts outstanding. Interest income is determined using a method that results in a level rate of return on principal amounts outstanding. Generally, when a debt investment becomes 90 not may may September 30, 2023 three December 31, 2022 three three nine September 30, 2023 2022, not The Company has a limited number of debt investments in its portfolio that contain a PIK provision. Contractual PIK interest, which represents contractually deferred interest added to the loan balance that is generally due at the end of the loan term, is generally recorded on an accrual basis to the extent such amounts are expected to be collected. The Company will generally cease accruing PIK interest if there is insufficient value to support the accrual or management does not three nine September 30, 2023 three nine September 30, 2022 The Company receives a variety of fees from borrowers in the ordinary course of conducting its business, including advisory fees, commitment fees, amendment fees, non-utilization fees, success fees and prepayment fees. In a limited number of cases, the Company may Certain debt investment agreements also require the borrower to make an ETP, that is accrued into interest receivable and taken into income over the life of the debt investment to the extent such amounts are expected to be collected. The Company will generally cease accruing the income if there is insufficient value to support the accrual or the Company does not not three September 30, 2023 2022 not nine September 30, 2023 2022 In connection with substantially all lending arrangements, the Company receives warrants to purchase shares of stock from the borrower. The warrants are recorded as assets at estimated fair value on the grant date using the Black-Scholes valuation model. The warrants are considered loan fees and are recorded as unearned income on the grant date. The unearned income is recognized as interest income over the contractual life of the related debt investment in accordance with the Company’s income recognition policy. Subsequent to debt investment origination, the fair value of the warrants is determined using the Black-Scholes valuation model. Any adjustment to fair value is recorded through earnings as net unrealized appreciation or depreciation on investments. Gains and losses from the disposition of the warrants or stock acquired from the exercise of warrants are recognized as realized gains and losses on investments. Realized gains or losses on the sale of investments, or upon the determination that an investment balance, or portion thereof, is not Debt issuance costs Debt issuance costs are fees and other direct incremental costs incurred by the Company in obtaining debt financing from its lenders and issuing debt securities. The unamortized balance of debt issuance costs as of September 30, 2023 December 31, 2022 September 30, 2023 December 31, 2022 three September 30, 2023 2022 nine September 30, 2023 2022 Income taxes As a BDC, the Company has elected to be treated as a RIC under Subchapter M of the Code and operates in a manner so as to qualify for the tax treatment applicable to RICs. In order to qualify as a RIC and to avoid the imposition of corporate-level income tax on the portion of its taxable income distributed to stockholders, among other things, the Company is required to meet certain source of income and asset diversification requirements and to timely distribute dividends out of assets legally available for distribution to its stockholders of an amount generally at least equal to 90% no 946, Financial Services Investment Companies no Depending on the level of taxable income earned in a tax year, the Company may three September 30, 2023 2022, nine September 30, 2023 2022, The Company evaluates tax positions taken in the course of preparing the Company’s tax returns to determine whether the tax positions are “more-likely-than- not” 740, Income Taxes 946. not not no September 30, 2023 December 31, 2022 2022, 2021 2020 Distributions Distributions to common stockholders are recorded on the declaration date. The amount to be paid out as distributions is determined by the Board. Net realized capital gains, if any, may may The Company has adopted a dividend reinvestment plan that provides for reinvestment of cash distributions on behalf of its stockholders, unless a stockholder elects to receive cash. As a result, if the Board declares a cash distribution, then stockholders who have not may Stockholders Equity On August 2, 2021, “2021 2021 may On September 22, 2023, 2021 “2023 2021 2023 may may 415 During the three September 30, 2023 2023 2021 During the three September 30, 2022 2021 During the nine September 30, 2023 2023 2021 During the nine September 30, 2022, 2021 The Company generally uses net proceeds from these sales to make investments, to pay down liabilities and for general corporate purposes. As of September 30, 2023 2023 On March 14, 2022, On June 2, 2023, Stock Repurchase Program On April 28, 2023, may, not 10b‑18 1934, 1940 June 30, 2024 $5.0 three nine September 30, 2023 2022 not September 30, 2023 Transfers of financial assets Assets related to transactions that do not 860, Transfers and Servicing not Transfers of financial assets are accounted for as sales when control over the assets has been surrendered. Control over transferred assets is deemed to be surrendered when ( 1 2 3 not Recently issued accounting pronouncement In June 2022, No. 2022 03, 2022 03” 2022 03 2022 03 December 15, 2023, 2022 03

Note 3 - Related Party Transact

Note 3 - Related Party Transactions	9 Months Ended
	Sep. 30, 2023
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	Note 3. Investment Management Agreement On October 28, 2022, March 7, 2019 ( “2019 May 25, 2023 June 28, 2023, June 30, 2023 ( 2019 2019 June 30, 2023. 2019 The Advisor’s services under the Investment Management Agreement are not not two The base management is calculated at an annual rate of 2.00% of the Company’s gross assets (less cash and cash equivalents) including any assets acquired with the proceeds of leverage; provided, that, to the extent the Company’s gross assets (less cash and cash equivalents) exceed $250 $250 The base management fee payable at September 30, 2023 December 31, 2022 three September 30, 2023 2022 nine September 30, 2023 2022 The incentive fee has two The first zero not no 1.75%, 2.1875% 20.00% not Pre-Incentive Fee Net Investment Income does not may 2.00% three The incentive fee on Pre-Incentive Fee Net Investment Income is subject to a fee cap and deferral mechanism which is determined based upon a look-back period of up to three 11 may 20.00% zero not three The second 20.00% not There was no performance based incentive fee expense for the three September 30, 2023. three September 30, 2022. nine September 30, 2023 2022 three nine September 30, 2023, not may three September 30, 2023 December 31, 2025, March 31, 2026, June 30, 2026, September 30, 2026, not three nine September 30, 2022. September 30, 2023. December 31, 2022 December 31, 2022 one Administration Agreement The Company entered into an administration agreement (the “Administration Agreement”) with the Advisor to provide administrative services to the Company. For providing these services, facilities and personnel, the Company reimburses the Advisor for the Company’s allocable portion of overhead and other expenses incurred by the Advisor in performing its obligations under the Administration Agreement, including rent, the fees and expenses associated with performing compliance functions and the Company’s allocable portion of the costs of compensation and related expenses of the Company’s Chief Financial Officer and Chief Compliance Officer and their respective staffs. The administrative fee expense was $0.4 million for the three September 30, 2023 2022 nine September 30, 2023 2022

Note 4 - Investments

Note 4 - Investments	9 Months Ended
	Sep. 30, 2023
Notes to Financial Statements
Investment Holdings [Text Block]	Note 4. The following table shows the Company’s investments as of September 30, 2023 December 31, 2022 September 30, 2023 December 31, 2022 Cost Fair Value Cost Fair Value (In thousands) Investments Debt $ 716,655 $ 679,838 $ 701,074 $ 686,458 Warrants 15,783 26,189 14,790 29,712 Other 7,354 7,254 1,200 1,300 Equity 15,022 15,772 4,184 2,556 Total investments $ 754,814 $ 729,053 $ 721,248 $ 720,026 The following table shows the Company’s investments by industry sector as of September 30, 2023 December 31, 2022 September 30, 2023 December 31, 2022 Cost Fair Value Cost Fair Value (In thousands) Life Science Biotechnology $ 158,953 $ 139,935 $ 193,372 $ 195,006 Medical Device 140,172 139,039 132,803 135,960 Technology Communications 21,057 24,317 22,892 26,176 Consumer-Related 110,245 106,559 121,961 114,050 Data Storage 417 1,070 476 1,316 Internet and Media 329 1,615 329 1,159 Networking 6,671 6,558 11,831 11,710 Power Management 1,585 2,901 1,585 2,610 Semiconductors 56 — 56 — Software 164,903 161,258 120,157 118,716 Sustainability Energy Efficiency 111 36 8 27 Other Sustainability 89,395 83,476 84,633 85,524 Healthcare Information and Services Diagnostics 9,971 9,939 9,851 9,858 Other 102 1,379 7,559 3,870 Software 50,847 50,971 13,735 14,044 Total investments $ 754,814 $ 729,053 $ 721,248 $ 720,026

Note 5 - Transactions With Affi

Note 5 - Transactions With Affiliated Companies	9 Months Ended
	Sep. 30, 2023
Notes to Financial Statements
Investments in and Advances to Affiliates, Schedule of Investments [Text Block]	Note 5. A non-controlled affiliated company is generally a portfolio company in which the Company owns 5% not 25% Transactions related to investments in non-controlled affiliated companies for the three September 30, 2023 Three months ended September 30, 2023 Fair value at Transfers Net Fair value at Portfolio June 30, Principal in/(out) at Discount unrealized Net realized September 30, Interest Company 2023 Purchases Payments fair value accretion gain/(loss) gain/(loss) 2023 income (In thousands) Aulea Medical, Inc. $ — $ — $ — $ — $ — $ — $ — $ — $ — Cadrenal Therapeutics, Inc. (1) 906 — — (906 ) — — — — — Evelo Biosciences, Inc. — — — 7,665 8 (5,007 ) — 2,666 277 — — — 11,496 11 (7,510 ) — 3,997 415 — — — 4,612 5 (3,013 ) — 1,604 166 — — — 4,598 3 (3,004 ) — 1,597 163 — — — 3,067 4 (2,003 ) — 1,068 114 — — — 3,067 4 (2,003 ) — 1,068 111 — — — 5,000 — 3,485 — 8,485 — Total non-controlled affiliates $ 906 $ — $ — $ 38,599 $ 35 $ (19,055 ) $ — $ 20,485 $ 1,246 ( 1 As of September 30, 2023, no Transactions related to investments in non-controlled affiliated companies for the nine September 30, 2023 Nine months ended September 30, 2023 Fair value at Transfers Net Fair value at Portfolio December 31, Principal in/(out) at Discount unrealized Net realized September 30, Interest Company 2022 Purchases Payments fair value accretion gain/(loss) gain/(loss) 2023 income (In thousands) Aulea Medical, Inc. $ — $ — $ — $ — $ — $ — $ — $ — $ — Cadrenal Therapeutics, Inc. (1) — — — (906 ) — 906 — — — Evelo Biosciences, Inc. — — — 7,665 8 (5,007 ) — 2,666 277 — — — 11,496 11 (7,510 ) — 3,997 415 — — — 4,612 5 (3,013 ) — 1,604 166 — — — 4,598 3 (3,004 ) — 1,597 163 — — — 3,067 4 (2,003 ) — 1,068 114 — — — 3,067 4 (2,003 ) — 1,068 111 — — — 5,000 — 3,485 — 8,485 — Total non-controlled affiliates $ — $ — $ — $ 38,599 $ 35 $ (18,149 ) $ — $ 20,485 $ 1,246 ( 1 As of September 30, 2023, no 5% Transactions related to investments in non-controlled affiliated companies for the three September 30, 2022 Three months ended September 30, 2022 Fair value at Transfers Net Fair value at Portfolio June 30, in/(out) at Discount unrealized Net realized September 30, Interest Company 2022 Purchases Sales fair value Accretion gain/(loss) gain/(loss) 2022 income (In thousands) MVI (ABC) LLC fka StereoVision, Inc. — — (30 ) — — — 30 — — Total non-controlled affiliates $ — $ — $ (30 ) $ — $ — $ — $ 30 $ — $ — Transactions related to investments in non-controlled affiliated companies for the nine September 30, 2022 Nine months ended September 30, 2022 Fair value at Transfers Net Fair value at Portfolio December 31, in/(out) at Discount unrealized Net realized September 30, Interest Company 2021 Purchases Sales fair value Accretion gain/(loss) gain/(loss) 2022 income (In thousands) MVI (ABC) LLC fka StereoVision, Inc. — — (30 ) — — — 30 — — Total non-controlled affiliates $ — $ — $ (30 ) $ — $ — $ — $ 30 $ — $ — A controlled affiliated company is generally a portfolio company in which the Company owns more than 25% Transactions related to investments in controlled affiliated companies for the three September 30, 2023 Three months ended September 30, 2023 Fair value at Transfers Net Fair value at Portfolio June 30, Principal in/(out) at Discount unrealized Net realized September 30, Interest Company 2023 Purchases Payments PIK fair value accretion gain/(loss) gain/(loss) 2023 income (In thousands) Better Place Forests Co. $ — $ 59 $ — $ 105 $ 1,759 $ 2 $ 1,080 $ — $ 3,005 $ 111 — — — 53 844 1 536 — 1,434 55 — — — — 2,061 — — — 2,061 — — 750 — — — — (259 ) — 491 — HIMV LLC — — — — 6,154 — — — 6,154 — Total controlled affiliates $ — $ 809 $ — $ 158 $ 10,818 $ 3 $ 1,357 $ — $ 13,145 $ 166 Transactions related to investments in controlled affiliated companies for the nine September 30, 2023 Nine months ended September 30, 2023 Fair value at Transfers Net Fair value at Portfolio December 31, Principal in/(out) at Discount unrealized Net realized September 30, Interest Company 2022 Purchases Payments PIK fair value accretion gain/(loss) gain/(loss) 2023 income (In thousands) Better Place Forests Co. $ — $ 59 $ — $ 105 $ 1,759 $ 2 $ 1,080 $ — $ 3,005 $ 111 — — — 53 844 1 536 — 1,434 55 — — — — 2,061 — — — 2,061 — — 750 — — — — (259 ) — 491 — HIMV LLC — — — — 6,154 — — — 6,154 — Total controlled affiliates $ — $ 809 $ — $ 158 $ 10,818 $ 3 $ 1,357 $ — $ 13,145 $ 166 Transactions related to investments in controlled affiliated companies for the three September 30, 2022 Three months ended September 30, 2022 Fair value at Transfers Net Fair value at Portfolio June 30, in/(out) at Discount unrealized Net realized September 30, Interest Company 2022 Purchases Sales fair value Accretion gain/(loss) gain/(loss) 2022 income (In thousands) HESP LLC — — (50 ) — — — 50 — — Total controlled affiliates $ — $ — $ (50 ) $ — $ — $ — $ 50 $ — $ — Transactions related to investments in controlled affiliated companies for the nine September 30, 2022 Nine months ended September 30, 2022 Fair value at Transfers Net Fair value at Portfolio December 31, in/(out) at Discount unrealized Net realized September 30, Interest Company 2021 Purchases Sales fair value accretion gain/(loss) gain/(loss) 2022 income (In thousands) HESP LLC — — (300 ) — — 1,450 (1,150 ) — — Total controlled affiliates $ — $ — $ (300 ) $ — $ — $ 1,450 $ (1,150 ) $ — $ —

Note 6 - Fair Value

Note 6 - Fair Value	9 Months Ended
	Sep. 30, 2023
Notes to Financial Statements
Fair Value Disclosures [Text Block]	Note 6. Prior to July 30, 2022, 2a 5 1940 July 29, 2022, twelve The Company uses fair value measurements made by the valuation designee to record fair value adjustments to certain assets and liabilities and to determine fair value disclosures. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Fair value is best determined based upon quoted market prices. However, in certain instances, there are no not may not Fair value measurements focus on exit prices in an orderly transaction (that is, not may The Company’s fair value measurements are classified into a fair value hierarchy in accordance with ASC Topic 820, Fair Value Measurement three Level 1 Quoted prices in active markets for identical assets and liabilities. Level 2 Observable inputs other than Level 1 not Level 3 Unobservable inputs that are supported by little or no 3 Due to the inherent uncertainty of determining the fair value of investments that do not may may may may Cash and interest receivable: not 1 Money market funds: 2 Debt investments: 3 Under certain circumstances, the Company may Warrant investments: ● Underlying asset value of the issuer is estimated based on information available, including any information regarding the most recent rounds of borrower funding. Significant increases (decreases) in this unobservable input would result in a significantly higher (lower) fair value measurement. ● Volatility, or the amount of uncertainty or risk about the size of the changes in the warrant price, is based on indices of publicly traded companies similar in nature to the underlying company issuing the warrant. A total of seven ● The risk-free interest rates are derived from the U.S. Treasury yield curve. The risk-free interest rates are calculated based on a weighted average of the risk-free interest rates that correspond closest to the expected remaining life of the warrant. ● Other adjustments, including a marketability discount on private company warrants, are estimated based on management’s judgment about the general industry environment. ● Historical portfolio experience on cancellations and exercises of the Company’s warrants are utilized as the basis for determining the estimated time to exit of the warrants in each financial reporting period. Warrants may Under certain circumstances the Company may may The fair value of the Company’s warrants held in publicly traded companies is determined based on inputs that are readily available in public markets or can be derived from information available in public markets. Therefore, the Company has categorized these warrants as Level 2 3 Equity investments: third may 3 1 Other investments: 3 The following tables detail the investments that are carried at fair value and measured at fair value on a recurring basis as of September 30, 2023 December 31, 2022 September 30, 2023 Level 1 Level 2 Level 3 Total (In thousands) Debt investments $ — $ — $ 679,838 $ 679,838 Warrant investments — 956 25,233 26,189 Other investments — — 7,254 7,254 Equity investments 8,962 — 6,810 15,772 Total investments $ 8,962 $ 956 $ 719,135 $ 729,053 December 31, 2022 Level 1 Level 2 Level 3 Total (In thousands) Debt investments $ — $ — $ 686,458 $ 686,458 Warrant investments — 3,567 26,145 29,712 Other investments — — 1,300 1,300 Equity investments 140 — 2,416 2,556 Total investments $ 140 $ 3,567 $ 716,319 $ 720,026 The following tables provide a summary of quantitative information about the Company’s Level 3 September 30, 2023 December 31, 2022 may The following table is not 3 September 30, 2023 September 30, 2023 Fair Valuation Techniques/ Unobservable Weighted Investment Type Value Methodologies Input Range Average(1) (Dollars in thousands, except per share data) Debt investments $ 607,193 Discounted Expected Future Cash Flows Hypothetical Market Yield 11% – 20% 14 % 72,645 Multiple Probability Weighted Cash Flow Model Probability Weighting 20% - 100% 50 % Warrant investments 25,171 Black-Scholes Valuation Model Price Per Share 0.000 –1,89999 $ 58.11 Average Industry Volatility 28% 28 % Marketability Discount 20% 20 % Estimated Time to Exit (in years) 1 to 5 3 62 Expected Proceeds Price Per Share $0.25 $ 0.25 Other investments 7,254 Multiple Probability Weighted Cash Flow Model Discount Rate 25% 25 % Probability Weighting 30% – 100% 83 % Equity investments 6,810 Last Equity Financing Price Per Share 0.03 215.03 $ 18.30 Total Level 3 investments $ 719,135 ( 1 Weighted average is calculated by multiplying (a) the unobservable input for each investment in the investment type by (b) ( 1 2 The following table is not 3 December 31, 2022 December 31, 2022 Fair Valuation Techniques/ Unobservable Weighted Investment Type Value Methodologies Input Range Average(1) (Dollars in thousands, except per share data) Debt investments $ 669,617 Discounted Expected Future Cash Flows Hypothetical Market Yield 3% – 22% 14 % 16,545 Multiple Probability Weighted Cash Flow Model Probability Weighting 10% - 75% 31 % 296 Convertible Note Analysis Price Per Share $168.93 $ 168.93 Warrant investments 26,145 Black-Scholes Valuation Model Price Per Share 0.000 –1.8989 $ 58.52 Average Industry Volatility 28% 28 % Marketability Discount 20% 20 % Estimated Time to Exit (in years) 1 to 5 3 Other investments 1,300 Multiple Probability Weighted Cash Flow Model Discount Rate 25% 25 % Probability Weighting 100% 100 % Equity investments 2,416 Last Equity Financing Price Per Share $1.00– $215.03 $ 26.93 Total Level 3 investments $ 716,319 ( 1 Weighted average is calculated by multiplying (a) the unobservable input for each investment in the investment type by (b) ( 1 2 Borrowings: 2 2026 7 September 30, 2023 2026 1 2027 7 September 30, 2023 2027 1 September 30, 2023 2019 3 September 30, 2023 2022 3 not Off-balance-sheet instruments: 3 The following table shows a reconciliation of the beginning and ending balances for Level 3 three September 30, 2023 Three months ended September 30, 2023 Debt Warrant Equity Other Investments Investments Investments Investments Total (In thousands) Level 3 assets, beginning of period $ 683,309 $ 24,376 $ 4,259 $ 1,300 $ 713,244 Purchase of investments 66,185 — 750 — 66,935 Warrants received and classified as Level 3 — 1,294 — — 1,294 Principal payments received on investments (25,726 ) — — — (25,726 ) Payment-in-kind interest on investments 3,934 — — — 3,934 Proceeds from sale of investments (2,528 ) (23 ) (6 ) — (2,557 ) Net realized (loss) gain on investments (11,440 ) (118 ) 6 — (11,552 ) Unrealized depreciation included in earnings (18,877 ) (296 ) (1,349 ) (200 ) (20,722 ) Transfer out of Level 3 (5,000 ) — — — (5,000 ) Transfer out of debt investments (9,304 ) — 3,150 6,154 — Other (715 ) — — — (715 ) Level 3 assets, end of period $ 679,838 $ 25,233 $ 6,810 $ 7,254 $ 719,135 During the three September 30, 2023 one 3. one 3 one 1 The following table shows a reconciliation of the beginning and ending balances for Level 3 three September 30, 2022 Three months ended September 30, 2022 Debt Warrant Equity Other Investments Investments Investments Investments Total (In thousands) Level 3 assets, beginning of period $ 551,560 $ 25,167 $ 453 $ 200 $ 577,380 Purchase of investments 94,627 — — — 94,627 Warrants received and classified as Level 3 — 964 — — 964 Principal payments received on investments (26,929 ) — — (31 ) (26,960 ) Proceeds from sale of investments (6,088 ) (38 ) — — (6,126 ) Net realized (loss) gain on investments (8,492 ) 266 — 31 (8,195 ) Unrealized appreciation (depreciation) included in earnings 8,095 (3,348 ) (420 ) (100 ) 4,227 Transfer out of Level 3 — (1,117 ) — — (1,117 ) Transfer out of debt investments (3,200 ) — 2,000 1,200 — Other (541 ) — — — (541 ) Level 3 assets, end of period $ 609,032 $ 21,894 $ 2,033 $ 1,300 $ 634,259 During the three September 30, 2022 two 3 . 3 one 2 3 one 1 The following table shows a reconciliation of the beginning and ending balances for Level 3 nine September 30, 2023 Nine months ended September 30, 2023 Debt Warrant Equity Other Investments Investments Investments Investments Total (In thousands) Level 3 assets, beginning of period $ 686,458 $ 26,145 $ 2,416 $ 1,300 $ 716,319 Purchase of investments 153,728 — 760 — 154,488 Warrants and equity received and classified as Level 3 — 1,950 89 — 2,039 Principal payments received on investments (90,222 ) — — — (90,222 ) Payment-in-kind interest on investments 6,088 — — — 6,088 Proceeds from sale of investments (9,564 ) (1,493 ) (6 ) — (11,063 ) Net realized (loss) gain on investments (29,105 ) 1,028 (121 ) — (28,198 ) Unrealized depreciation included in earnings (21,325 ) (2,392 ) (2,467 ) (200 ) (26,384 ) Transfer out of Level 3 (5,000 ) — (111 ) — (5,111 ) Transfer out of debt investments (12,399 ) (5 ) 6,250 6,154 — Other 1,179 — — — 1,179 Level 3 assets, end of period $ 679,838 $ 25,233 $ 6,810 $ 7,254 $ 719,135 During the nine September 30, 2023 two 3. 3 one 1 one 1 The change in unrealized depreciation included in the consolidated statement of operations attributable to Level 3 September 30, 2023 The following table shows a reconciliation of the beginning and ending balances for Level 3 nine September 30, 2022 Nine months ended September 30, 2022 Debt Warrant Equity Other Investments Investments Investments Investments Total (In thousands) Level 3 assets, beginning of period $ 437,317 $ 19,837 $ 203 $ 200 $ 457,557 Purchase of investments 348,097 — 250 — 348,347 Warrants received and classified as Level 3 — 2,441 — — 2,441 Principal payments received on investments (114,120 ) — — (313 ) (114,433 ) Proceeds from sale of investments (49,088 ) (464 ) — — (49,552 ) Net realized (loss) gain on investments (8,492 ) 535 — (1,137 ) (9,094 ) Unrealized appreciation (depreciation) included in earnings 1,128 662 (420 ) 1,350 2,720 Transfer out of Level 3 — (1,117 ) — — (1,117 ) Transfer out of debt investments (3,200 ) — 2,000 1,200 — Other (2,610 ) — — — (2,610 ) Level 3 assets, end of period $ 609,032 $ 21,894 $ 2,033 $ 1,300 $ 634,259 During the nine September 30, 2022 two 3 . 3 one 2 3 one 1 The change in unrealized appreciation included in the consolidated statement of operations attributable to Level 3 September 30, 2022 The Company discloses fair value information about financial instruments, whether or not not The fair value amounts have been measured as of the reporting date and have not may As of September 30, 2023 December 31, 2022 Market risk The Company assumes interest rate risk (the risk that general interest rate levels will change) as a result of its normal operations. As a result, the fair values of the Company’s financial instruments will change when interest rate levels change, and that change may

Note 7 - Borrowings

Note 7 - Borrowings	9 Months Ended
	Sep. 30, 2023
Notes to Financial Statements
Debt Disclosure [Text Block]	Note 7. The following table shows the Company’s borrowings as of September 30, 2023 December 31, 2022 September 30, 2023 December 31, 2022 Total Balance Unused Total Balance Unused Commitment Outstanding Commitment Commitment Outstanding Commitment (In thousands) Key Facility $ 150,000 $ 25,000 $ 125,000 $ 125,000 $ 5,000 $ 120,000 NYL Facility 250,000 181,000 69,000 200,000 176,750 23,250 2019 Asset-Backed Notes 18,696 18,696 — 42,573 42,573 — 2022 Asset-Backed Notes 100,000 100,000 — 100,000 100,000 — 2027 Notes 57,500 57,500 — 57,500 57,500 — 2026 Notes 57,500 57,500 — 57,500 57,500 — Total before debt issuance costs 633,696 439,696 194,000 582,573 439,323 143,250 Unamortized debt issuance costs attributable to term borrowings — (4,196 ) — — (5,245 ) — Total borrowings outstanding, net $ 633,696 $ 435,500 $ 194,000 $ 582,573 $ 434,078 $ 143,250 As of September 30, 2023 1940 September 30, 2023 Credit Facilities Key Facility The Company entered into the Key Facility with Key effective November 4, 2013. June 29, 2023, may June 22, 2024 June 22, 2026. September 30, 2023 December 31, 2022 three September 30, 2023 2022 nine September 30, 2023 2022 September 30, 2023 December 31, 2022 September 30, 2023 December 31, 2022 NYL Facility On April 21, 2020, June 1, 2018, three On February 25, 2022, three On May 24, 2023, June 2024 June 2029. May 24, 2023, 4.60% 3.50%, There were $181.0 million and $176.8 million in advances made by the NYL Noteholders as of September 30, 2023 December 31, 2022 September 30, 2023 December 31, 2022 September 30, 2023 December 31, 2022 September 30, 2023 December 31, 2022 Under the terms of the NYL Facility, the Company is required to maintain a reserve cash balance, which may September 30, 2023 December 31, 2022 Securitizations 2019 On August 13, 2019, 2019 2019 no August 13, 2019. The 2019 2019‑1 August 13, 2019, 2019 2019 July 15, 2021 September 15, 2027. As of September 30, 2023 December 31, 2022 2019 Under the terms of the 2019 2019 may 2019 September 30, 2023 December 31, 2022 2022 On November 9, 2022, 2022 2022 no November 9, 2022. The 2022 2022‑1 November 9, 2022, 2022 2022 November 15, 2024 November 15, 2030. As of September 30, 2023 December 31, 2022 2022 $100.0 Under the terms of the 2022 2022 may 2022 September 30, 2023 December 31, 2022 Unsecured Notes 2026 On March 30, 2021, 2026 “2026 2026 2026 March 30, 2026 may March 30, 2023 2026 4.875% March 30, June 30, September 30 December 30 2026 2026 September 30, 2023 2026 2026 2027 On June 15, 2022, 2027 July 11, 2022, 30 “2027 2027 June 15, 2027 may June 15, 2024 2027 6.25% March 30, June 30, September 30 December 30 September 30, 2022. 2027 2027 September 30, 2023 2027 2027

Note 8 - Financial Instruments

Note 8 - Financial Instruments With Off-balance-sheet Risk	9 Months Ended
	Sep. 30, 2023
Notes to Financial Statements
Financial Instruments Disclosure [Text Block]	Note 8. In the normal course of business, the Company is party to financial instruments with off-balance-sheet risk to meet the financing needs of its borrowers. These financial instruments include commitments to extend credit and involve, to varying degrees, elements of credit risk in excess of the amount recognized in the consolidated statement of assets and liabilities. The Company attempts to limit its credit risk by conducting extensive due diligence and obtaining collateral where appropriate. The balance of unfunded commitments to extend credit was $181.8 million and $190.0 million as of September 30, 2023 December 31, 2022 may not The following table provides the Company’s unfunded commitments by portfolio company as of September 30, 2023 December 31, 2022 September 30, 2023 December 31, 2022 Fair Value of Fair Value of Unfunded Unfunded Principal Commitment Principal Commitment Balance Liability Balance Liability (In thousands) (In thousands) BrightInsight, Inc. $ 18,250 $ 241 $ 21,000 $ 278 Britecore Holdings, Inc. 5,000 72 5,000 66 Candesant Biomedical Corporation 10,000 151 — — Castle Creek Biosciences 4,000 72 4,000 72 Divergent Technologies, Inc. 11,250 118 22,500 236 Elligo Healthcare Research, Inc. 15,000 194 — — Engage3, LLC — — 8,000 40 Groundspeed Analytics, Inc. — — 15,000 150 Hound Labs, Inc. — — 7,500 88 KSQ Therapeutics, Inc. — — 10,000 100 Lytics, Inc. 4,000 52 5,000 65 Mirantis, Inc. 15,000 136 — — Native Microbials, Inc. — — 7,500 72 Noodle Partners, Inc. 5,000 61 — — Optoro, Inc. 6,250 — 15,000 38 PDS Biotechnology Corporation — — 10,000 158 Robin Healthcare, Inc. — — 10,000 100 SafelyYou, Inc. 20,000 270 — — Scientia Vascular, Inc. 5,000 55 10,000 110 Slingshot Aerospace, Inc. — — 5,000 64 Sonex Health, Inc. 15,000 176 — — Supply Network Visibility Holdings, LLC 10,000 35 — — Swift Health Systems Inc. 11,500 — 25,500 105 Tallac Therapeutics, Inc. 10,000 229 — — Temperpack Technologies, Inc. 6,500 14 9,000 19 Viken Detection Corporation 10,000 160 — — Total $ 181,750 $ 2,036 $ 190,000 $ 1,761 The table above also provides the fair value of the Company’s unfunded commitment liability as of September 30, 2023 December 31, 2022,

Note 9 - Concentrations of Cred

Note 9 - Concentrations of Credit Risk	9 Months Ended
	Sep. 30, 2023
Notes to Financial Statements
Concentration Risk Disclosure [Text Block]	Note 9. The Company’s debt investments consist primarily of loans to development-stage companies at various stages of development in the technology, life science, healthcare information and services and sustainability industries. Many of these companies may may The Company’s largest debt investments may five September 30, 2023 December 31, 2022 five September 30, 2023 December 31, 2022, No 10% September 30, 2023 December 31, 2022 five three September 30, 2023 2022 five three September 30, 2023 2022, five nine September 30, 2023 2022 five nine September 30, 2023 2022,

Note 10 - Distributions

Note 10 - Distributions	9 Months Ended
	Sep. 30, 2023
Notes to Financial Statements
Equity [Text Block]	Note 10. The Company’s distributions are recorded on the declaration date. The following table summarizes the Company’s distribution activity for the nine September 30, 2023 December 31, 2022 DRIP DRIP Date Amount Cash Shares Share Declared Record Date Payment Date Per Share Distribution Issued Value (In thousands, except share and per share data) Nine Months Ended September 30, 2023 7/28/2023 11/17/23 12/15/23 $ 0.11 $ — — $ — 7/28/2023 10/18/23 11/15/23 0.11 — — — 7/28/2023 9/19/23 10/16/23 0.11 3,445 15,067 184 4/28/2023 8/17/23 9/15/23 0.11 3,458 8,665 106 4/28/2023 7/18/23 8/15/23 0.11 3,427 8,307 105 4/28/2023 6/16/23 7/14/23 0.11 3,434 7,424 96 2/23/2023 5/18/23 6/14/23 0.11 3,087 7,128 86 2/23/2023 4/18/23 5/16/23 0.11 3,068 6,705 84 2/23/2023 3/17/23 4/14/23 0.11 3,035 6,894 81 $ 0.99 $ 22,954 60,190 $ 742 Year Ended December 31, 2022 10/28/2022 2/17/23 3/15/23 $ 0.11 $ 3,040 6,764 $ 75 10/28/2022 1/18/23 2/15/23 0.11 3,021 5,754 74 10/28/2022 12/19/22 1/13/23 0.11 2,978 5,618 69 10/28/2022 11/17/22 12/15/22 0.05 1,319 2,171 27 7/29/2022 11/17/22 12/15/22 0.10 2,638 4,341 57 7/29/2022 10/18/22 11/15/22 0.10 2,580 4,621 60 7/29/2022 9/19/22 10/14/22 0.10 2,558 7,703 81 4/29/2022 8/18/22 9/15/22 0.10 2,528 4,925 60 4/29/2022 7/19/22 8/16/22 0.10 2,484 3,939 55 4/29/2022 6/17/22 7/15/22 0.10 2,434 4,286 51 2/25/2022 5/18/22 6/15/22 0.10 2,378 4,428 50 2/25/2022 4/19/22 5/16/22 0.10 2,349 4,088 49 2/25/2022 3/18/22 4/14/22 0.10 2,352 3,221 46 $ 1.28 $ 32,659 61,859 $ 754 On October 27, 2023, Monthly distributions Ex-Dividend Date Record Date Payment Date Distributions Declared February 15, 2024 February 16, 2024 March 15, 2024 $ 0.11 January 17, 2024 January 18, 2024 February 14, 2024 $ 0.11 December 18, 2023 December 19, 2023 January 16, 2024 $ 0.11 Special distribution Ex-Dividend Date Record Date Payment Date Distributions Declared November 16, 2023 November 17, 2023 December 15, 2023 $ 0.05 After paying distributions of $0.33 per share and earning net investment income of $0.53 per share for the quarter, the Company’s undistributed spillover income as of September 30, 2023 not

Note 11 - Financial Highlights

Note 11 - Financial Highlights	9 Months Ended
	Sep. 30, 2023
Notes to Financial Statements
Investment Company, Financial Highlights [Text Block]	Note 11. The following table shows financial highlights for the Company: Nine months ended September 30, 2023 2022 (In thousands, except share and per share data) Per share data: Net asset value at beginning of period $ 11.47 $ 11.56 Net investment income 1.54 1.06 Realized loss (0.95 ) (0.40 ) Unrealized (depreciation) appreciation on investments (0.81 ) 0.05 Net increase in net assets resulting from operations (0.22 ) 0.71 Distributions declared (1) (0.99 ) (0.90 ) From net investment income (0.99 ) (0.90 ) From net realized gain on investments — — Return of capital — — Other (2) 0.15 0.29 Net asset value at end of period $ 10.41 $ 11.66 Per share market value, beginning of period $ 11.60 $ 15.92 Per share market value, end of period $ 11.88 $ 10.01 Total return based on a market value (3) 10.9 % (31.5 )% Shares outstanding at end of period 33,306,958 26,393,773 Ratios to average net assets: Expenses without incentive value (4) 14.0 % 11.4 % Incentive fees (4) 1.2 % 3.0 % Net expenses (4) 15.2 % 14.4 % Net investment income with incentive fees (4) 18.5 % 12.1 % Net assets at the end of the period $ 346,575 $ 307,687 Average net asset value $ 335,531 $ 280,904 Average debt per share $ 14.29 $ 13.32 Portfolio turnover ratio 10.0 % (5) 14.9 % (5) ( 1 Distributions are determined based on taxable income calculated in accordance with income tax regulations, which may ( 2 Includes the impact of the different share amounts as a result of calculating per share data based on the weighted average basic shares outstanding during the period and certain per share data based on the shares outstanding as of a period end or transaction date. The issuance of common stock on a per share basis reflects the incremental net asset value changes as a result of the issuance of common stock in the Company’s continuous public offering and pursuant to the Company’s distribution reinvestment plan. The issuance of common stock at an offering price, net of sales commissions and dealer manager fees, that is greater than the net asset value per share results in an increase in net asset value per share. ( 3 The total return equals the change in the ending market value over the beginning of period price per share plus distributions paid per share during the period, divided by the beginning price. ( 4 Annualized. ( 5 Calculated by dividing the lesser of purchases or the sum of ( 1 2

Note 12 - Subsequent Events

Note 12 - Subsequent Events	9 Months Ended
	Sep. 30, 2023
Notes to Financial Statements
Subsequent Events [Text Block]	Note 12. On October 27, 2023 , $11.0 December 15, 2022, As of October 30, 2023, September 30, 2023

Significant Accounting Policies

Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2023
Accounting Policies [Abstract]
Consolidation, Policy [Policy Text Block]	Principles of consolidation As required under GAAP and Regulation S- X, Assets related to transactions that do not 860, Transfers and Servicing 2019‑1 2022 1 not
Use of Estimates, Policy [Policy Text Block]	Use of estimates In preparing the consolidated financial statements in accordance with GAAP, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities, and disclosures of contingent assets and liabilities, as of the date of the balance sheet and income and expenses for the period. Actual results could differ from those estimates. Material estimates that are particularly susceptible to significant change in the near term relate to the valuation of investments.
Fair Value Measurement, Policy [Policy Text Block]	Fair value The Company records all of its investments at fair value in accordance with relevant GAAP, which establishes a framework used to measure fair value and requires disclosures for fair value measurements. The Company has categorized its investments carried at fair value, based on the priority of the valuation technique, into a three 6. not The availability of observable inputs can vary depending on the financial instrument and is affected by a wide variety of factors, including, for example, the type of product, whether the product is new, whether the product is traded on an active exchange or in the secondary market and the current market conditions. To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for financial instruments classified as Level 3. See Note 6
Segment Reporting, Policy [Policy Text Block]	Segments The Company has determined that it has a single reporting segment and operating unit structure. The Company lends to and invests in portfolio companies in various technology, life science, healthcare information and services and sustainability industries. The Company separately evaluates the performance of each of its lending and investment relationships. However, because each of these debt investments and investment relationships has similar business and economic characteristics, they have been aggregated into a single lending and investment segment.
Investment, Policy [Policy Text Block]	Investments Investments are recorded at fair value. Pursuant to the amended SEC Rule 2a 5 1940 July 29, 2022, Interest on debt investments is accrued and included in income based on contractual rates applied to principal amounts outstanding. Interest income is determined using a method that results in a level rate of return on principal amounts outstanding. Generally, when a debt investment becomes 90 not may may September 30, 2023 three December 31, 2022 three three nine September 30, 2023 2022, not The Company has a limited number of debt investments in its portfolio that contain a PIK provision. Contractual PIK interest, which represents contractually deferred interest added to the loan balance that is generally due at the end of the loan term, is generally recorded on an accrual basis to the extent such amounts are expected to be collected. The Company will generally cease accruing PIK interest if there is insufficient value to support the accrual or management does not three nine September 30, 2023 three nine September 30, 2022 The Company receives a variety of fees from borrowers in the ordinary course of conducting its business, including advisory fees, commitment fees, amendment fees, non-utilization fees, success fees and prepayment fees. In a limited number of cases, the Company may Certain debt investment agreements also require the borrower to make an ETP, that is accrued into interest receivable and taken into income over the life of the debt investment to the extent such amounts are expected to be collected. The Company will generally cease accruing the income if there is insufficient value to support the accrual or the Company does not not three September 30, 2023 2022 not nine September 30, 2023 2022 In connection with substantially all lending arrangements, the Company receives warrants to purchase shares of stock from the borrower. The warrants are recorded as assets at estimated fair value on the grant date using the Black-Scholes valuation model. The warrants are considered loan fees and are recorded as unearned income on the grant date. The unearned income is recognized as interest income over the contractual life of the related debt investment in accordance with the Company’s income recognition policy. Subsequent to debt investment origination, the fair value of the warrants is determined using the Black-Scholes valuation model. Any adjustment to fair value is recorded through earnings as net unrealized appreciation or depreciation on investments. Gains and losses from the disposition of the warrants or stock acquired from the exercise of warrants are recognized as realized gains and losses on investments. Realized gains or losses on the sale of investments, or upon the determination that an investment balance, or portion thereof, is not
Debt, Policy [Policy Text Block]	Debt issuance costs Debt issuance costs are fees and other direct incremental costs incurred by the Company in obtaining debt financing from its lenders and issuing debt securities. The unamortized balance of debt issuance costs as of September 30, 2023 December 31, 2022 September 30, 2023 December 31, 2022 three September 30, 2023 2022 nine September 30, 2023 2022
Income Tax, Policy [Policy Text Block]	Income taxes As a BDC, the Company has elected to be treated as a RIC under Subchapter M of the Code and operates in a manner so as to qualify for the tax treatment applicable to RICs. In order to qualify as a RIC and to avoid the imposition of corporate-level income tax on the portion of its taxable income distributed to stockholders, among other things, the Company is required to meet certain source of income and asset diversification requirements and to timely distribute dividends out of assets legally available for distribution to its stockholders of an amount generally at least equal to 90% no 946, Financial Services Investment Companies no Depending on the level of taxable income earned in a tax year, the Company may three September 30, 2023 2022, nine September 30, 2023 2022, The Company evaluates tax positions taken in the course of preparing the Company’s tax returns to determine whether the tax positions are “more-likely-than- not” 740, Income Taxes 946. not not no September 30, 2023 December 31, 2022 2022, 2021 2020
Distributions [Policy Text Block]	Distributions Distributions to common stockholders are recorded on the declaration date. The amount to be paid out as distributions is determined by the Board. Net realized capital gains, if any, may may The Company has adopted a dividend reinvestment plan that provides for reinvestment of cash distributions on behalf of its stockholders, unless a stockholder elects to receive cash. As a result, if the Board declares a cash distribution, then stockholders who have not may
Stockholders' Equity, Policy [Policy Text Block]	Stockholders Equity On August 2, 2021, “2021 2021 may On September 22, 2023, 2021 “2023 2021 2023 may may 415 During the three September 30, 2023 2023 2021 During the three September 30, 2022 2021 During the nine September 30, 2023 2023 2021 During the nine September 30, 2022, 2021 The Company generally uses net proceeds from these sales to make investments, to pay down liabilities and for general corporate purposes. As of September 30, 2023 2023 On March 14, 2022, On June 2, 2023,
Stock Repurchase Program [Policy Text Block]	Stock Repurchase Program On April 28, 2023, may, not 10b‑18 1934, 1940 June 30, 2024 $5.0 three nine September 30, 2023 2022 not September 30, 2023
Transfers and Servicing of Financial Assets, Policy [Policy Text Block]	Transfers of financial assets Assets related to transactions that do not 860, Transfers and Servicing not Transfers of financial assets are accounted for as sales when control over the assets has been surrendered. Control over transferred assets is deemed to be surrendered when ( 1 2 3 not
New Accounting Pronouncements, Policy [Policy Text Block]	Recently issued accounting pronouncement In June 2022, No. 2022 03, 2022 03” 2022 03 2022 03 December 15, 2023, 2022 03

Consolidated Schedule of Inve_2

Consolidated Schedule of Investments (Unaudited) (Tables)	9 Months Ended
	Sep. 30, 2023
Notes Tables
Investment [Table Text Block]	Portfolio Company (1)(3) Sector Type of Investment (7) Cash Rate (4) Index Margin Floor Ceiling ETP (10) Maturity Date Principal Amount Cost of Investments (6)(9) Fair Value (9) Non-Affiliate Investments — 200.7% Non-Affiliate Debt Investments — 191.4% Non-Affiliate Debt Investments — Life Science — 69.7% Castle Creek Biosciences, Inc. (2)(12) Biotechnology Term Loan 13.25 % Prime 4.75 % 9.55 % 13.50 % 5.50 % May 1, 2026 5,000 4,903 4,903 Term Loan 13.25 % Prime 4.75 % 9.55 % 13.50 % 5.50 % May 1, 2026 5,000 4,975 4,975 Term Loan 13.25 % Prime 4.75 % 9.55 % 13.50 % 5.50 % May 1, 2026 3,000 2,985 2,985 Term Loan 13.25 % Prime 4.75 % 9.55 % 13.50 % 5.50 % May 1, 2026 5,000 4,975 4,975 Term Loan 13.25 % Prime 4.75 % 9.55 % 13.50 % 5.50 % May 1, 2026 5,000 4,975 4,975 Term Loan 13.25 % Prime 4.75 % 9.55 % 13.50 % 5.50 % May 1, 2026 3,000 2,985 2,985 Emalex Biosciences, Inc. (2)(12) Biotechnology Term Loan 13.22 % Prime 4.72 % 9.75 % - 5.00 % June 1, 2024 1,979 1,971 1,971 Term Loan 13.22 % Prime 4.72 % 9.75 % - 5.00 % June 1, 2024 1,979 1,972 1,972 Term Loan 13.22 % Prime 4.72 % 9.75 % - 5.00 % November 1, 2025 5,000 4,943 4,943 Term Loan 13.22 % Prime 4.72 % 9.75 % - 5.00 % May 1, 2026 5,000 4,939 4,939 Greenlight Biosciences, Inc. (2)(12) Biotechnology Term Loan 14.25 % Prime 5.75 % 9.00 % - 3.00 % July 1, 2025 3,500 3,399 3,365 Term Loan 14.25 % Prime 5.75 % 9.00 % - 3.00 % July 1, 2025 1,750 1,699 1,684 KSQ Therapeutics, Inc. (2)(12) Biotechnology Term Loan 13.25 % Prime 4.75 % 8.50 % - 5.50 % May 1, 2027 6,250 6,193 6,193 Term Loan 13.25 % Prime 4.75 % 8.50 % - 5.50 % May 1, 2027 6,250 6,193 6,193 Native Microbials, Inc (2)(12) Biotechnology Term Loan 13.75 % Prime 5.25 % 8.50 % - 5.00 % November 1, 2026 3,750 3,716 3,716 Term Loan 13.75 % Prime 5.25 % 8.50 % - 5.00 % November 1, 2026 2,500 2,478 2,478 PDS Biotechnology Corporation (2)(5)(12) Biotechnology Term Loan 14.25 % Prime 5.75 % 9.75 % - 3.75 % September 1, 2026 10,000 9,898 9,898 Term Loan 14.25 % Prime 5.75 % 9.75 % - 3.75 % September 1, 2026 3,750 3,712 3,712 Term Loan 14.25 % Prime 5.75 % 9.75 % - 3.75 % September 1, 2026 3,750 3,712 3,712 Provivi, Inc. (2)(12) Biotechnology Term Loan 13.86 % Prime 5.36 % 9.50 % - 5.50 % December 1, 2024 4,667 4,594 4,594 Term Loan 13.86 % Prime 5.36 % 9.50 % - 5.50 % December 1, 2024 4,667 4,594 4,594 Term Loan 13.86 % Prime 5.36 % 9.50 % - 5.50 % December 1, 2024 2,333 2,286 2,286 Term Loan 13.86 % Prime 5.36 % 9.50 % - 5.50 % December 1, 2024 2,333 2,286 2,286 Term Loan 13.86 % Prime 5.36 % 9.50 % - 5.50 % December 1, 2024 2,333 2,282 2,282 Term Loan 13.86 % Prime 5.36 % 9.50 % - 5.50 % December 1, 2024 2,333 2,282 2,282 Stealth Biotherapeutics Inc. (2)(12) Biotechnology Term Loan 14.00 % Prime 5.50 % 8.75 % - 6.00 % October 1, 2025 4,500 4,434 4,434 Term Loan 14.00 % Prime 5.50 % 8.75 % - 6.00 % October 1, 2025 2,250 2,217 2,217 Tallac Therapeutics, Inc. (2)(12) Biotechnology Term Loan 12.75 % Prime 4.25 % 12.25 % - 4.00 % August 1, 2027 2,500 2,226 2,226 Term Loan 12.75 % Prime 4.25 % 12.25 % - 4.00 % August 1, 2027 2,500 2,455 2,455 Aerobiotix, LLC (2)(12) Medical Device Term Loan 9.00 % Fixed - - - 18.00 % April 1, 2028 2,500 2,466 2,344 Term Loan 9.00 % Fixed - - - 18.00 % April 1, 2028 2,500 2,466 2,344 Term Loan 9.00 % Fixed - - - 18.00 % June 30, 2024 200 200 190 Candesant Biomedical, Inc. (2)(12) Medical Device Term Loan 12.00 % Prime 3.50 % 11.50 % - 5.00 % September 1, 2027 5,000 4,751 4,751 Term Loan 12.00 % Prime 3.50 % 11.50 % - 5.00 % September 1, 2027 2,500 2,451 2,451 Term Loan 12.00 % Prime 3.50 % 11.50 % - 5.00 % September 1, 2027 2,500 2,451 2,451 Ceribell, Inc. (2)(12) Medical Device Term Loan 12.00 % Prime 3.50 % 8.25 % - 5.50 % October 1, 2024 5,000 4,985 4,985 Term Loan 12.00 % Prime 3.50 % 8.25 % - 5.50 % October 1, 2024 5,000 4,985 4,985 Term Loan 12.00 % Prime 3.50 % 8.25 % - 5.50 % October 1, 2024 2,500 2,488 2,488 Term Loan 12.00 % Prime 3.50 % 8.25 % - 5.50 % October 1, 2024 2,500 2,488 2,488 Cognoa, Inc. (2)(12) Medical Device Term Loan 14.00 % Prime 5.50 % 8.75 % - 6.00 % August 1, 2026 4,722 4,678 4,678 Term Loan 14.00 % Prime 5.50 % 8.75 % - 6.00 % August 1, 2026 2,361 2,339 2,339 Conventus Orthopaedics, Inc. (2)(12) Medical Device Term Loan 13.32 % Prime 4.82 % 9.25 % - 10.36 % July 1, 2025 3,960 3,916 3,916 Term Loan 13.32 % Prime 4.82 % 9.25 % - 10.36 % July 1, 2025 3,960 3,916 3,916 CSA Medical, Inc. (2)(12) Medical Device Term Loan 13.59 % Prime 5.09 % 10.00 % - 5.00 % January 1, 2024 750 739 739 Term Loan 13.59 % Prime 5.09 % 10.00 % - 5.00 % January 1, 2024 50 49 49 Term Loan 13.59 % Prime 5.09 % 10.00 % - 5.00 % March 1, 2024 1,067 1,052 1,052 InfoBionic, Inc. (2)(12) Medical Device Term Loan 14.75 % Prime 6.25 % 9.50 % - 4.00 % October 1, 2024 2,771 2,733 2,733 Term Loan 14.75 % Prime 6.25 % 9.50 % - 4.00 % June 1, 2025 1,000 982 982 Magnolia Medical Technologies, Inc. (2)(12) Medical Device Term Loan 13.50 % Prime 5.00 % 9.75 % - 4.00 % March 1, 2025 5,000 4,960 4,960 Term Loan 13.50 % Prime 5.00 % 9.75 % - 4.00 % March 1, 2025 5,000 4,960 4,960 Term Loan 13.50 % Prime 5.00 % 9.75 % - 4.00 % March 1, 2025 5,000 4,956 4,956 Term Loan 13.50 % Prime 5.00 % 9.75 % - 4.00 % March 1, 2025 5,000 4,956 4,956 Term Loan 13.50 % Prime 5.00 % 9.75 % - 4.00 % January 1, 2027 5,000 4,934 4,934 Term Loan 13.50 % Prime 5.00 % 9.75 % - 4.00 % January 1, 2027 5,000 4,934 4,934 Portfolio Company (1)(3) Sector Type of Investment (7) Cash Rate (4) Index Margin Floor Ceiling ETP (10) Maturity Date Principal Amount Cost of Investments (6)(9) Fair Value (9) Robin Healthcare, Inc. (2)(12)(13) Medical Device Term Loan 14.00 % Prime 5.50 % 10.25 % - 4.00 % November 1, 2026 3,500 3,468 1,749 Term Loan 14.00 % Prime 5.50 % 10.25 % - 4.00 % November 1, 2026 3,500 3,468 1,749 Scientia Vascular, Inc. (2)(12) Medical Device Term Loan 13.25 % Prime 4.75 % 8.50 % - 5.00 % January 1, 2027 3,750 3,663 3,663 Term Loan 13.25 % Prime 4.75 % 8.50 % - 5.00 % January 1, 2027 3,750 3,718 3,718 Term Loan 13.75 % Prime 5.25 % 9.00 % - 5.00 % March 1, 2027 5,000 4,938 4,938 Sonex Health, Inc. (2)(12) Medical Device Term Loan 12.00 % Prime 3.50 % 11.75 % - 8.00 % September 1, 2027 2,500 2,295 2,295 Term Loan 12.00 % Prime 3.50 % 11.75 % - 8.00 % September 1, 2027 2,500 2,471 2,471 Term Loan 12.00 % Prime 3.50 % 11.75 % - 8.00 % September 1, 2027 5,000 4,943 4,943 Term Loan 12.00 % Prime 3.50 % 11.75 % - 8.00 % September 1, 2027 5,000 4,943 4,943 Spineology, Inc. (2)(12) Medical Device Term Loan 15.50 % Prime 7.00 % 10.25 % - 1.00 % October 1, 2025 5,000 4,975 4,975 Term Loan 15.50 % Prime 7.00 % 10.25 % - 1.00 % April 1, 2026 2,500 2,487 2,487 Swift Health Systems Inc. (2)(12) Medical Device Term Loan 13.75 % Prime 5.25 % 9.00 % - 5.00 % July 1, 2027 3,500 3,464 3,464 Term Loan 13.75 % Prime 5.25 % 9.00 % - 5.00 % July 1, 2027 3,500 3,464 3,464 Term Loan 13.75 % Prime 5.25 % 9.00 % - 5.00 % July 1, 2027 3,500 3,453 3,453 Term Loan 13.75 % Prime 5.25 % 9.00 % - 5.00 % July 1, 2027 3,500 3,453 3,453 Total Non-Affiliate Debt Investments — Life Science 245,317 241,576 Non-Affiliate Debt Investments — Sustainability — 23.8% New Aerofarms, Inc. assignee of Aerofarms, Inc. (2)(12)(15) Other Sustainability Term Loan 15.25 % Prime 6.75 % 10.00 % - 4.33 % December 1, 2026 3,750 3,675 3,675 Term Loan 15.25 % Prime 6.75 % 10.00 % - 4.33 % December 1, 2026 3,750 3,675 3,675 Nexii Building Solutions, Inc. (2)(12)(14) Other Sustainability Term Loan 15.50 % (11) Prime 7.00 % 10.25 % - 2.50 % September 1, 2025 8,102 8,009 6,754 Term Loan 15.50 % (11) Prime 7.00 % 10.25 % - 2.50 % September 1, 2025 8,102 8,009 6,754 Term Loan 15.50 % (11) Prime 7.00 % 10.25 % - 2.50 % September 1, 2025 8,102 8,009 6,754 Term Loan 15.50 % (11) Prime 7.00 % 10.25 % - 2.50 % July 1, 2026 5,402 5,332 4,496 Term Loan 15.50 % (11) Prime 7.00 % 10.25 % - 2.50 % July 1, 2026 5,402 5,332 4,496 Term Loan 15.50 % (11) Prime 7.00 % 10.25 % - 2.50 % September 30, 2023 707 707 596 Term Loan 15.50 % (11) Prime 7.00 % 10.25 % - 2.50 % September 30, 2023 564 564 475 Term Loan 15.50 % (11) Prime 7.00 % 10.25 % - 2.50 % September 30, 2023 281 281 237 Term Loan 15.50 % (11) Prime 7.00 % 10.25 % - 2.50 % September 30, 2023 279 279 235 Term Loan 15.50 % (11) Prime 7.00 % 10.25 % - 2.50 % September 30, 2023 167 167 141 Soli Organic, Inc. (2)(12) Other Sustainability Term Loan 15.25 % Prime 6.75 % 10.00 % - 2.75 % April 1, 2026 5,000 4,951 4,951 Term Loan 15.25 % Prime 6.75 % 10.00 % - 2.75 % April 1, 2026 2,500 2,475 2,475 Term Loan 15.25 % Prime 6.75 % 10.00 % - 2.75 % May 1, 2026 5,000 4,948 4,948 Term Loan 15.25 % Prime 6.75 % 10.00 % - 2.75 % May 1, 2026 2,500 2,474 2,474 Term Loan 14.00 % Prime 5.50 % 11.75 % - 2.75 % December 1, 2026 5,000 4,926 4,926 Term Loan 14.00 % Prime 5.50 % 11.75 % - 2.75 % December 1, 2026 2,500 2,463 2,463 Temperpack Technologies, Inc. (2)(12) Other Sustainability Term Loan 15.25 % Prime 6.75 % 10.00 % - 2.50 % April 1, 2028 3,750 3,678 3,678 Term Loan 15.25 % Prime 6.75 % 10.00 % - 2.50 % April 1, 2028 3,750 3,692 3,692 Term Loan 15.25 % Prime 6.75 % 10.00 % - 2.50 % April 1, 2028 7,500 7,374 7,374 Term Loan 15.25 % Prime 6.75 % 10.00 % - 2.50 % April 1, 2028 3,750 3,687 3,687 Term Loan 15.25 % Prime 6.75 % 10.00 % - 2.50 % April 1, 2028 3,750 3,687 3,687 Total Non-Affiliate Debt Investments — Sustainability 88,394 82,643 Portfolio Company (1)(3) Sector Type of Investment (7) Cash Rate (4) Index Margin Floor Ceiling ETP (10) Maturity Date Principal Amount Cost of Investments (6)(9) Fair Value (9) Non-Affiliate Debt Investments — Technology — 80.5% Axiom Space, Inc. (2)(12) Communications Term Loan 14.50 % Prime 6.00 % 9.25 % - 2.50 % June 1, 2026 6,875 6,840 6,840 Term Loan 14.50 % Prime 6.00 % 9.25 % - 2.50 % June 1, 2026 6,875 6,840 6,840 Term Loan 14.50 % Prime 6.00 % 9.25 % - 2.50 % June 1, 2026 6,875 6,840 6,840 CAMP NYC, Inc. (2)(12) Consumer-related Technologies Term Loan 15.75 % Prime 7.25 % 10.50 % - 3.00 % May 1, 2026 3,500 3,470 3,470 Clara Foods Co. (2)(12) Consumer-related Technologies Term Loan 14.25 % Prime 5.75 % 9.00 % - 5.50 % August 1, 2025 1,833 1,821 1,821 Term Loan 14.25 % Prime 5.75 % 9.00 % - 5.50 % August 1, 2025 1,833 1,821 1,821 Divergent Technologies, Inc. (2)(12) Consumer-related Technologies Term Loan 11.25 % Prime 6.00 % 9.50 % 11.25 % 3.00 % July 1, 2027 3,750 3,605 3,605 Term Loan 11.25 % Prime 6.00 % 9.50 % 11.25 % 3.00 % July 1, 2027 1,250 1,241 1,241 Term Loan 11.25 % Prime 6.00 % 9.50 % 11.25 % 3.00 % July 1, 2027 3,750 3,723 3,723 Term Loan 11.25 % Prime 6.00 % 9.50 % 11.25 % 3.00 % July 1, 2027 1,250 1,241 1,241 Term Loan 11.25 % Prime 6.00 % 9.50 % 11.25 % 3.00 % July 1, 2027 3,750 3,723 3,723 Term Loan 11.25 % Prime 6.00 % 9.50 % 11.25 % 3.00 % July 1, 2027 1,250 1,241 1,241 Term Loan 11.25 % Prime 6.00 % 9.50 % 11.25 % 3.00 % January 1, 2028 3,750 3,709 3,709 Term Loan 11.25 % Prime 6.00 % 9.50 % 11.25 % 3.00 % January 1, 2028 3,750 3,703 3,703 Term Loan 11.25 % Prime 6.00 % 9.50 % 11.25 % 3.00 % April 1, 2028 3,750 3,709 3,709 Term Loan 11.25 % Prime 6.00 % 9.50 % 11.25 % 3.00 % July 1, 2028 3,750 3,705 3,705 Term Loan 11.25 % Prime 6.00 % 9.50 % 11.25 % 3.00 % July 1, 2028 3,750 3,705 3,705 Havenly, Inc. (2)(12) Consumer-related Technologies Term Loan 13.50 % Prime 5.00 % 5.00 % - 4.00 % March 1, 2027 2,000 1,335 1,335 Term Loan 13.50 % Prime 5.00 % 5.00 % - 4.00 % March 1, 2027 3,000 2,003 2,003 Term Loan 12.00 % Prime 3.50 % 10.50 % - 7.78 % February 1, 2028 2,813 2,813 2,813 Term Loan 12.00 % Prime 3.50 % 10.50 % - 7.78 % February 1, 2028 2,813 2,813 2,813 Lyrical Foods, Inc. (2)(12) Consumer-related Technologies Term Loan 11.00 % Prime 2.50 % 8.00 % - - September 1, 2027 2,598 2,589 2,351 MyForest Foods Co. (2)(12) Consumer-related Technologies Term Loan 15.25 % Prime 6.75 % 10.00 % - 3.00 % October 1, 2025 4,000 3,975 3,975 Term Loan 15.25 % Prime 6.75 % 10.00 % - 3.00 % October 1, 2025 2,000 1,987 1,987 NextCar Holding Company, Inc. (2)(12) Consumer-related Technologies Term Loan 14.25 % (11) Prime 5.75 % 9.00 % - 5.25 % October 31, 2023 5,547 5,505 4,894 Term Loan 14.25 % (11) Prime 5.75 % 9.00 % - 5.25 % October 31, 2023 2,219 2,204 1,960 Term Loan 14.25 % (11) Prime 5.75 % 9.00 % - 5.25 % October 31, 2023 2,774 2,759 2,453 Term Loan 14.25 % (11) Prime 5.75 % 9.00 % - 5.25 % October 31, 2023 3,328 3,310 2,943 Term Loan 14.25 % (11) Prime 5.75 % 9.00 % - 5.25 % October 31, 2023 2,774 2,747 2,443 Term Loan 14.25 % (11) Prime 5.75 % 9.00 % - 5.25 % October 31, 2023 2,774 2,747 2,443 Term Loan 14.25 % (11) Prime 5.75 % 9.00 % - 5.25 % October 31, 2023 5,547 5,493 4,884 Term Loan 14.25 % (11) Prime 5.75 % 9.00 % - 5.25 % October 31, 2023 2,774 2,746 2,441 Optoro, Inc. (2)(12) Consumer-related Technologies Term Loan 14.75 % Prime 6.25 % 9.50 % - 4.00 % August 1, 2027 2,500 2,408 2,408 Term Loan 14.75 % Prime 6.25 % 9.50 % - 4.00 % July 1, 2028 1,875 1,783 1,783 Primary Kids, Inc. (2)(12) Consumer-related Technologies Term Loan 15.75 % Prime 7.25 % 10.50 % - 3.00 % March 1, 2025 1,700 1,683 1,683 Term Loan 15.75 % Prime 7.25 % 10.50 % - 3.00 % March 1, 2025 1,700 1,683 1,683 Term Loan 15.75 % Prime 7.25 % 10.50 % - 3.00 % September 1, 2025 2,300 2,277 2,277 Unagi, Inc. (2)(12)(13) Consumer-related Technologies Term Loan 16.25 % (11) Prime 7.75 % 11.00 % - - May 1, 2027 1,108 1,086 872 Term Loan 16.25 % (11) Prime 7.75 % 11.00 % - - May 1, 2027 554 543 436 Term Loan 16.25 % (11) Prime 7.75 % 11.00 % - - May 1, 2027 554 543 436 Liqid, Inc. (2)(12) Networking Term Loan 14.75 % Prime 6.25 % 9.50 % - 4.00 % September 1, 2024 1,833 1,807 1,807 Term Loan 14.75 % Prime 6.25 % 9.50 % - 4.00 % September 1, 2024 1,833 1,807 1,807 Term Loan 14.75 % Prime 6.25 % 9.50 % - 4.00 % September 1, 2024 917 903 903 Term Loan 14.75 % Prime 6.25 % 9.50 % - 4.00 % September 1, 2024 917 903 903 Term Loan 14.75 % Prime 6.25 % 9.50 % - 4.00 % September 1, 2024 917 887 887 BriteCore Holdings, Inc. (2)(12) Software Term Loan 14.00 % Prime 5.50 % 14.00 % - 3.00 % October 1, 2028 5,000 4,857 4,857 Term Loan 14.00 % Prime 5.50 % 14.00 % - 3.00 % October 1, 2028 2,500 2,464 2,464 Term Loan 14.00 % Prime 5.50 % 14.00 % - 3.00 % October 1, 2028 2,500 2,464 2,464 Term Loan 14.00 % Prime 5.50 % 14.00 % - 3.00 % October 1, 2028 2,500 2,464 2,464 Portfolio Company (1)(3) Sector Type of Investment (7) Cash Rate (4) Index Margin Floor Ceiling ETP (10) Maturity Date Principal Amount Cost of Investments (6)(9) Fair Value (9) Dropoff, Inc. (2)(12) Software Term Loan 15.00 % (11) Prime 6.50 % 9.75 % - 3.50 % April 1, 2026 6,550 6,432 6,377 Term Loan 15.00 % (11) Prime 6.50 % 9.75 % - 3.50 % April 1, 2026 6,046 5,937 5,886 Term Loan 15.00 % (11) Prime 6.50 % 9.75 % - 3.50 % August 1, 2026 2,519 2,472 2,451 Engage3, LLC (2)(12) Software Term Loan 14.75 % Prime 6.25 % 9.75 % - 4.50 % July 1, 2027 3,750 3,726 3,726 Term Loan 14.75 % Prime 6.25 % 9.75 % - 4.50 % July 1, 2027 3,750 3,726 3,726 Kodiak Robotics, Inc. (2)(12) Software Term Loan 14.00 % Prime 5.50 % 10.25 % - 4.00 % April 1, 2026 10,000 9,877 9,877 Term Loan 14.00 % Prime 5.50 % 10.25 % - 4.00 % April 1, 2026 10,000 9,877 9,877 Term Loan 14.00 % Prime 5.50 % 10.25 % - 4.00 % April 1, 2026 5,000 4,939 4,939 Term Loan 14.00 % Prime 5.50 % 10.25 % - 4.00 % April 1, 2026 5,000 4,939 4,939 Lemongrass Holdings, Inc. (2)(12) Software Term Loan 15.00 % Prime 6.50 % 9.75 % - 2.50 % March 1, 2026 5,000 4,965 4,965 Term Loan 15.00 % Prime 6.50 % 9.75 % - 2.50 % March 1, 2026 2,500 2,483 2,483 Lytics, Inc. (2)(12) Software Term Loan 14.50 % Prime 6.00 % 14.25 % - 4.00 % November 1, 2026 2,500 2,418 2,350 Term Loan 14.50 % Prime 6.00 % 14.25 % - 4.00 % December 1, 2026 1,250 1,236 1,201 Term Loan 14.50 % Prime 6.00 % 14.25 % - 4.00 % April 1, 2027 1,000 993 966 Mirantis, Inc. (2)(12) Software Term Loan 12.00 % Prime 3.50 % 11.75 % - 4.00 % October 1, 2028 5,000 4,774 4,774 Term Loan 12.00 % Prime 3.50 % 11.75 % - 4.00 % October 1, 2028 5,000 4,910 4,910 Term Loan 12.00 % Prime 3.50 % 11.75 % - 4.00 % October 1, 2028 5,000 4,910 4,910 Term Loan 12.00 % Prime 3.50 % 11.75 % - 4.00 % October 1, 2028 5,000 4,910 4,910 Noodle Partners, Inc. (2)(12) Software Term Loan 13.50 % Prime 5.00 % 12.00 % - 3.00 % March 1, 2027 10,000 9,814 9,814 Term Loan 13.50 % Prime 5.00 % 12.00 % - 3.00 % March 1, 2027 5,000 4,938 4,938 Term Loan 13.50 % Prime 5.00 % 12.00 % - 3.00 % March 1, 2027 5,000 4,939 4,939 Reputation Institute, Inc. (2)(12) Software Term Loan 15.75 % Prime 7.25 % 10.50 % - 3.00 % August 1, 2025 3,833 3,785 3,785 Slingshot Aerospace, Inc. (2)(12) Software Term Loan 14.25 % Prime 5.75 % 9.75 % - 5.00 % August 1, 2026 5,000 4,952 4,952 Term Loan 14.25 % Prime 5.75 % 9.75 % - 5.00 % August 1, 2026 5,000 4,952 4,952 Term Loan 14.25 % Prime 5.75 % 9.75 % - 5.00 % August 1, 2026 5,000 4,952 4,952 Term Loan 14.25 % Prime 5.75 % 9.75 % - 5.00 % August 1, 2026 5,000 4,952 4,952 Supply Network Visibility Holdings LLC (2)(12) Software Term Loan 12.75 % Prime 4.25 % 12.00 % - 2.50 % June 1, 2028 2,500 2,457 2,457 Term Loan 12.75 % Prime 4.25 % 12.00 % - 2.50 % June 1, 2028 3,500 3,489 3,489 Term Loan 12.75 % Prime 4.25 % 12.00 % - 2.50 % June 1, 2028 2,500 2,492 2,492 Term Loan 12.75 % Prime 4.25 % 12.00 % - 2.50 % June 1, 2028 1,500 1,495 1,495 Viken Detection Corporation (2)(12) Software Term Loan 12.50 % Prime 4.00 % 11.75 % - 3.50 % June 1, 2027 5,000 4,768 4,768 Term Loan 12.50 % Prime 4.00 % 11.75 % - 3.50 % June 1, 2027 2,500 2,464 2,464 Term Loan 12.50 % Prime 4.00 % 11.75 % - 3.50 % June 1, 2027 2,500 2,464 2,464 Total Non-Affiliate Debt Investments — Technology 282,962 278,989 Non-Affiliate Debt Investments — Healthcare information and services — 17.4% Hound Labs inc. (2) (12) Diagnostics Term Loan 14.50 % Prime 6.00 % 9.25 % - 3.50 % June 1, 2026 2,500 2,481 2,481 Term Loan 14.50 % Prime 6.00 % 9.25 % - 3.50 % June 1, 2026 2,500 2,481 2,481 Term Loan 14.50 % Prime 6.00 % 9.25 % - 3.50 % June 1, 2026 5,000 4,962 4,962 BrightInsight, Inc. (2)(12) Software Term Loan 14.00 % Prime 5.50 % 9.50 % - 3.00 % August 1, 2027 7,000 6,677 6,677 Term Loan 14.00 % Prime 5.50 % 9.50 % - 3.00 % August 1, 2027 3,500 3,459 3,459 Term Loan 14.00 % Prime 5.50 % 9.50 % - 3.00 % August 1, 2027 3,500 3,459 3,459 Term Loan 14.00 % Prime 5.50 % 9.50 % - 3.00 % April 1, 2028 2,750 2,708 2,708 Elligo Health Research, Inc. (2)(12) Software Term Loan 12.00 % Prime 3.50 % 11.75 % - 4.00 % October 1, 2027 10,000 9,647 9,647 Term Loan 12.00 % Prime 3.50 % 11.75 % - 4.00 % October 1, 2027 5,000 4,921 4,921 Term Loan 12.00 % Prime 3.50 % 11.75 % - 4.00 % October 1, 2027 5,000 4,921 4,921 Term Loan 12.00 % Prime 3.50 % 11.75 % - 4.00 % October 1, 2027 5,000 4,921 4,921 SafelyYou, Inc. (2)(12) Software Term Loan 11.75 % Prime 3.25 % 11.00 % - 5.00 % June 1, 2027 5,000 4,642 4,642 Term Loan 11.75 % Prime 3.25 % 11.00 % - 5.00 % June 1, 2027 5,000 4,912 4,912 Total Non-Affiliate Debt Investments — Healthcare information and services 60,191 60,191 Total Non- Affiliate Debt Investments 676,864 663,399 Cost of Fair Portfolio Company (1)(3) Sector Type of Investment (7) Number of Shares Investments (6)(9) Value (9) Non-Affiliate Warrant Investments — 7.6% Non-Affiliate Warrants — Life Science — 2.0% Avalo Therapeutics, Inc. (2)(5)(12) Biotechnology Common Stock Warrant 26,444 311 — Castle Creek Biosciences, Inc. (2)(12) Biotechnology Preferred Stock Warrant 7,404 214 348 Emalex Biosciences, Inc. (2)(12) Biotechnology Preferred Stock Warrant 110,402 176 269 Imunon, Inc. (2)(5)(12) Biotechnology Common Stock Warrant 19,671 65 — KSQ Therapeutics, Inc. (2) (12) Biotechnology Preferred Stock Warrant 48,076 50 60 Mustang Bio, Inc. (2)(5)(12) Biotechnology Common Stock Warrant 16,611 146 — Native Microbials, Inc (2)(12) Biotechnology Preferred Stock Warrant 103,679 64 165 PDS Biotechnology Corporation (2)(5)(12) Biotechnology Common Stock Warrant 299,848 162 667 Provivi, Inc. (2)(12) Biotechnology Preferred Stock Warrant 345,327 487 205 Stealth Biotherapeutics Inc. (2)(12) Biotechnology Common Stock Warrant 318,181 264 127 Tallac Therapeutics, Inc. (2)(12) Biotechnology Preferred Stock Warrant 1,600,002 194 194 vTv Therapeutics Inc. (2)(5)(12) Biotechnology Common Stock Warrant 95,293 44 — Xeris Pharmaceuticals, Inc. (2)(5)(12) Biotechnology Common Stock Warrant 126,000 72 17 AccuVein Inc. (2)(12) Medical Device Common Stock Warrant 1,175 24 — Aerin Medical, Inc. (2)(12) Medical Device Preferred Stock Warrant 1,818,183 66 1,210 Aerobiotix, LLC (2)(12) Medical Device Preferred Stock Warrant 8,800 48 10 Canary Medical Inc. (2)(12) Medical Device Preferred Stock Warrant 12,153 86 1,307 Candesant Biomedical, Inc. (2)(12) Medical Device Preferred Stock Warrant 93,336 152 152 Ceribell, Inc. (2)(12) Medical Device Preferred Stock Warrant 145,483 69 213 Cognoa, Inc. (2)(12) Medical Device Preferred Stock Warrant 4,106,174 148 184 Conventus Orthopaedics, Inc. (2)(12) Medical Device Preferred Stock Warrant 7,972,222 218 236 CSA Medical, Inc. (2)(12) Medical Device Preferred Stock Warrant 1,730,746 172 176 CVRx, Inc. (2)(5)(12) Medical Device Common Stock Warrant 47,410 76 272 Infobionic, Inc. (2)(12) Medical Device Preferred Stock Warrant 317,647 124 59 Magnolia Medical Technologies, Inc. (2)(12) Medical Device Preferred Stock Warrant 809,931 194 395 Meditrina, Inc. (2)(12) Medical Device Preferred Stock Warrant 233,993 83 104 Robin Healthcare, Inc. (2)(12) Medical Device Preferred Stock Warrant 86,066 16 — Scientia Vascular, Inc (2)(12) Medical Device Preferred Stock Warrant 27,036 59 230 Sonex Health, Inc. (2)(12) Medical Device Preferred Stock Warrant 2,637,043 275 304 VERO Biotech LLC (2)(12) Medical Device Preferred Stock Warrant 408 53 1 Swift Health Systems Inc. (2)(12) Medical Device Preferred Stock Warrant 135,484 71 40 Total Non-Affiliate Warrants — Life Science 4,183 6,945 Cost of Fair Portfolio Company (1)(3) Sector Type of Investment (7) Number of Shares Investments (6)(9) Value (9) Non-Affiliate Warrants — Sustainability — 0.2% New Aerofarms, Inc. assignee of Aerofarms, Inc. (2)(12)(15) Other Sustainability Preferred Stock Warrant 400,000 81 81 LiquiGlide, Inc. (2)(12) Other Sustainability Common Stock Warrant 61,359 41 59 Nexii Building Solutions, Inc. (2)(12)(14) Other Sustainability Common Stock Warrant 217,726 490 — Soli Organic, Inc. (2)(12) Other Sustainability Preferred Stock Warrant 681 214 371 Temperpack Technologies, Inc. (2)(12) Other Sustainability Preferred Stock Warrant 46,311 175 322 Total Non-Affiliate Warrants — Sustainability 1,001 833 Non-Affiliate Warrants — Technology — 4.7% Axiom Space, Inc. (2)(12) Communications Common Stock Warrant 1,991 46 69 Intelepeer Holdings, Inc. (2)(12) Communications Preferred Stock Warrant 2,936,535 138 3,283 PebblePost, Inc. (2)(12) Communications Preferred Stock Warrant 598,850 92 139 Alula Holdings, Inc. (2)(12) Consumer-related Technologies Preferred Stock Warrant 20,000 93 — Aterian, Inc. (2)(5)(12) Consumer-related Technologies Common Stock Warrant 76,923 195 — Caastle, Inc. (2)(12) Consumer-related Technologies Preferred Stock Warrant 268,591 68 1,060 CAMP NYC, Inc. (2)(12) Consumer-related Technologies Preferred Stock Warrant 75,997 22 30 Clara Foods Co. (2)(12) Consumer-related Technologies Preferred Stock Warrant 46,745 31 128 CZV, Inc. (2)(12) Consumer-related Technologies Common Stock Warrant 65,569 81 81 Divergent Technologies, Inc. (2)(12) Consumer-related Technologies Preferred Stock Warrant 37,294 92 279 Havenly, Inc. (2)(12) Consumer-related Technologies Common Stock Warrant 1,312,500 2,945 2,676 MyForest Foods Co. (2)(12) Consumer-related Technologies Preferred Stock Warrant 250 29 63 NextCar Holding Company, Inc. (2)(12) Consumer-related Technologies Preferred and Common Stock Warrant 1,237,370 197 — Optoro, Inc. (2)(12) Consumer-related Technologies Preferred Stock Warrant 11,550 182 182 Primary Kids, Inc. (2)(12) Consumer-related Technologies Preferred Stock Warrant 553,778 57 596 Quip NYC Inc. (2)(12) Consumer-related Technologies Preferred Stock Warrant 6,191 325 538 Unagi, Inc. (2)(12) Consumer-related Technologies Preferred Stock Warrant 171,081 32 — Updater, Inc.(2)(12) Consumer-related Technologies Common Stock Warrant 108,333 34 — CPG Beyond, Inc. (2)(12) Data Storage Preferred Stock Warrant 500,000 242 917 Silk, Inc. (2)(12) Data Storage Preferred Stock Warrant 394,110 175 153 Global Worldwide LLC (2)(12) Internet and Media Preferred Stock Warrant 245,810 75 63 Rocket Lawyer Incorporated (2)(12) Internet and Media Preferred Stock Warrant 261,721 92 336 Skillshare, Inc. (2)(12) Internet and Media Preferred Stock Warrant 139,074 162 1,216 Liqid, Inc. (2)(12) Networking Preferred Stock Warrant 344,102 364 251 Halio, Inc. (2)(12) Power Management Preferred Stock Warrant 5,002,574 1,585 2,901 Avalanche Technology, Inc. (2)(12) Semiconductors Preferred and Common Stock Warrant 6,081 56 — BriteCore Holdings, Inc. (2)(12) Software Preferred Stock Warrant 161,215 98 147 Dropoff, Inc. (2)(12) Software Common Stock Warrant 516,732 455 54 Mirantis, Inc. (2)(12) Software Common Stock Warrant 948,275 223 223 E La Carte, Inc. (2)(5)(12) Software Common Stock Warrant 147,361 60 — Everstream Holdings, LLC (2)(12) Software Preferred Stock Warrant 350,000 70 71 Kodiak Robotics, Inc. (2)(12) Software Preferred Stock Warrant 639,918 273 124 Lemongrass Holdings, Inc. (2)(12) Software Preferred Stock Warrant 101,308 32 43 Lotame Solutions, Inc. (2)(12) Software Preferred Stock Warrant 71,305 18 44 Lytics, Inc. (2)(12) Software Preferred Stock Warrant 85,543 43 1 Noodle Partners, Inc. (2)(12) Software Preferred Stock Warrant 84,037 115 79 Reputation Institute, Inc. (2)(12) Software Preferred Stock Warrant 3,731 56 48 Revinate Holdings, Inc. (2)(12) Software Preferred Stock Warrant 682,034 44 103 SIGNiX, Inc. (12) Software Preferred Stock Warrant 186,235 225 — Slingshot Aerospace, Inc. (2)(12) Software Preferred Stock Warrant 309,208 123 135 Supply Network Visibility Holdings LLC (2)(12) Software Preferred Stock Warrant 682 64 146 Topia Mobility, Inc. (2)(12) Software Preferred Stock Warrant 3,049,607 138 — Viken Detection Corporation (2)(12) Software Preferred Stock Warrant 345,443 120 122 xAd, Inc. (2)(12) Software Preferred Stock Warrant 4,343,348 177 12 Total Non-Affiliate Warrants — Technology 9,744 16,313 Cost of Fair Portfolio Company (1)(3) Sector Type of Investment (7) Number of Shares Investments (6)(9) Value (9) Non-Affiliate Warrants — Healthcare information and services — 0.6% Hound Labs, Inc (2) (12) Diagnostics Preferred Stock Warrant 171,370 47 15 Kate Farms, Inc. (2)(12) Other Healthcare Preferred Stock Warrant 82,965 102 1,379 BrightInsight, Inc. (2)(12) Software Preferred Stock Warrant 85,066 167 — Elligo Health Research, Inc. (2)(12) Software Preferred Stock Warrant 652,250 189 191 Medsphere Systems Corporation (2)(12) Software Preferred Stock Warrant 7,097,792 61 346 SafelyYou, Inc. (2)(12) Software Preferred Stock Warrant 150,353 163 167 Total Non-Affiliate Warrants — Healthcare information and services 729 2,098 Total Non-Affiliate Warrants 15,657 26,189 Non-Affiliate Other Investments — Life Science — 0.3% Lumithera, Inc. (12) Medical Device Royalty Agreement 1,200 1,100 ZetrOZ, Inc. (12) Medical Device Royalty Agreement — — Total Non-Affiliate Other Investments 1,200 1,100 Non-Affiliate Equity — 1.4% Cadrenal Therapeutics, Inc. (5) Biotechnology Common Stock 600,000 — 408 Castle Creek Biosciences, Inc. (12) Biotechnology Common Stock 1,162 250 250 Emalex Biosciences, Inc. (12) Biotechnology Common Stock 32,831 355 356 Getaround, Inc. (2)(5) Consumer-related Technologies Common Stock 87,082 253 30 NextCar Holding Company, Inc. (2)(12) Technology Preferred Stock 2,688,971 89 89 SnagAJob.com, Inc. (12) Consumer-related Technologies Common Stock 82,974 9 83 Lumithera, Inc. (12) Medical Device Common Stock 392,651 2,000 1,700 Tigo Energy, Inc. (5) Other Sustainability Common Stock 5,205 111 36 Branded Online, Inc. (2)(5) Software Common Stock 5,398 1,079 3 Decisyon, Inc. (12) Software Preferred Stock 280,000 2,800 1,281 Lotame, Inc. (12) Software Preferred Stock 66,127 4 193 Axiom Space, Inc. (12) Technology Preferred Stock 1,810 261 306 Total Non-Affiliate Equity 7,211 4,735 Total Non-Affiliate Portfolio Investment Assets $ 700,932 $ 695,423 Portfolio Company (1)(3) Sector Type of Investment (7) Cash Rate (4) Index Margin Floor Ceiling ETP (10) Maturity Date Principal Amount Cost of Investments (6)(9) Fair Value (9) Non-Controlled Affiliate Investments — 5.9% Non-Controlled Affiliate Debt Investments — Life Sciences — 3.5% Evelo Biosciences, Inc. (2)(5)(12)(13) Biotechnology Term Loan 12.75 % Prime 4.25 % 11.00 % - 4.25 % January 1, 2028 7,778 7,672 2,666 Term Loan 12.75 % Prime 4.25 % 11.00 % - 4.25 % January 1, 2028 11,667 11,509 3,997 Term Loan 12.75 % Prime 4.25 % 11.00 % - 4.25 % January 1, 2028 4,681 4,618 1,604 Term Loan 12.75 % Prime 4.25 % 11.00 % - 4.25 % January 1, 2028 4,667 4,603 1,597 Term Loan 12.75 % Prime 4.25 % 11.00 % - 4.25 % January 1, 2028 3,111 3,069 1,068 Term Loan 12.75 % Prime 4.25 % 11.00 % - 4.25 % January 1, 2028 3,111 3,069 1,068 Total Non-Controlled Affiliate Debt Investments 34,540 12,000 Cost of Fair Portfolio Company (1)(3) Sector Type of Investment (7) Number of Shares Investments (6)(9) Value (9) Non-controlled Affiliate Equity — Life Sciences — 2.4% Aulea Medical, Inc. (12)(16) Medical Device Common Stock 660,537 — — Evelo Biosciences, Inc. (5) Biotechnology Common Stock 2,164,502 5,000 8,485 Total Non-Controlled Affiliate Equity 5,000 8,485 Non-controlled Affiliate Warrants — Life Sciences — 0.0% Evelo Biosciences, Inc. (2)(5)(12) Biotechnology Common Stock 23,196 126 — Total Non-Controlled Affiliate Warrants 126 — Total Non-Controlled Affiliate Portfolio Investment Assets $ 39,666 $ 20,485 Portfolio Company (1)(3) Sector Type of Investment (7) Cash Rate (4) Index Margin Floor Ceiling ETP (10) Maturity Date Principal Amount Cost of Investments (6)(9) Fair Value (9) Controlled Affiliate Investments — 3.8% Controlled Affiliate Debt Investments — Technology — 1.3% Better Place Forests Co. (12) Consumer-related Technologies Term Loan 12.25 % (11) Prime 3.75 % 12.00 % - 2.78 % August 1, 2029 3,604 3,556 3,006 Term Loan 12.25 % (11) Prime 3.75 % 12.00 % - 2.78 % August 1, 2029 1,719 1,695 1,433 Total Controlled Affiliate Debt Investments 5,251 4,439 Cost of Fair Portfolio Company (1)(3) Sector Type of Investment (7) Number of Shares Investments (6)(9) Value (9) Controlled Affiliate Equity — Technology — 0.7% Better Place Forests Co. (12) Technology Preferred and Common Stock 2,551,596 2,811 2,552 Total Controlled Affiliate Equity 2,811 2,552 Controlled Affiliate Other Investments — Life Sciences — 1.8% HIMV LLC (12)(17) Biotechnology Other Investment 6,154 6,154 Total Controlled Affiliate Equity 6,154 6,154 Total Controlled Affiliate Portfolio Investment Assets $ 14,216 $ 13,145 Total Portfolio Investment Assets — 210.4% $ 754,814 $ 729,053 Portfolio Company (1)(3) Sector Type of Investment (7) Cash Rate (4) Index Margin Floor Ceiling ETP (10) Maturity Date Principal Amount Cost of Investments (6)(9) Fair Value (9) Non-Affiliate Investments — 226.1% Non-Affiliate Debt Investments — 215.5% Non-Affiliate Debt Investments — Life Science — 99.7% Avalo Therapeutics, Inc. (2)(5)(12) Biotechnology Term Loan 13.75 % Prime 6.25 % 9.50 % - 3.00 % January 1, 2025 $ 2,885 $ 2,853 $ 2,777 Term Loan 13.75 % Prime 6.25 % 9.50 % - 3.00 % January 1, 2025 2,885 2,823 2,750 Term Loan 13.75 % Prime 6.25 % 9.50 % - 3.00 % January 1, 2025 1,442 1,411 1,374 Term Loan 13.75 % Prime 6.25 % 9.50 % - 3.00 % February 1, 2025 2,885 2,821 2,748 Term Loan 13.75 % Prime 6.25 % 9.50 % - 3.00 % February 1, 2025 2,885 2,821 2,748 Term Loan 13.75 % Prime 6.25 % 9.50 % - 3.00 % April 1, 2025 1,442 1,408 1,371 Term Loan 13.75 % Prime 6.25 % 9.50 % - 3.00 % April 1, 2025 1,442 1,408 1,371 Castle Creek Biosciences, Inc. (2)(12) Biotechnology Term Loan 12.50 % Prime 6.05 % 9.55 % 13.50 % 5.50 % May 1, 2026 5,000 4,891 4,891 Term Loan 12.50 % Prime 6.05 % 9.55 % 13.50 % 5.50 % May 1, 2026 5,000 4,963 4,963 Term Loan 12.50 % Prime 6.05 % 9.55 % 13.50 % 5.50 % May 1, 2026 3,000 2,978 2,978 Term Loan 12.50 % Prime 6.05 % 9.55 % 13.50 % 5.50 % May 1, 2026 5,000 4,963 4,963 Term Loan 12.50 % Prime 6.05 % 9.55 % 13.50 % 5.50 % May 1, 2026 5,000 4,963 4,963 Term Loan 12.50 % Prime 6.05 % 9.55 % 13.50 % 5.50 % May 1, 2026 3,000 2,978 2,978 Emalex Biosciences, Inc. (2)(12) Biotechnology Term Loan 12.07 % Libor 7.90 % 9.75 % - 5.00 % June 1, 2024 1,979 1,962 1,962 Term Loan 12.07 % Libor 7.90 % 9.75 % - 5.00 % June 1, 2024 1,979 1,963 1,963 Term Loan 12.07 % Libor 7.90 % 9.75 % - 5.00 % November 1, 2025 5,0

Note 4 - Investments (Tables)

Note 4 - Investments (Tables)	9 Months Ended
	Sep. 30, 2023
Notes Tables
Investment Holdings, Schedule of Investments [Table Text Block]	September 30, 2023 December 31, 2022 Cost Fair Value Cost Fair Value (In thousands) Investments Debt $ 716,655 $ 679,838 $ 701,074 $ 686,458 Warrants 15,783 26,189 14,790 29,712 Other 7,354 7,254 1,200 1,300 Equity 15,022 15,772 4,184 2,556 Total investments $ 754,814 $ 729,053 $ 721,248 $ 720,026 September 30, 2023 December 31, 2022 Cost Fair Value Cost Fair Value (In thousands) Life Science Biotechnology $ 158,953 $ 139,935 $ 193,372 $ 195,006 Medical Device 140,172 139,039 132,803 135,960 Technology Communications 21,057 24,317 22,892 26,176 Consumer-Related 110,245 106,559 121,961 114,050 Data Storage 417 1,070 476 1,316 Internet and Media 329 1,615 329 1,159 Networking 6,671 6,558 11,831 11,710 Power Management 1,585 2,901 1,585 2,610 Semiconductors 56 — 56 — Software 164,903 161,258 120,157 118,716 Sustainability Energy Efficiency 111 36 8 27 Other Sustainability 89,395 83,476 84,633 85,524 Healthcare Information and Services Diagnostics 9,971 9,939 9,851 9,858 Other 102 1,379 7,559 3,870 Software 50,847 50,971 13,735 14,044 Total investments $ 754,814 $ 729,053 $ 721,248 $ 720,026

Note 5 - Transactions With Af_2

Note 5 - Transactions With Affiliated Companies (Tables)	9 Months Ended
	Sep. 30, 2023
Notes Tables
Investments in and Advances to Affiliates [Table Text Block]	Three months ended September 30, 2023 Fair value at Transfers Net Fair value at Portfolio June 30, Principal in/(out) at Discount unrealized Net realized September 30, Interest Company 2023 Purchases Payments fair value accretion gain/(loss) gain/(loss) 2023 income (In thousands) Aulea Medical, Inc. $ — $ — $ — $ — $ — $ — $ — $ — $ — Cadrenal Therapeutics, Inc. (1) 906 — — (906 ) — — — — — Evelo Biosciences, Inc. — — — 7,665 8 (5,007 ) — 2,666 277 — — — 11,496 11 (7,510 ) — 3,997 415 — — — 4,612 5 (3,013 ) — 1,604 166 — — — 4,598 3 (3,004 ) — 1,597 163 — — — 3,067 4 (2,003 ) — 1,068 114 — — — 3,067 4 (2,003 ) — 1,068 111 — — — 5,000 — 3,485 — 8,485 — Total non-controlled affiliates $ 906 $ — $ — $ 38,599 $ 35 $ (19,055 ) $ — $ 20,485 $ 1,246 Nine months ended September 30, 2023 Fair value at Transfers Net Fair value at Portfolio December 31, Principal in/(out) at Discount unrealized Net realized September 30, Interest Company 2022 Purchases Payments fair value accretion gain/(loss) gain/(loss) 2023 income (In thousands) Aulea Medical, Inc. $ — $ — $ — $ — $ — $ — $ — $ — $ — Cadrenal Therapeutics, Inc. (1) — — — (906 ) — 906 — — — Evelo Biosciences, Inc. — — — 7,665 8 (5,007 ) — 2,666 277 — — — 11,496 11 (7,510 ) — 3,997 415 — — — 4,612 5 (3,013 ) — 1,604 166 — — — 4,598 3 (3,004 ) — 1,597 163 — — — 3,067 4 (2,003 ) — 1,068 114 — — — 3,067 4 (2,003 ) — 1,068 111 — — — 5,000 — 3,485 — 8,485 — Total non-controlled affiliates $ — $ — $ — $ 38,599 $ 35 $ (18,149 ) $ — $ 20,485 $ 1,246 Three months ended September 30, 2022 Fair value at Transfers Net Fair value at Portfolio June 30, in/(out) at Discount unrealized Net realized September 30, Interest Company 2022 Purchases Sales fair value Accretion gain/(loss) gain/(loss) 2022 income (In thousands) MVI (ABC) LLC fka StereoVision, Inc. — — (30 ) — — — 30 — — Total non-controlled affiliates $ — $ — $ (30 ) $ — $ — $ — $ 30 $ — $ — Nine months ended September 30, 2022 Fair value at Transfers Net Fair value at Portfolio December 31, in/(out) at Discount unrealized Net realized September 30, Interest Company 2021 Purchases Sales fair value Accretion gain/(loss) gain/(loss) 2022 income (In thousands) MVI (ABC) LLC fka StereoVision, Inc. — — (30 ) — — — 30 — — Total non-controlled affiliates $ — $ — $ (30 ) $ — $ — $ — $ 30 $ — $ — Three months ended September 30, 2023 Fair value at Transfers Net Fair value at Portfolio June 30, Principal in/(out) at Discount unrealized Net realized September 30, Interest Company 2023 Purchases Payments PIK fair value accretion gain/(loss) gain/(loss) 2023 income (In thousands) Better Place Forests Co. $ — $ 59 $ — $ 105 $ 1,759 $ 2 $ 1,080 $ — $ 3,005 $ 111 — — — 53 844 1 536 — 1,434 55 — — — — 2,061 — — — 2,061 — — 750 — — — — (259 ) — 491 — HIMV LLC — — — — 6,154 — — — 6,154 — Total controlled affiliates $ — $ 809 $ — $ 158 $ 10,818 $ 3 $ 1,357 $ — $ 13,145 $ 166 Nine months ended September 30, 2023 Fair value at Transfers Net Fair value at Portfolio December 31, Principal in/(out) at Discount unrealized Net realized September 30, Interest Company 2022 Purchases Payments PIK fair value accretion gain/(loss) gain/(loss) 2023 income (In thousands) Better Place Forests Co. $ — $ 59 $ — $ 105 $ 1,759 $ 2 $ 1,080 $ — $ 3,005 $ 111 — — — 53 844 1 536 — 1,434 55 — — — — 2,061 — — — 2,061 — — 750 — — — — (259 ) — 491 — HIMV LLC — — — — 6,154 — — — 6,154 — Total controlled affiliates $ — $ 809 $ — $ 158 $ 10,818 $ 3 $ 1,357 $ — $ 13,145 $ 166 Three months ended September 30, 2022 Fair value at Transfers Net Fair value at Portfolio June 30, in/(out) at Discount unrealized Net realized September 30, Interest Company 2022 Purchases Sales fair value Accretion gain/(loss) gain/(loss) 2022 income (In thousands) HESP LLC — — (50 ) — — — 50 — — Total controlled affiliates $ — $ — $ (50 ) $ — $ — $ — $ 50 $ — $ — Nine months ended September 30, 2022 Fair value at Transfers Net Fair value at Portfolio December 31, in/(out) at Discount unrealized Net realized September 30, Interest Company 2021 Purchases Sales fair value accretion gain/(loss) gain/(loss) 2022 income (In thousands) HESP LLC — — (300 ) — — 1,450 (1,150 ) — — Total controlled affiliates $ — $ — $ (300 ) $ — $ — $ 1,450 $ (1,150 ) $ — $ —

Note 6 - Fair Value (Tables)

Note 6 - Fair Value (Tables)	9 Months Ended
	Sep. 30, 2023
Notes Tables
Fair Value, Assets Measured on Recurring Basis [Table Text Block]	September 30, 2023 Level 1 Level 2 Level 3 Total (In thousands) Debt investments $ — $ — $ 679,838 $ 679,838 Warrant investments — 956 25,233 26,189 Other investments — — 7,254 7,254 Equity investments 8,962 — 6,810 15,772 Total investments $ 8,962 $ 956 $ 719,135 $ 729,053 December 31, 2022 Level 1 Level 2 Level 3 Total (In thousands) Debt investments $ — $ — $ 686,458 $ 686,458 Warrant investments — 3,567 26,145 29,712 Other investments — — 1,300 1,300 Equity investments 140 — 2,416 2,556 Total investments $ 140 $ 3,567 $ 716,319 $ 720,026
Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]	September 30, 2023 Fair Valuation Techniques/ Unobservable Weighted Investment Type Value Methodologies Input Range Average(1) (Dollars in thousands, except per share data) Debt investments $ 607,193 Discounted Expected Future Cash Flows Hypothetical Market Yield 11% – 20% 14 % 72,645 Multiple Probability Weighted Cash Flow Model Probability Weighting 20% - 100% 50 % Warrant investments 25,171 Black-Scholes Valuation Model Price Per Share 0.000 –1,89999 $ 58.11 Average Industry Volatility 28% 28 % Marketability Discount 20% 20 % Estimated Time to Exit (in years) 1 to 5 3 62 Expected Proceeds Price Per Share $0.25 $ 0.25 Other investments 7,254 Multiple Probability Weighted Cash Flow Model Discount Rate 25% 25 % Probability Weighting 30% – 100% 83 % Equity investments 6,810 Last Equity Financing Price Per Share 0.03 215.03 $ 18.30 Total Level 3 investments $ 719,135 December 31, 2022 Fair Valuation Techniques/ Unobservable Weighted Investment Type Value Methodologies Input Range Average(1) (Dollars in thousands, except per share data) Debt investments $ 669,617 Discounted Expected Future Cash Flows Hypothetical Market Yield 3% – 22% 14 % 16,545 Multiple Probability Weighted Cash Flow Model Probability Weighting 10% - 75% 31 % 296 Convertible Note Analysis Price Per Share $168.93 $ 168.93 Warrant investments 26,145 Black-Scholes Valuation Model Price Per Share 0.000 –1.8989 $ 58.52 Average Industry Volatility 28% 28 % Marketability Discount 20% 20 % Estimated Time to Exit (in years) 1 to 5 3 Other investments 1,300 Multiple Probability Weighted Cash Flow Model Discount Rate 25% 25 % Probability Weighting 100% 100 % Equity investments 2,416 Last Equity Financing Price Per Share $1.00– $215.03 $ 26.93 Total Level 3 investments $ 716,319
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	Three months ended September 30, 2023 Debt Warrant Equity Other Investments Investments Investments Investments Total (In thousands) Level 3 assets, beginning of period $ 683,309 $ 24,376 $ 4,259 $ 1,300 $ 713,244 Purchase of investments 66,185 — 750 — 66,935 Warrants received and classified as Level 3 — 1,294 — — 1,294 Principal payments received on investments (25,726 ) — — — (25,726 ) Payment-in-kind interest on investments 3,934 — — — 3,934 Proceeds from sale of investments (2,528 ) (23 ) (6 ) — (2,557 ) Net realized (loss) gain on investments (11,440 ) (118 ) 6 — (11,552 ) Unrealized depreciation included in earnings (18,877 ) (296 ) (1,349 ) (200 ) (20,722 ) Transfer out of Level 3 (5,000 ) — — — (5,000 ) Transfer out of debt investments (9,304 ) — 3,150 6,154 — Other (715 ) — — — (715 ) Level 3 assets, end of period $ 679,838 $ 25,233 $ 6,810 $ 7,254 $ 719,135 Three months ended September 30, 2022 Debt Warrant Equity Other Investments Investments Investments Investments Total (In thousands) Level 3 assets, beginning of period $ 551,560 $ 25,167 $ 453 $ 200 $ 577,380 Purchase of investments 94,627 — — — 94,627 Warrants received and classified as Level 3 — 964 — — 964 Principal payments received on investments (26,929 ) — — (31 ) (26,960 ) Proceeds from sale of investments (6,088 ) (38 ) — — (6,126 ) Net realized (loss) gain on investments (8,492 ) 266 — 31 (8,195 ) Unrealized appreciation (depreciation) included in earnings 8,095 (3,348 ) (420 ) (100 ) 4,227 Transfer out of Level 3 — (1,117 ) — — (1,117 ) Transfer out of debt investments (3,200 ) — 2,000 1,200 — Other (541 ) — — — (541 ) Level 3 assets, end of period $ 609,032 $ 21,894 $ 2,033 $ 1,300 $ 634,259 Nine months ended September 30, 2023 Debt Warrant Equity Other Investments Investments Investments Investments Total (In thousands) Level 3 assets, beginning of period $ 686,458 $ 26,145 $ 2,416 $ 1,300 $ 716,319 Purchase of investments 153,728 — 760 — 154,488 Warrants and equity received and classified as Level 3 — 1,950 89 — 2,039 Principal payments received on investments (90,222 ) — — — (90,222 ) Payment-in-kind interest on investments 6,088 — — — 6,088 Proceeds from sale of investments (9,564 ) (1,493 ) (6 ) — (11,063 ) Net realized (loss) gain on investments (29,105 ) 1,028 (121 ) — (28,198 ) Unrealized depreciation included in earnings (21,325 ) (2,392 ) (2,467 ) (200 ) (26,384 ) Transfer out of Level 3 (5,000 ) — (111 ) — (5,111 ) Transfer out of debt investments (12,399 ) (5 ) 6,250 6,154 — Other 1,179 — — — 1,179 Level 3 assets, end of period $ 679,838 $ 25,233 $ 6,810 $ 7,254 $ 719,135 Nine months ended September 30, 2022 Debt Warrant Equity Other Investments Investments Investments Investments Total (In thousands) Level 3 assets, beginning of period $ 437,317 $ 19,837 $ 203 $ 200 $ 457,557 Purchase of investments 348,097 — 250 — 348,347 Warrants received and classified as Level 3 — 2,441 — — 2,441 Principal payments received on investments (114,120 ) — — (313 ) (114,433 ) Proceeds from sale of investments (49,088 ) (464 ) — — (49,552 ) Net realized (loss) gain on investments (8,492 ) 535 — (1,137 ) (9,094 ) Unrealized appreciation (depreciation) included in earnings 1,128 662 (420 ) 1,350 2,720 Transfer out of Level 3 — (1,117 ) — — (1,117 ) Transfer out of debt investments (3,200 ) — 2,000 1,200 — Other (2,610 ) — — — (2,610 ) Level 3 assets, end of period $ 609,032 $ 21,894 $ 2,033 $ 1,300 $ 634,259

Note 7 - Borrowings (Tables)

Note 7 - Borrowings (Tables)	9 Months Ended
	Sep. 30, 2023
Notes Tables
Schedule of Debt [Table Text Block]	September 30, 2023 December 31, 2022 Total Balance Unused Total Balance Unused Commitment Outstanding Commitment Commitment Outstanding Commitment (In thousands) Key Facility $ 150,000 $ 25,000 $ 125,000 $ 125,000 $ 5,000 $ 120,000 NYL Facility 250,000 181,000 69,000 200,000 176,750 23,250 2019 Asset-Backed Notes 18,696 18,696 — 42,573 42,573 — 2022 Asset-Backed Notes 100,000 100,000 — 100,000 100,000 — 2027 Notes 57,500 57,500 — 57,500 57,500 — 2026 Notes 57,500 57,500 — 57,500 57,500 — Total before debt issuance costs 633,696 439,696 194,000 582,573 439,323 143,250 Unamortized debt issuance costs attributable to term borrowings — (4,196 ) — — (5,245 ) — Total borrowings outstanding, net $ 633,696 $ 435,500 $ 194,000 $ 582,573 $ 434,078 $ 143,250

Note 8 - Financial Instrument_2

Note 8 - Financial Instruments With Off-balance-sheet Risk (Tables)	9 Months Ended
	Sep. 30, 2023
Notes Tables
Schedule of Fair Value, off-Balance-Sheet Risks [Table Text Block]	September 30, 2023 December 31, 2022 Fair Value of Fair Value of Unfunded Unfunded Principal Commitment Principal Commitment Balance Liability Balance Liability (In thousands) (In thousands) BrightInsight, Inc. $ 18,250 $ 241 $ 21,000 $ 278 Britecore Holdings, Inc. 5,000 72 5,000 66 Candesant Biomedical Corporation 10,000 151 — — Castle Creek Biosciences 4,000 72 4,000 72 Divergent Technologies, Inc. 11,250 118 22,500 236 Elligo Healthcare Research, Inc. 15,000 194 — — Engage3, LLC — — 8,000 40 Groundspeed Analytics, Inc. — — 15,000 150 Hound Labs, Inc. — — 7,500 88 KSQ Therapeutics, Inc. — — 10,000 100 Lytics, Inc. 4,000 52 5,000 65 Mirantis, Inc. 15,000 136 — — Native Microbials, Inc. — — 7,500 72 Noodle Partners, Inc. 5,000 61 — — Optoro, Inc. 6,250 — 15,000 38 PDS Biotechnology Corporation — — 10,000 158 Robin Healthcare, Inc. — — 10,000 100 SafelyYou, Inc. 20,000 270 — — Scientia Vascular, Inc. 5,000 55 10,000 110 Slingshot Aerospace, Inc. — — 5,000 64 Sonex Health, Inc. 15,000 176 — — Supply Network Visibility Holdings, LLC 10,000 35 — — Swift Health Systems Inc. 11,500 — 25,500 105 Tallac Therapeutics, Inc. 10,000 229 — — Temperpack Technologies, Inc. 6,500 14 9,000 19 Viken Detection Corporation 10,000 160 — — Total $ 181,750 $ 2,036 $ 190,000 $ 1,761

Note 10 - Distributions (Tables

Note 10 - Distributions (Tables)	9 Months Ended
	Sep. 30, 2023
Notes Tables
Dividends Declared [Table Text Block]	DRIP DRIP Date Amount Cash Shares Share Declared Record Date Payment Date Per Share Distribution Issued Value (In thousands, except share and per share data) Nine Months Ended September 30, 2023 7/28/2023 11/17/23 12/15/23 $ 0.11 $ — — $ — 7/28/2023 10/18/23 11/15/23 0.11 — — — 7/28/2023 9/19/23 10/16/23 0.11 3,445 15,067 184 4/28/2023 8/17/23 9/15/23 0.11 3,458 8,665 106 4/28/2023 7/18/23 8/15/23 0.11 3,427 8,307 105 4/28/2023 6/16/23 7/14/23 0.11 3,434 7,424 96 2/23/2023 5/18/23 6/14/23 0.11 3,087 7,128 86 2/23/2023 4/18/23 5/16/23 0.11 3,068 6,705 84 2/23/2023 3/17/23 4/14/23 0.11 3,035 6,894 81 $ 0.99 $ 22,954 60,190 $ 742 Year Ended December 31, 2022 10/28/2022 2/17/23 3/15/23 $ 0.11 $ 3,040 6,764 $ 75 10/28/2022 1/18/23 2/15/23 0.11 3,021 5,754 74 10/28/2022 12/19/22 1/13/23 0.11 2,978 5,618 69 10/28/2022 11/17/22 12/15/22 0.05 1,319 2,171 27 7/29/2022 11/17/22 12/15/22 0.10 2,638 4,341 57 7/29/2022 10/18/22 11/15/22 0.10 2,580 4,621 60 7/29/2022 9/19/22 10/14/22 0.10 2,558 7,703 81 4/29/2022 8/18/22 9/15/22 0.10 2,528 4,925 60 4/29/2022 7/19/22 8/16/22 0.10 2,484 3,939 55 4/29/2022 6/17/22 7/15/22 0.10 2,434 4,286 51 2/25/2022 5/18/22 6/15/22 0.10 2,378 4,428 50 2/25/2022 4/19/22 5/16/22 0.10 2,349 4,088 49 2/25/2022 3/18/22 4/14/22 0.10 2,352 3,221 46 $ 1.28 $ 32,659 61,859 $ 754 Ex-Dividend Date Record Date Payment Date Distributions Declared February 15, 2024 February 16, 2024 March 15, 2024 $ 0.11 January 17, 2024 January 18, 2024 February 14, 2024 $ 0.11 December 18, 2023 December 19, 2023 January 16, 2024 $ 0.11 Ex-Dividend Date Record Date Payment Date Distributions Declared November 16, 2023 November 17, 2023 December 15, 2023 $ 0.05

Note 11 - Financial Highlights

Note 11 - Financial Highlights (Tables)	9 Months Ended
	Sep. 30, 2023
Notes Tables
Investment Company, Financial Highlights [Table Text Block]	Nine months ended September 30, 2023 2022 (In thousands, except share and per share data) Per share data: Net asset value at beginning of period $ 11.47 $ 11.56 Net investment income 1.54 1.06 Realized loss (0.95 ) (0.40 ) Unrealized (depreciation) appreciation on investments (0.81 ) 0.05 Net increase in net assets resulting from operations (0.22 ) 0.71 Distributions declared (1) (0.99 ) (0.90 ) From net investment income (0.99 ) (0.90 ) From net realized gain on investments — — Return of capital — — Other (2) 0.15 0.29 Net asset value at end of period $ 10.41 $ 11.66 Per share market value, beginning of period $ 11.60 $ 15.92 Per share market value, end of period $ 11.88 $ 10.01 Total return based on a market value (3) 10.9 % (31.5 )% Shares outstanding at end of period 33,306,958 26,393,773 Ratios to average net assets: Expenses without incentive value (4) 14.0 % 11.4 % Incentive fees (4) 1.2 % 3.0 % Net expenses (4) 15.2 % 14.4 % Net investment income with incentive fees (4) 18.5 % 12.1 % Net assets at the end of the period $ 346,575 $ 307,687 Average net asset value $ 335,531 $ 280,904 Average debt per share $ 14.29 $ 13.32 Portfolio turnover ratio 10.0 % (5) 14.9 % (5)

Consolidated Schedule of Inve_3

Consolidated Schedule of Investments (Unaudited) (Details Textual) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022	Nov. 09, 2022	Aug. 13, 2019
Debt Instrument, Face Amount	$ 633,696	$ 582,573
Percentage of Nonqualifying Assets on a Cost Basis	4.50%	6.50%
Percentage of Nonqualifying Assets on a Fair Value Basis	3.90%	6.60%
Asset-backed Notes 2019 [Member]
Debt Instrument, Face Amount	$ 18,696	$ 42,573		$ 160,000
Asset-backed Notes 2019 [Member] | Affiliated Entity [Member]
Debt Instrument, Face Amount				$ 100,000
Asset-backed Notes 2022 [Member]
Debt Instrument, Face Amount	$ 100,000	$ 100,000	$ 157,800
Asset-backed Notes 2022 [Member] | Affiliated Entity [Member]
Debt Instrument, Face Amount			$ 100,000

Consolidated Schedule of Inve_4

Consolidated Schedule of Investments (Unaudited) - Investments (Details) - USD ($) $ in Thousands		Sep. 30, 2023	Jun. 30, 2023	Dec. 31, 2022	Sep. 30, 2022	Jun. 30, 2022	Dec. 31, 2021
Investments at cost		$ 754,814		$ 721,248
Investments at fair value		729,053		720,026
Biotechnology Sector [Member]
Investments at cost		158,953		193,372
Investments at fair value		139,935		195,006
Medical Device Sector [Member]
Investments at cost		140,172		132,803
Investments at fair value		139,039		135,960
Communications Sector [Member]
Investments at cost		21,057		22,892
Investments at fair value		24,317		26,176
Software Sector [Member]
Investments at cost		164,903		120,157
Investments at fair value		161,258		118,716
Other Sustainability Sector [Member]
Investments at cost		89,395		84,633
Investments at fair value		83,476		85,524
Diagnostics Sector [Member]
Investments at cost		9,971		9,851
Investments at fair value		9,939		9,858
Other Healthcare Sector [Member]
Investments at cost		102		7,559
Investments at fair value		1,379		3,870
Data Storage Sector [Member]
Investments at cost		417		476
Investments at fair value		1,070		1,316
Internet and Media Sector [Member]
Investments at cost		329		329
Investments at fair value		1,615		1,159
Networking Sector [Member]
Investments at cost		6,671		11,831
Investments at fair value		6,558		11,710
Power Management Sector [Member]
Investments at cost		1,585		1,585
Investments at fair value		2,901		2,610
Semiconductor Sector [Member]
Investments at cost		56		56
Investments at fair value		0		0
Software, Healthcare Information and Service [Member]
Investments at cost		50,847		13,735
Investments at fair value		50,971		14,044
Evelo Biosciences, Inc. [Member]
Investments at fair value		8,500
Investment, Unaffiliated Issuer [Member]
Investments at cost		700,932		721,248
Investments at fair value		695,423		720,026
Investment, Unaffiliated Issuer [Member] | Debt Securities [Member]
Investments at cost		676,864		701,074
Investments at fair value		663,399		686,458
Investment, Unaffiliated Issuer [Member] | Equity Securities [Member]
Investments at cost		7,211		4,184
Investments at fair value		4,735		2,556
Investment, Unaffiliated Issuer [Member] | Warrant [Member]
Investments at cost		15,657		14,790
Investments at fair value		26,189		29,712
Investment, Unaffiliated Issuer [Member] | Other Long-Term Investments [Member]
Investments at cost		1,200		1,200
Investments at fair value		1,100		1,300
Investment, Unaffiliated Issuer [Member] | Other Sustainability Sector [Member] | Debt Securities [Member]
Investments at cost		88,394
Investments at fair value		82,643
Investment, Unaffiliated Issuer [Member] | Other Sustainability Sector [Member] | Warrant [Member]
Investments at cost		1,001
Investments at fair value		$ 833
Number of Shares (in shares)
Investment, Unaffiliated Issuer [Member] | Technology Sector [Member] | Debt Securities [Member]
Ceiling
Investments at cost		$ 282,962		268,468
Investments at fair value		278,989		259,366
Investment, Unaffiliated Issuer [Member] | Technology Sector [Member] | Warrant [Member]
Investments at cost		9,744		9,249
Investments at fair value		16,313		16,148
Investment, Unaffiliated Issuer [Member] | Life Science [Member] | Debt Securities [Member]
Investments at cost		245,317		318,172
Investments at fair value		241,576		317,568
Investment, Unaffiliated Issuer [Member] | Life Science [Member] | Warrant [Member]
Investments at cost				4,197
Investments at fair value				$ 9,792
Number of Shares (in shares)
Investment, Unaffiliated Issuer [Member] | Healthcare Sector [Member] | Debt Securities [Member]
Investments at cost		60,191		$ 30,729
Investments at fair value		60,191		25,819
Investment, Unaffiliated Issuer [Member] | Healthcare Sector [Member] | Warrant [Member]
Investments at cost		729		416
Investments at fair value		2,098		1,953
Investment, Unaffiliated Issuer [Member] | Life Science Segment [Member] | Warrant [Member]
Investments at cost		4,183
Investments at fair value		$ 6,945
Investment, Unaffiliated Issuer [Member] | Sustainability Segment [Member] | Debt Securities [Member]
Investments at cost				83,705
Investments at fair value				83,705
Investment, Unaffiliated Issuer [Member] | Sustainability Segment [Member] | Warrant [Member]
Investments at cost				928
Investments at fair value				$ 1,819
Number of Shares (in shares)
Investment, Unaffiliated Issuer [Member] | Castle Creek Biosciences, Inc [Member] | Biotechnology Sector [Member] | Term Loan, Prime Index, One [Member]
Cash Rate		13.25%		12.50%
Margin		4.75%		6.05%
Floor		9.55%		9.55%
Ceiling		13.50%		13.50%
ETP		5.50%		5.50%
Maturity Date		May 01, 2026		May 01, 2026
Principal Amount		$ 5,000		$ 5,000
Investments at cost		4,903		4,891
Investments at fair value		$ 4,903		$ 4,891
Investment, Unaffiliated Issuer [Member] | Castle Creek Biosciences, Inc [Member] | Biotechnology Sector [Member] | Term Loan, Prime Index Two [Member]
Cash Rate		13.25%		12.50%
Margin		4.75%		6.05%
Floor		9.55%		9.55%
Ceiling		13.50%		13.50%
ETP		5.50%		5.50%
Maturity Date		May 01, 2026		May 01, 2026
Principal Amount		$ 5,000		$ 5,000
Investments at cost		4,975		4,963
Investments at fair value		4,975		4,963
Investment, Unaffiliated Issuer [Member] | Castle Creek Biosciences, Inc [Member] | Biotechnology Sector [Member] | Preferred Stock Warrants [Member]
Investments at cost		214		214
Investments at fair value		$ 348		$ 335
Number of Shares (in shares)		7,404		7,404
Investment, Unaffiliated Issuer [Member] | Castle Creek Biosciences, Inc [Member] | Biotechnology Sector [Member] | Common Stock [Member]
Investments at cost		$ 250		$ 250
Investments at fair value		$ 250		$ 250
Number of Shares (in shares)		1,162		1,162
Investment, Unaffiliated Issuer [Member] | Castle Creek Biosciences, Inc [Member] | Biotechnology Sector [Member] | Term Loan, Prime Index Three [Member]
Cash Rate		13.25%		12.50%
Margin		4.75%		6.05%
Floor		9.55%		9.55%
Ceiling		13.50%		13.50%
ETP		5.50%		5.50%
Maturity Date		May 01, 2026		May 01, 2026
Principal Amount		$ 3,000		$ 3,000
Investments at cost		2,985		2,978
Investments at fair value		$ 2,985		$ 2,978
Investment, Unaffiliated Issuer [Member] | Castle Creek Biosciences, Inc [Member] | Biotechnology Sector [Member] | Term Loan, Prime Index, Four [Member]
Cash Rate		13.25%		12.50%
Margin		4.75%		6.05%
Floor		9.55%		9.55%
Ceiling		13.50%		13.50%
ETP		5.50%		5.50%
Maturity Date		May 01, 2026		May 01, 2026
Principal Amount		$ 5,000		$ 5,000
Investments at cost		4,975		4,963
Investments at fair value		$ 4,975		$ 4,963
Investment, Unaffiliated Issuer [Member] | Castle Creek Biosciences, Inc [Member] | Biotechnology Sector [Member] | Term Loan, Prime Index, Five [Member]
Cash Rate		13.25%		12.50%
Margin		4.75%		6.05%
Floor		9.55%		9.55%
Ceiling		13.50%		13.50%
ETP		5.50%		5.50%
Maturity Date		May 01, 2026		May 01, 2026
Principal Amount		$ 5,000		$ 5,000
Investments at cost		4,975		4,963
Investments at fair value		$ 4,975		$ 4,963
Investment, Unaffiliated Issuer [Member] | Castle Creek Biosciences, Inc [Member] | Biotechnology Sector [Member] | Term Loan, Prime Index, Six [Member]
Cash Rate		13.25%		12.50%
Margin		4.75%		6.05%
Floor		9.55%		9.55%
Ceiling		13.50%		13.50%
ETP		5.50%		5.50%
Maturity Date		May 01, 2026		May 01, 2026
Principal Amount		$ 3,000		$ 3,000
Investments at cost		2,985		2,978
Investments at fair value		$ 2,985		$ 2,978
Investment, Unaffiliated Issuer [Member] | Robin Healthcare, Inc. [Member] | Medical Device Sector [Member] | Term Loan, Prime Index, One [Member]
Cash Rate		14%		13%
Margin		5.50%		5.50%
Floor		10.25%		10.25%
Ceiling		0%		0%
ETP		4%		4%
Maturity Date		Nov. 01, 2026		Nov. 01, 2026
Principal Amount		$ 3,500		$ 3,500
Investments at cost		3,468		3,360
Investments at fair value		$ 1,749		$ 3,360
Investment, Unaffiliated Issuer [Member] | Robin Healthcare, Inc. [Member] | Medical Device Sector [Member] | Term Loan, Prime Index Two [Member]
Cash Rate		14%		13%
Margin		5.50%		5.50%
Floor		10.25%		10.25%
Ceiling		0%		0%
ETP		4%		4%
Maturity Date		Nov. 01, 2026		Nov. 01, 2026
Principal Amount		$ 3,500		$ 3,500
Investments at cost		3,468		3,460
Investments at fair value		1,749		3,460
Investment, Unaffiliated Issuer [Member] | Robin Healthcare, Inc. [Member] | Medical Device Sector [Member] | Preferred Stock Warrants [Member]
Investments at cost		16		16
Investments at fair value		$ 0		$ 16
Number of Shares (in shares)		86,066		86,066
Investment, Unaffiliated Issuer [Member] | Axiom Space, Inc [Member] | Communications Sector [Member] | Term Loan, Prime Index, One [Member]
Cash Rate		14.50%		13%
Margin		6%		6%
Floor		9.25%		9.25%
Ceiling		0%		0%
ETP		2.50%		2.50%
Maturity Date		Jun. 01, 2026		Jun. 01, 2026
Principal Amount		$ 6,875		$ 7,500
Investments at cost		6,840		7,455
Investments at fair value		$ 6,840		$ 7,455
Investment, Unaffiliated Issuer [Member] | Axiom Space, Inc [Member] | Communications Sector [Member] | Term Loan, Prime Index Two [Member]
Cash Rate		14.50%		13%
Margin		6%		6%
Floor		9.25%		9.25%
Ceiling		0%		0%
ETP		2.50%		2.50%
Maturity Date		Jun. 01, 2026		Jun. 01, 2026
Principal Amount		$ 6,875		$ 7,500
Investments at cost		6,840		7,455
Investments at fair value		6,840		7,455
Investment, Unaffiliated Issuer [Member] | Axiom Space, Inc [Member] | Communications Sector [Member] | Common Stock Warrants [Member]
Investments at cost		46		46
Investments at fair value		$ 69		$ 67
Number of Shares (in shares)		1,991		1,991
Investment, Unaffiliated Issuer [Member] | Axiom Space, Inc [Member] | Communications Sector [Member] | Term Loan, Prime Index Three [Member]
Cash Rate		14.50%		13%
Margin		6%		6%
Floor		9.25%		9.25%
Ceiling		0%		0%
ETP		2.50%		2.50%
Maturity Date		Jun. 01, 2026		Jun. 01, 2026
Principal Amount		$ 6,875		$ 7,500
Investments at cost		6,840		7,455
Investments at fair value		6,840		$ 7,455
Investment, Unaffiliated Issuer [Member] | Axiom Space, Inc [Member] | Communications Sector [Member] | Convertible Debt Securities [Member]
Cash Rate				3%
Maturity Date				Jul. 01, 2023
Principal Amount				$ 250
Investments at cost				250
Investments at fair value				$ 306
Investment, Unaffiliated Issuer [Member] | Axiom Space, Inc [Member] | Technology Sector [Member] | Preferred Stock [Member]
Investments at cost		261
Investments at fair value		$ 306
Number of Shares (in shares)		1,810
Investment, Unaffiliated Issuer [Member] | DropOff, Inc. [Member] | Software Sector [Member] | Term Loan, Prime Index, One [Member]
Cash Rate		15%		14%
Margin		6.50%		6.50%
Floor		9.75%		9.75%
Ceiling		0%		0%
ETP		3.50%		3.50%
Maturity Date		Apr. 01, 2026		Apr. 01, 2026
Principal Amount		$ 6,550		$ 6,500
Investments at cost		6,432		6,347
Investments at fair value		$ 6,377		$ 6,347
Investment, Unaffiliated Issuer [Member] | DropOff, Inc. [Member] | Software Sector [Member] | Term Loan, Prime Index Two [Member]
Cash Rate		15%		14%
Margin		6.50%		6.50%
Floor		9.75%		9.75%
Ceiling		0%		0%
ETP		3.50%		3.50%
Maturity Date		Apr. 01, 2026		Apr. 01, 2026
Principal Amount		$ 6,046		$ 6,000
Investments at cost		5,937		5,859
Investments at fair value		5,886		5,859
Investment, Unaffiliated Issuer [Member] | DropOff, Inc. [Member] | Software Sector [Member] | Common Stock Warrants [Member]
Investments at cost		455		455
Investments at fair value		$ 54		$ 197
Number of Shares (in shares)		516,732		516,732
Investment, Unaffiliated Issuer [Member] | DropOff, Inc. [Member] | Software Sector [Member] | Term Loan, Prime Index Three [Member]
Cash Rate		15%		14%
Margin		6.50%		6.50%
Floor		9.75%		9.75%
Ceiling		0%		0%
ETP		3.50%		3.50%
Maturity Date		Aug. 01, 2026		Aug. 01, 2026
Principal Amount		$ 2,519		$ 2,500
Investments at cost		2,472		2,436
Investments at fair value		2,451		$ 2,436
Investment, Unaffiliated Issuer [Member] | Evelo Biosciences, Inc. [Member] | Biotechnology Sector [Member] | Term Loan, Prime Index, One [Member]
Cash Rate				11.75%
Margin				4.75%
Floor				11%
Ceiling				0%
ETP				4.25%
Maturity Date				Jan. 01, 2028
Principal Amount				$ 10,000
Investments at cost				9,872
Investments at fair value				$ 9,872
Investment, Unaffiliated Issuer [Member] | Evelo Biosciences, Inc. [Member] | Biotechnology Sector [Member] | Term Loan, Prime Index Two [Member]
Cash Rate				11.75%
Margin				4.75%
Floor				11%
Ceiling				0%
ETP				4.25%
Maturity Date				Jan. 01, 2028
Principal Amount				$ 15,000
Investments at cost				14,808
Investments at fair value				14,808
Investment, Unaffiliated Issuer [Member] | Evelo Biosciences, Inc. [Member] | Biotechnology Sector [Member] | Common Stock Warrants [Member]
Investments at cost				126
Investments at fair value				$ 125
Number of Shares (in shares)				463,915
Investment, Unaffiliated Issuer [Member] | Evelo Biosciences, Inc. [Member] | Biotechnology Sector [Member] | Term Loan, Prime Index Three [Member]
Cash Rate				11.75%
Margin				4.75%
Floor				11%
Ceiling				0%
ETP				4.25%
Maturity Date				Jan. 01, 2028
Principal Amount				$ 6,000
Investments at cost				5,923
Investments at fair value				$ 5,923
Investment, Unaffiliated Issuer [Member] | Evelo Biosciences, Inc. [Member] | Biotechnology Sector [Member] | Term Loan, Prime Index, Four [Member]
Cash Rate				11.75%
Margin				4.75%
Floor				11%
Ceiling				0%
ETP				4.25%
Maturity Date				Jan. 01, 2028
Principal Amount				$ 6,000
Investments at cost				5,923
Investments at fair value				$ 5,923
Investment, Unaffiliated Issuer [Member] | Evelo Biosciences, Inc. [Member] | Biotechnology Sector [Member] | Term Loan, Prime Index, Five [Member]
Cash Rate				11.75%
Margin				4.75%
Floor				11%
Ceiling				0%
ETP				4.25%
Maturity Date				Jan. 01, 2028
Principal Amount				$ 4,000
Investments at cost				3,949
Investments at fair value				$ 3,949
Investment, Unaffiliated Issuer [Member] | Evelo Biosciences, Inc. [Member] | Biotechnology Sector [Member] | Term Loan, Prime Index, Six [Member]
Cash Rate				11.75%
Margin				4.75%
Floor				11%
Ceiling				0%
ETP				4.25%
Maturity Date				Jan. 01, 2028
Principal Amount				$ 4,000
Investments at cost				3,949
Investments at fair value				$ 3,949
Investment, Unaffiliated Issuer [Member] | Better Place Forests Co. [Member] | Consumer-related Technologies [Member] | Term Loan, Prime Index, One [Member]
Cash Rate				13.75%
Margin				6.25%
Floor				9.50%
Ceiling				0%
ETP				1.85%
Maturity Date				Jul. 01, 2025
Principal Amount				$ 5,000
Investments at cost				4,951
Investments at fair value				$ 3,834
Investment, Unaffiliated Issuer [Member] | Better Place Forests Co. [Member] | Consumer-related Technologies [Member] | Term Loan, Prime Index Two [Member]
Cash Rate				13.75%
Margin				6.25%
Floor				9.50%
Ceiling				0%
ETP				1.85%
Maturity Date				Oct. 01, 2025
Principal Amount				$ 2,500
Investments at cost				2,474
Investments at fair value				1,916
Investment, Unaffiliated Issuer [Member] | Better Place Forests Co. [Member] | Consumer-related Technologies [Member] | Preferred Stock Warrants [Member]
Investments at cost				26
Investments at fair value				$ 0
Number of Shares (in shares)				10,690
Investment, Unaffiliated Issuer [Member] | Avalo Therapeutics, Inc. [Member] | Biotechnology Sector [Member] | Term Loan, Prime Index, One [Member]
Cash Rate				13.75%
Margin				6.25%
Floor				9.50%
Ceiling				0%
ETP				3%
Maturity Date				Jan. 01, 2025
Principal Amount				$ 2,885
Investments at cost				2,853
Investments at fair value				$ 2,777
Investment, Unaffiliated Issuer [Member] | Avalo Therapeutics, Inc. [Member] | Biotechnology Sector [Member] | Term Loan, Prime Index Two [Member]
Cash Rate				13.75%
Margin				6.25%
Floor				9.50%
Ceiling				0%
ETP				3%
Maturity Date				Jan. 01, 2025
Principal Amount				$ 2,885
Investments at cost				2,823
Investments at fair value				2,750
Investment, Unaffiliated Issuer [Member] | Avalo Therapeutics, Inc. [Member] | Biotechnology Sector [Member] | Common Stock Warrants [Member]
Investments at cost		311		311
Investments at fair value		$ 0		$ 0
Number of Shares (in shares)		26,444		26,442
Investment, Unaffiliated Issuer [Member] | Avalo Therapeutics, Inc. [Member] | Biotechnology Sector [Member] | Term Loan, Prime Index Three [Member]
Cash Rate				13.75%
Margin				6.25%
Floor				9.50%
Ceiling				0%
ETP				3%
Maturity Date				Jan. 01, 2025
Principal Amount				$ 1,442
Investments at cost				1,411
Investments at fair value				$ 1,374
Investment, Unaffiliated Issuer [Member] | Avalo Therapeutics, Inc. [Member] | Biotechnology Sector [Member] | Term Loan, Prime Index, Four [Member]
Cash Rate				13.75%
Margin				6.25%
Floor				9.50%
Ceiling				0%
ETP				3%
Maturity Date				Feb. 01, 2025
Principal Amount				$ 2,885
Investments at cost				2,821
Investments at fair value				$ 2,748
Investment, Unaffiliated Issuer [Member] | Avalo Therapeutics, Inc. [Member] | Biotechnology Sector [Member] | Term Loan, Prime Index, Five [Member]
Cash Rate				13.75%
Margin				6.25%
Floor				9.50%
Ceiling				0%
ETP				3%
Maturity Date				Feb. 01, 2025
Principal Amount				$ 2,885
Investments at cost				2,821
Investments at fair value				$ 2,748
Investment, Unaffiliated Issuer [Member] | Avalo Therapeutics, Inc. [Member] | Biotechnology Sector [Member] | Term Loan, Prime Index, Six [Member]
Cash Rate				13.75%
Margin				6.25%
Floor				9.50%
Ceiling				0%
ETP				3%
Maturity Date				Apr. 01, 2025
Principal Amount				$ 1,442
Investments at cost				1,408
Investments at fair value				$ 1,371
Investment, Unaffiliated Issuer [Member] | Avalo Therapeutics, Inc. [Member] | Biotechnology Sector [Member] | Term Loan, Prime Index, Seven [Member]
Cash Rate				13.75%
Margin				6.25%
Floor				9.50%
Ceiling				0%
ETP				3%
Maturity Date				Apr. 01, 2025
Principal Amount				$ 1,442
Investments at cost				1,408
Investments at fair value				$ 1,371
Investment, Unaffiliated Issuer [Member] | Corinth Medtech, Inc [Member] | Medical Device Sector [Member] | Term Loan, Prime Index, One [Member]
Cash Rate				12.25%
Margin				5.25%
Floor				8.50%
Ceiling				0%
ETP				20%
Maturity Date				Sep. 15, 2022
Principal Amount				$ 2,500
Investments at cost				2,500
Investments at fair value				$ 2,500
Investment, Unaffiliated Issuer [Member] | Corinth Medtech, Inc [Member] | Medical Device Sector [Member] | Term Loan, Prime Index Two [Member]
Cash Rate				12.25%
Margin				5.25%
Floor				8.50%
Ceiling				0%
ETP				20%
Maturity Date				Sep. 15, 2022
Principal Amount				$ 2,500
Investments at cost				2,500
Investments at fair value				$ 2,500
Investment, Unaffiliated Issuer [Member] | Divergent Technologies, Inc. [Member] | Consumer-related Technologies [Member] | Term Loan, Prime Index, One [Member]
Cash Rate		11.25%		11.25%
Margin		6%		6%
Floor		9.50%		9.50%
Ceiling		11.25%		11.25%
ETP		3%		3%
Maturity Date		Jul. 01, 2027		Jul. 01, 2027
Principal Amount		$ 3,750		$ 3,750
Investments at cost		3,605		3,478
Investments at fair value		$ 3,605		$ 3,478
Investment, Unaffiliated Issuer [Member] | Divergent Technologies, Inc. [Member] | Consumer-related Technologies [Member] | Term Loan, Prime Index Two [Member]
Cash Rate		11.25%		11.25%
Margin		6%		6%
Floor		9.50%		9.50%
Ceiling		11.25%		11.25%
ETP		3%		3%
Maturity Date		Jul. 01, 2027		Jul. 01, 2027
Principal Amount		$ 1,250		$ 1,250
Investments at cost		1,241		1,238
Investments at fair value		1,241		1,238
Investment, Unaffiliated Issuer [Member] | Divergent Technologies, Inc. [Member] | Consumer-related Technologies [Member] | Preferred Stock Warrants [Member]
Investments at cost		92		56
Investments at fair value		$ 279		$ 233
Number of Shares (in shares)		37,294		31,966
Investment, Unaffiliated Issuer [Member] | Divergent Technologies, Inc. [Member] | Consumer-related Technologies [Member] | Term Loan, Prime Index Three [Member]
Cash Rate		11.25%		11.25%
Margin		6%		6%
Floor		9.50%		9.50%
Ceiling		11.25%		11.25%
ETP		3%		3%
Maturity Date		Jul. 01, 2027		Jul. 01, 2027
Principal Amount		$ 3,750		$ 3,750
Investments at cost		3,723		3,715
Investments at fair value		$ 3,723		$ 3,715
Investment, Unaffiliated Issuer [Member] | Divergent Technologies, Inc. [Member] | Consumer-related Technologies [Member] | Term Loan, Prime Index, Four [Member]
Cash Rate		11.25%		11.25%
Margin		6%		6%
Floor		9.50%		9.50%
Ceiling		11.25%		11.25%
ETP		3%		3%
Maturity Date		Jul. 01, 2027		Jul. 01, 2027
Principal Amount		$ 1,250		$ 1,250
Investments at cost		1,241		1,238
Investments at fair value		$ 1,241		$ 1,238
Investment, Unaffiliated Issuer [Member] | Divergent Technologies, Inc. [Member] | Consumer-related Technologies [Member] | Term Loan, Prime Index, Five [Member]
Cash Rate		11.25%		11.25%
Margin		6%		6%
Floor		9.50%		9.50%
Ceiling		11.25%		11.25%
ETP		3%		3%
Maturity Date		Jul. 01, 2027		Jul. 01, 2027
Principal Amount		$ 3,750		$ 3,750
Investments at cost		3,723		3,715
Investments at fair value		$ 3,723		$ 3,715
Investment, Unaffiliated Issuer [Member] | Divergent Technologies, Inc. [Member] | Consumer-related Technologies [Member] | Term Loan, Prime Index, Six [Member]
Cash Rate		11.25%		11.25%
Margin		6%		6%
Floor		9.50%		9.50%
Ceiling		11.25%		11.25%
ETP		3%		3%
Maturity Date		Jul. 01, 2027		Jul. 01, 2027
Principal Amount		$ 1,250		$ 1,250
Investments at cost		1,241		1,238
Investments at fair value		$ 1,241		$ 1,238
Investment, Unaffiliated Issuer [Member] | Divergent Technologies, Inc. [Member] | Consumer-related Technologies [Member] | Term Loan, Prime Index, Seven [Member]
Cash Rate		11.25%		11.25%
Margin		6%		6%
Floor		9.50%		9.50%
Ceiling		11.25%		11.25%
ETP		3%		3%
Maturity Date		Jan. 01, 2028		Jan. 01, 2028
Principal Amount		$ 3,750		$ 3,750
Investments at cost		3,709		3,698
Investments at fair value		$ 3,709		$ 3,698
Investment, Unaffiliated Issuer [Member] | Divergent Technologies, Inc. [Member] | Consumer-related Technologies [Member] | Term Loan, Prime Index, Eight [Member]
Cash Rate		11.25%		11.25%
Margin		6%		6%
Floor		9.50%		9.50%
Ceiling		11.25%		11.25%
ETP		3%		3%
Maturity Date		Jan. 01, 2028		Jan. 01, 2028
Principal Amount		$ 3,750		$ 3,750
Investments at cost		3,703		3,698
Investments at fair value		$ 3,703		$ 3,698
Investment, Unaffiliated Issuer [Member] | Divergent Technologies, Inc. [Member] | Consumer-related Technologies [Member] | Term Loan, Prime Index, Nine [Member]
Cash Rate		11.25%
Margin		6%
Floor		9.50%
Ceiling		11.25%
ETP		3%
Maturity Date		Apr. 01, 2028
Principal Amount		$ 3,750
Investments at cost		3,709
Investments at fair value		$ 3,709
Investment, Unaffiliated Issuer [Member] | Divergent Technologies, Inc. [Member] | Consumer-related Technologies [Member] | Term Loan, Prime Index, Ten [Member]
Cash Rate		11.25%
Margin		6%
Floor		9.50%
Ceiling		11.25%
ETP		3%
Maturity Date		Jul. 01, 2028
Principal Amount		$ 3,750
Investments at cost		3,705
Investments at fair value		$ 3,705
Investment, Unaffiliated Issuer [Member] | Divergent Technologies, Inc. [Member] | Consumer-related Technologies [Member] | Term Loan, Prime Index, Eleven [Member]
Cash Rate		11.25%
Margin		6%
Floor		9.50%
Ceiling		11.25%
ETP		3%
Maturity Date		Jul. 01, 2028
Principal Amount		$ 3,750
Investments at cost		3,705
Investments at fair value		$ 3,705
Investment, Unaffiliated Issuer [Member] | New Aerofarms, Inc. assignee of Aerofarms, Inc [Member] | Other Sustainability Sector [Member] | Term Loan, Prime Index, One [Member]
Cash Rate		15.25%
Margin		6.75%
Floor		10%
Ceiling		0%
ETP		4.33%
Maturity Date		Dec. 01, 2026
Principal Amount		$ 3,750
Investments at cost		3,675
Investments at fair value		$ 3,675
Investment, Unaffiliated Issuer [Member] | New Aerofarms, Inc. assignee of Aerofarms, Inc [Member] | Other Sustainability Sector [Member] | Term Loan, Prime Index Two [Member]
Cash Rate		15.25%
Margin		6.75%
Floor		10%
Ceiling		0%
ETP		4.33%
Maturity Date		Dec. 01, 2026
Principal Amount		$ 3,750
Investments at cost		3,675
Investments at fair value		3,675
Investment, Unaffiliated Issuer [Member] | New Aerofarms, Inc. assignee of Aerofarms, Inc [Member] | Other Sustainability Sector [Member] | Preferred Stock Warrants [Member]
Investments at cost		81
Investments at fair value		$ 81
Number of Shares (in shares)		400,000
Investment, Unaffiliated Issuer [Member] | Hound Labs, Inc. [Member] | Diagnostics Sector [Member] | Term Loan, Prime Index, One [Member]
Cash Rate		14.50%		13.50%
Margin		6%		6%
Floor		9.25%		9.25%
Ceiling		0%		0%
ETP		3.50%		3.50%
Maturity Date		Jun. 01, 2026		Jun. 01, 2026
Principal Amount		$ 2,500		$ 2,500
Investments at cost		2,481		2,385
Investments at fair value		$ 2,481		$ 2,385
Investment, Unaffiliated Issuer [Member] | Hound Labs, Inc. [Member] | Diagnostics Sector [Member] | Term Loan, Prime Index Two [Member]
Cash Rate		14.50%		13.50%
Margin		6%		6%
Floor		9.25%		9.25%
Ceiling		0%		0%
ETP		3.50%		3.50%
Maturity Date		Jun. 01, 2026		Jun. 01, 2026
Principal Amount		$ 2,500		$ 2,500
Investments at cost		2,481		2,473
Investments at fair value		2,481		2,473
Investment, Unaffiliated Issuer [Member] | Hound Labs, Inc. [Member] | Diagnostics Sector [Member] | Preferred Stock Warrants [Member]
Investments at cost		47		47
Investments at fair value		$ 15		$ 54
Number of Shares (in shares)		171,370		159,893
Investment, Unaffiliated Issuer [Member] | Hound Labs, Inc. [Member] | Diagnostics Sector [Member] | Term Loan, Prime Index Three [Member]
Cash Rate		14.50%		13.50%
Margin		6%		6%
Floor		9.25%		9.25%
Ceiling		0%		0%
ETP		3.50%		3.50%
Maturity Date		Jun. 01, 2026		Jun. 01, 2026
Principal Amount		$ 5,000		$ 5,000
Investments at cost		4,962		4,946
Investments at fair value		$ 4,962		$ 4,946
Investment, Unaffiliated Issuer [Member] | Scientia Vascular, Inc. [Member] | Medical Device Sector [Member] | Term Loan, Prime Index, One [Member]
Cash Rate		13.25%		11.75%
Margin		4.75%		4.75%
Floor		8.50%		8.50%
Ceiling		0%		0%
ETP		5%		5%
Maturity Date		Jan. 01, 2027		Jan. 01, 2027
Principal Amount		$ 3,750		$ 3,750
Investments at cost		3,663		3,597
Investments at fair value		$ 3,663		$ 3,597
Investment, Unaffiliated Issuer [Member] | Scientia Vascular, Inc. [Member] | Medical Device Sector [Member] | Term Loan, Prime Index Two [Member]
Cash Rate		13.25%		11.75%
Margin		4.75%		4.75%
Floor		8.50%		8.50%
Ceiling		0%		0%
ETP		5%		5%
Maturity Date		Jan. 01, 2027		Jan. 01, 2027
Principal Amount		$ 3,750		$ 3,750
Investments at cost		3,718		3,706
Investments at fair value		3,718		3,706
Investment, Unaffiliated Issuer [Member] | Scientia Vascular, Inc. [Member] | Medical Device Sector [Member] | Preferred Stock Warrants [Member]
Investments at cost		59		40
Investments at fair value		$ 230		$ 46
Number of Shares (in shares)		27,036		19,662
Investment, Unaffiliated Issuer [Member] | Scientia Vascular, Inc. [Member] | Medical Device Sector [Member] | Term Loan, Prime Index Three [Member]
Cash Rate		13.75%
Margin		5.25%
Floor		9%
Ceiling		0%
ETP		5%
Maturity Date		Mar. 01, 2027
Principal Amount		$ 5,000
Investments at cost		4,938
Investments at fair value		4,938
Investment, Unaffiliated Issuer [Member] | LiquiGlide, Inc [Member] | Other Sustainability Sector [Member] | Common Stock Warrants [Member]
Investments at cost		41		$ 39
Investments at fair value		$ 59		$ 55
Number of Shares (in shares)		61,359		61,539
Investment, Unaffiliated Issuer [Member] | Kate Farms, Inc [Member] | Other Healthcare Sector [Member] | Preferred Stock Warrants [Member]
Investments at cost		$ 102		$ 102
Investments at fair value		$ 1,379		$ 1,370
Number of Shares (in shares)		82,965		82,965
Investment, Unaffiliated Issuer [Member] | CSA Medical, Inc [Member] | Medical Device Sector [Member] | Term Loan, Prime Index, One [Member]
Cash Rate		13.59%
Margin		5.09%
Floor		10%
Ceiling		0%
ETP		5%
Maturity Date		Jan. 01, 2024
Principal Amount		$ 750
Investments at cost		739
Investments at fair value		$ 739
Investment, Unaffiliated Issuer [Member] | CSA Medical, Inc [Member] | Medical Device Sector [Member] | Term Loan, Prime Index Two [Member]
Cash Rate		13.59%
Margin		5.09%
Floor		10%
Ceiling		0%
ETP		5%
Maturity Date		Jan. 01, 2024
Principal Amount		$ 50
Investments at cost		49
Investments at fair value		49
Investment, Unaffiliated Issuer [Member] | CSA Medical, Inc [Member] | Medical Device Sector [Member] | Preferred Stock Warrants [Member]
Investments at cost		172		$ 153
Investments at fair value		$ 176		$ 150
Number of Shares (in shares)		1,730,746		1,375,727
Investment, Unaffiliated Issuer [Member] | CSA Medical, Inc [Member] | Medical Device Sector [Member] | Term Loan, Prime Index Three [Member]
Cash Rate		13.59%
Margin		5.09%
Floor		10%
Ceiling		0%
ETP		5%
Maturity Date		Mar. 01, 2024
Principal Amount		$ 1,067
Investments at cost		1,052
Investments at fair value		1,052
Investment, Unaffiliated Issuer [Member] | CSA Medical, Inc [Member] | Medical Device Sector [Member] | Term Loan, LIBOR Index, One [Member]
Cash Rate				12.37%
Margin				8.20%
Floor				10%
Ceiling				0%
ETP				5%
Maturity Date				Jan. 01, 2024
Principal Amount				$ 1,625
Investments at cost				1,610
Investments at fair value				$ 1,610
Investment, Unaffiliated Issuer [Member] | CSA Medical, Inc [Member] | Medical Device Sector [Member] | Term Loan, LIBOR Index, Two [Member]
Cash Rate				12.37%
Margin				8.20%
Floor				10%
Ceiling				0%
ETP				5%
Maturity Date				Jan. 01, 2024
Principal Amount				$ 108
Investments at cost				107
Investments at fair value				$ 107
Investment, Unaffiliated Issuer [Member] | CSA Medical, Inc [Member] | Medical Device Sector [Member] | Term Loan, LIBOR Index, Three [Member]
Cash Rate				12.37%
Margin				8.20%
Floor				10%
Ceiling				0%
ETP				5%
Maturity Date				Mar. 01, 2024
Principal Amount				$ 2,000
Investments at cost				1,983
Investments at fair value				1,983
Investment, Unaffiliated Issuer [Member] | Intelepeer Holdings, Inc [Member] | Communications Sector [Member] | Preferred Stock Warrants [Member]
Investments at cost		138		139
Investments at fair value		$ 3,283		$ 3,265
Number of Shares (in shares)		2,936,535		2,936,535
Investment, Unaffiliated Issuer [Member] | CAMP NYC, Inc [Member] | Consumer-related Technologies [Member] | Term Loan, Prime Index, One [Member]
Cash Rate		15.75%		14.75%
Margin		7.25%		7.25%
Floor		10.50%		10.50%
Ceiling		0%		0%
ETP		3%		3%
Maturity Date		May 01, 2026		May 01, 2026
Principal Amount		$ 3,500		$ 3,500
Investments at cost		3,470		3,461
Investments at fair value		3,470		3,461
Investment, Unaffiliated Issuer [Member] | CAMP NYC, Inc [Member] | Consumer-related Technologies [Member] | Preferred Stock Warrants [Member]
Investments at cost		22		20
Investments at fair value		$ 30		$ 61
Number of Shares (in shares)		75,997		17,605
Investment, Unaffiliated Issuer [Member] | Engage3, LLC [Member] | Software Sector [Member] | Term Loan, Prime Index, One [Member]
Cash Rate		14.75%		13.25%
Margin		6.25%		6.25%
Floor		9.75%		9.75%
Ceiling		0%		0%
ETP		4.50%		4.50%
Maturity Date		Jul. 01, 2027		Jul. 01, 2027
Principal Amount		$ 3,750		$ 3,750
Investments at cost		3,726		3,678
Investments at fair value		$ 3,726		$ 3,678
Investment, Unaffiliated Issuer [Member] | Engage3, LLC [Member] | Software Sector [Member] | Term Loan, Prime Index Two [Member]
Cash Rate		14.75%		13.25%
Margin		6.25%		6.25%
Floor		9.75%		9.75%
Ceiling		0%		0%
ETP		4.50%		4.50%
Maturity Date		Jul. 01, 2027		Jul. 01, 2027
Principal Amount		$ 3,750		$ 3,750
Investments at cost		3,726		3,718
Investments at fair value		$ 3,726		3,718
Investment, Unaffiliated Issuer [Member] | Emalex Biosciences, Inc. [Member] | Biotechnology Sector [Member] | Term Loan, Prime Index, One [Member]
Cash Rate		13.22%
Margin		4.72%
Floor		9.75%
Ceiling		0%
ETP		5%
Maturity Date		Jun. 01, 2024
Principal Amount		$ 1,979
Investments at cost		1,971
Investments at fair value		$ 1,971
Investment, Unaffiliated Issuer [Member] | Emalex Biosciences, Inc. [Member] | Biotechnology Sector [Member] | Term Loan, Prime Index Two [Member]
Cash Rate		13.22%
Margin		4.72%
Floor		9.75%
Ceiling		0%
ETP		5%
Maturity Date		Jun. 01, 2024
Principal Amount		$ 1,979
Investments at cost		1,972
Investments at fair value		1,972
Investment, Unaffiliated Issuer [Member] | Emalex Biosciences, Inc. [Member] | Biotechnology Sector [Member] | Preferred Stock Warrants [Member]
Investments at cost		176		176
Investments at fair value		$ 269		$ 263
Number of Shares (in shares)		110,402		110,402
Investment, Unaffiliated Issuer [Member] | Emalex Biosciences, Inc. [Member] | Biotechnology Sector [Member] | Common Stock [Member]
Investments at cost		$ 355		$ 356
Investments at fair value		$ 356		$ 356
Number of Shares (in shares)		32,831		32,831
Investment, Unaffiliated Issuer [Member] | Emalex Biosciences, Inc. [Member] | Biotechnology Sector [Member] | Term Loan, Prime Index Three [Member]
Cash Rate		13.22%
Margin		4.72%
Floor		9.75%
Ceiling		0%
ETP		5%
Maturity Date		Nov. 01, 2025
Principal Amount		$ 5,000
Investments at cost		4,943
Investments at fair value		$ 4,943
Investment, Unaffiliated Issuer [Member] | Emalex Biosciences, Inc. [Member] | Biotechnology Sector [Member] | Term Loan, LIBOR Index, One [Member]
Cash Rate				12.07%
Margin				7.90%
Floor				9.75%
Ceiling				0%
ETP				5%
Maturity Date				Jun. 01, 2024
Principal Amount				$ 1,979
Investments at cost				1,962
Investments at fair value				$ 1,962
Investment, Unaffiliated Issuer [Member] | Emalex Biosciences, Inc. [Member] | Biotechnology Sector [Member] | Term Loan, Prime Index, Four [Member]
Cash Rate		13.22%
Margin		4.72%
Floor		9.75%
Ceiling		0%
ETP		5%
Maturity Date		May 01, 2026
Principal Amount		$ 5,000
Investments at cost		4,939
Investments at fair value		4,939
Investment, Unaffiliated Issuer [Member] | Emalex Biosciences, Inc. [Member] | Biotechnology Sector [Member] | Term Loan, LIBOR Index, Two [Member]
Cash Rate				12.07%
Margin				7.90%
Floor				9.75%
Ceiling				0%
ETP				5%
Maturity Date				Jun. 01, 2024
Principal Amount				$ 1,979
Investments at cost				1,963
Investments at fair value				$ 1,963
Investment, Unaffiliated Issuer [Member] | Emalex Biosciences, Inc. [Member] | Biotechnology Sector [Member] | Term Loan, LIBOR Index, Three [Member]
Cash Rate				12.07%
Margin				7.90%
Floor				9.75%
Ceiling				0%
ETP				5%
Maturity Date				Nov. 01, 2025
Principal Amount				$ 5,000
Investments at cost				4,923
Investments at fair value				$ 4,923
Investment, Unaffiliated Issuer [Member] | Emalex Biosciences, Inc. [Member] | Biotechnology Sector [Member] | Term Loan, LIBOR Index, Four [Member]
Cash Rate				12.07%
Margin				7.90%
Floor				9.75%
Ceiling				0%
ETP				5%
Maturity Date				May 01, 2026
Principal Amount				$ 5,000
Investments at cost				4,912
Investments at fair value				$ 4,912
Investment, Unaffiliated Issuer [Member] | Nexii Building Solutions, Inc [Member] | Other Sustainability Sector [Member] | Common Stock Warrants [Member]
Investments at cost		490
Investments at fair value		$ 0
Number of Shares (in shares)		217,726
Investment, Unaffiliated Issuer [Member] | BrightInsight, Inc. [Member] | Software Sector [Member] | Term Loan, Prime Index, One [Member]
Cash Rate		14%
Margin		5.50%
Floor		9.50%
Ceiling		0%
ETP		3%
Maturity Date		Aug. 01, 2027
Principal Amount		$ 7,000
Investments at cost		6,677
Investments at fair value		$ 6,677
Investment, Unaffiliated Issuer [Member] | BrightInsight, Inc. [Member] | Software Sector [Member] | Term Loan, Prime Index Two [Member]
Cash Rate		14%
Margin		5.50%
Floor		9.50%
Ceiling		0%
ETP		3%
Maturity Date		Aug. 01, 2027
Principal Amount		$ 3,500
Investments at cost		3,459
Investments at fair value		3,459
Investment, Unaffiliated Issuer [Member] | BrightInsight, Inc. [Member] | Software Sector [Member] | Preferred Stock Warrants [Member]
Investments at cost		167
Investments at fair value		$ 0
Number of Shares (in shares)		85,066
Investment, Unaffiliated Issuer [Member] | BrightInsight, Inc. [Member] | Software Sector [Member] | Term Loan, Prime Index Three [Member]
Cash Rate		14%
Margin		5.50%
Floor		9.50%
Ceiling		0%
ETP		3%
Maturity Date		Aug. 01, 2027
Principal Amount		$ 3,500
Investments at cost		3,459
Investments at fair value		$ 3,459
Investment, Unaffiliated Issuer [Member] | BrightInsight, Inc. [Member] | Software Sector [Member] | Term Loan, Prime Index, Four [Member]
Cash Rate		14%
Margin		5.50%
Floor		9.50%
Ceiling		0%
ETP		3%
Maturity Date		Apr. 01, 2028
Principal Amount		$ 2,750
Investments at cost		2,708
Investments at fair value		2,708
Investment, Unaffiliated Issuer [Member] | BrightInsight, Inc. [Member] | Software, Healthcare Information and Service [Member] | Term Loan, Prime Index, One [Member]
Cash Rate				12.50%
Margin				5.50%
Floor				9.50%
Ceiling				0%
ETP				3%
Maturity Date				Aug. 01, 2027
Principal Amount				$ 7,000
Investments at cost				6,619
Investments at fair value				$ 6,619
Investment, Unaffiliated Issuer [Member] | BrightInsight, Inc. [Member] | Software, Healthcare Information and Service [Member] | Term Loan, Prime Index Two [Member]
Cash Rate				12.50%
Margin				5.50%
Floor				9.50%
Ceiling				0%
ETP				3%
Maturity Date				Aug. 01, 2027
Principal Amount				$ 3,500
Investments at cost				3,448
Investments at fair value				3,448
Investment, Unaffiliated Issuer [Member] | BrightInsight, Inc. [Member] | Software, Healthcare Information and Service [Member] | Preferred Stock Warrants [Member]
Investments at cost				160
Investments at fair value				$ 170
Number of Shares (in shares)				80,544
Investment, Unaffiliated Issuer [Member] | BrightInsight, Inc. [Member] | Software, Healthcare Information and Service [Member] | Term Loan, Prime Index Three [Member]
Cash Rate				12.50%
Margin				5.50%
Floor				9.50%
Ceiling				0%
ETP				3%
Maturity Date				Aug. 01, 2027
Principal Amount				$ 3,500
Investments at cost				3,448
Investments at fair value				3,448
Investment, Unaffiliated Issuer [Member] | Corvium, Inc [Member] | Biotechnology Sector [Member] | Preferred Stock Warrants [Member]
Investments at cost				53
Investments at fair value				$ 0
Number of Shares (in shares)				661,956
Investment, Unaffiliated Issuer [Member] | PebblePost, Inc [Member] | Communications Sector [Member] | Preferred Stock Warrants [Member]
Investments at cost		92		$ 92
Investments at fair value		$ 139		$ 173
Number of Shares (in shares)		598,850		598,850
Investment, Unaffiliated Issuer [Member] | Clara Foods Co [Member] | Consumer-related Technologies [Member] | Term Loan, Prime Index, One [Member]
Cash Rate		14.25%		12.75%
Margin		5.75%		5.75%
Floor		9%		9%
Ceiling		0%		0%
ETP		5.50%		5.50%
Maturity Date		Aug. 01, 2025		Aug. 01, 2025
Principal Amount		$ 1,833		$ 2,500
Investments at cost		1,821		2,482
Investments at fair value		$ 1,821		$ 2,482
Investment, Unaffiliated Issuer [Member] | Clara Foods Co [Member] | Consumer-related Technologies [Member] | Term Loan, Prime Index Two [Member]
Cash Rate		14.25%		12.75%
Margin		5.75%		5.75%
Floor		9%		9%
Ceiling		0%		0%
ETP		5.50%		5.50%
Maturity Date		Aug. 01, 2025		Aug. 01, 2025
Principal Amount		$ 1,833		$ 2,500
Investments at cost		1,821		2,482
Investments at fair value		1,821		2,482
Investment, Unaffiliated Issuer [Member] | Clara Foods Co [Member] | Consumer-related Technologies [Member] | Preferred Stock Warrants [Member]
Investments at cost		31		30
Investments at fair value		$ 128		$ 125
Number of Shares (in shares)		46,745		46,745
Investment, Unaffiliated Issuer [Member] | Imunon, Inc [Member] | Biotechnology Sector [Member] | Common Stock Warrants [Member]
Investments at cost		$ 65		$ 66
Investments at fair value		$ 0		$ 0
Number of Shares (in shares)		19,671		16,502
Investment, Unaffiliated Issuer [Member] | Soli Organic, Inc [Member] | Other Sustainability Sector [Member] | Term Loan, Prime Index, One [Member]
Cash Rate		15.25%		14.25%
Margin		6.75%		6.75%
Floor		10%		10%
Ceiling		0%		0%
ETP		2.75%		2.75%
Maturity Date		Apr. 01, 2026		Apr. 01, 2026
Principal Amount		$ 5,000		$ 2,500
Investments at cost		4,951		2,463
Investments at fair value		$ 4,951		$ 2,463
Investment, Unaffiliated Issuer [Member] | Soli Organic, Inc [Member] | Other Sustainability Sector [Member] | Term Loan, Prime Index Two [Member]
Cash Rate		15.25%		14.25%
Margin		6.75%		6.75%
Floor		10%		10%
Ceiling		0%		0%
ETP		2.75%		2.75%
Maturity Date		Apr. 01, 2026		Apr. 01, 2026
Principal Amount		$ 2,500		$ 5,000
Investments at cost		2,475		4,927
Investments at fair value		2,475		4,927
Investment, Unaffiliated Issuer [Member] | Soli Organic, Inc [Member] | Other Sustainability Sector [Member] | Preferred Stock Warrants [Member]
Investments at cost		214		214
Investments at fair value		$ 371		$ 361
Number of Shares (in shares)		681		681
Investment, Unaffiliated Issuer [Member] | Soli Organic, Inc [Member] | Other Sustainability Sector [Member] | Term Loan, Prime Index Three [Member]
Cash Rate		15.25%		14.25%
Margin		6.75%		6.75%
Floor		10%		10%
Ceiling		0%		0%
ETP		2.75%		2.75%
Maturity Date		May 01, 2026		May 01, 2026
Principal Amount		$ 5,000		$ 5,000
Investments at cost		4,948		4,924
Investments at fair value		$ 4,948		$ 4,924
Investment, Unaffiliated Issuer [Member] | Soli Organic, Inc [Member] | Other Sustainability Sector [Member] | Term Loan, Prime Index, Four [Member]
Cash Rate		15.25%		14.25%
Margin		6.75%		6.75%
Floor		10%		10%
Ceiling		0%		0%
ETP		2.75%		2.75%
Maturity Date		May 01, 2026		May 01, 2026
Principal Amount		$ 2,500		$ 2,500
Investments at cost		2,474		2,462
Investments at fair value		$ 2,474		$ 2,462
Investment, Unaffiliated Issuer [Member] | Soli Organic, Inc [Member] | Other Sustainability Sector [Member] | Term Loan, Prime Index, Five [Member]
Cash Rate		14%		13%
Margin		5.50%		5.50%
Floor		11.75%		10%
Ceiling		0%		0%
ETP		2.75%		2.75%
Maturity Date		Dec. 01, 2026		Dec. 01, 2026
Principal Amount		$ 5,000		$ 5,000
Investments at cost		4,926		4,900
Investments at fair value		$ 4,926		$ 4,900
Investment, Unaffiliated Issuer [Member] | Soli Organic, Inc [Member] | Other Sustainability Sector [Member] | Term Loan, Prime Index, Six [Member]
Cash Rate		14%		13%
Margin		5.50%		5.50%
Floor		11.75%		10%
Ceiling		0%		0%
ETP		2.75%		2.75%
Maturity Date		Dec. 01, 2026		Dec. 01, 2026
Principal Amount		$ 2,500		$ 2,500
Investments at cost		2,463		2,450
Investments at fair value		$ 2,463		$ 2,450
Investment, Unaffiliated Issuer [Member] | Elligo Health Research, Inc [Member] | Software Sector [Member] | Term Loan, Prime Index, One [Member]
Cash Rate		12%
Margin		3.50%
Floor		11.75%
Ceiling		0%
ETP		4%
Maturity Date		Oct. 01, 2027
Principal Amount		$ 10,000
Investments at cost		9,647
Investments at fair value		$ 9,647
Investment, Unaffiliated Issuer [Member] | Elligo Health Research, Inc [Member] | Software Sector [Member] | Term Loan, Prime Index Two [Member]
Cash Rate		12%
Margin		3.50%
Floor		11.75%
Ceiling		0%
ETP		4%
Maturity Date		Oct. 01, 2027
Principal Amount		$ 5,000
Investments at cost		4,921
Investments at fair value		4,921
Investment, Unaffiliated Issuer [Member] | Elligo Health Research, Inc [Member] | Software Sector [Member] | Preferred Stock Warrants [Member]
Investments at cost		189
Investments at fair value		$ 191
Number of Shares (in shares)		652,250
Investment, Unaffiliated Issuer [Member] | Elligo Health Research, Inc [Member] | Software Sector [Member] | Term Loan, Prime Index Three [Member]
Cash Rate		12%
Margin		3.50%
Floor		11.75%
Ceiling		0%
ETP		4%
Maturity Date		Oct. 01, 2027
Principal Amount		$ 5,000
Investments at cost		4,921
Investments at fair value		$ 4,921
Investment, Unaffiliated Issuer [Member] | Elligo Health Research, Inc [Member] | Software Sector [Member] | Term Loan, Prime Index, Four [Member]
Cash Rate		12%
Margin		3.50%
Floor		11.75%
Ceiling		0%
ETP		4%
Maturity Date		Oct. 01, 2027
Principal Amount		$ 5,000
Investments at cost		4,921
Investments at fair value		4,921
Investment, Unaffiliated Issuer [Member] | Alula Holdings, Inc [Member] | Consumer-related Technologies [Member] | Term Loan, Prime Index, One [Member]
Cash Rate				13.75%
Margin				6.75%
Floor				10%
Ceiling				0%
ETP				3%
Maturity Date				Jan. 01, 2025
Principal Amount				$ 5,000
Investments at cost				4,966
Investments at fair value				$ 4,966
Investment, Unaffiliated Issuer [Member] | Alula Holdings, Inc [Member] | Consumer-related Technologies [Member] | Term Loan, Prime Index Two [Member]
Cash Rate				13.75%
Margin				6.75%
Floor				10%
Ceiling				0%
ETP				3%
Maturity Date				Jan. 01, 2025
Principal Amount				$ 5,000
Investments at cost				4,966
Investments at fair value				4,966
Investment, Unaffiliated Issuer [Member] | Alula Holdings, Inc [Member] | Consumer-related Technologies [Member] | Preferred Stock Warrants [Member]
Investments at cost		93		93
Investments at fair value		$ 0		$ 64
Number of Shares (in shares)		20,000		20,000
Investment, Unaffiliated Issuer [Member] | Alula Holdings, Inc [Member] | Consumer-related Technologies [Member] | Term Loan, Prime Index Three [Member]
Cash Rate				13.75%
Margin				6.75%
Floor				10%
Ceiling				0%
ETP				3%
Maturity Date				Jan. 01, 2025
Principal Amount				$ 3,000
Investments at cost				2,979
Investments at fair value				$ 2,979
Investment, Unaffiliated Issuer [Member] | Alula Holdings, Inc [Member] | Consumer-related Technologies [Member] | Term Loan, Prime Index, Four [Member]
Cash Rate				13.75%
Margin				6.75%
Floor				10%
Ceiling				0%
ETP				3%
Maturity Date				Dec. 01, 2025
Principal Amount				$ 1,000
Investments at cost				976
Investments at fair value				$ 976
Investment, Unaffiliated Issuer [Member] | Alula Holdings, Inc [Member] | Consumer-related Technologies [Member] | Term Loan, Prime Index, Five [Member]
Cash Rate				13.75%
Margin				6.75%
Floor				10%
Ceiling				0%
ETP				3%
Maturity Date				Feb. 01, 2026
Principal Amount				$ 1,000
Investments at cost				977
Investments at fair value				$ 977
Investment, Unaffiliated Issuer [Member] | Sonex Health, Inc. [Member] | Medical Device Sector [Member] | Term Loan, Prime Index, One [Member]
Cash Rate		12%		13.50%
Margin		3.50%		6.50%
Floor		11.75%		9.75%
Ceiling		0%		0%
ETP		8%		8%
Maturity Date		Sep. 01, 2027		Jun. 01, 2025
Principal Amount		$ 2,500		$ 2,500
Investments at cost		2,295		2,476
Investments at fair value		$ 2,295		$ 2,476
Investment, Unaffiliated Issuer [Member] | Sonex Health, Inc. [Member] | Medical Device Sector [Member] | Term Loan, Prime Index Two [Member]
Cash Rate		12%		13.50%
Margin		3.50%		6.50%
Floor		11.75%		9.75%
Ceiling		0%		0%
ETP		8%		8%
Maturity Date		Sep. 01, 2027		Jun. 01, 2025
Principal Amount		$ 2,500		$ 2,500
Investments at cost		2,471		2,476
Investments at fair value		2,471		2,476
Investment, Unaffiliated Issuer [Member] | Sonex Health, Inc. [Member] | Medical Device Sector [Member] | Preferred Stock Warrants [Member]
Investments at cost		275		98
Investments at fair value		$ 304		$ 123
Number of Shares (in shares)		2,637,043		605,313
Investment, Unaffiliated Issuer [Member] | Sonex Health, Inc. [Member] | Medical Device Sector [Member] | Term Loan, Prime Index Three [Member]
Cash Rate		12%		13.50%
Margin		3.50%		6.50%
Floor		11.75%		9.75%
Ceiling		0%		0%
ETP		8%		8%
Maturity Date		Sep. 01, 2027		Jun. 01, 2025
Principal Amount		$ 5,000		$ 2,500
Investments at cost		4,943		2,476
Investments at fair value		$ 4,943		$ 2,476
Investment, Unaffiliated Issuer [Member] | Sonex Health, Inc. [Member] | Medical Device Sector [Member] | Term Loan, Prime Index, Four [Member]
Cash Rate		12%		13.50%
Margin		3.50%		6.50%
Floor		11.75%		9.75%
Ceiling		0%		0%
ETP		8%		8%
Maturity Date		Sep. 01, 2027		Apr. 01, 2026
Principal Amount		$ 5,000		$ 2,500
Investments at cost		4,943		2,453
Investments at fair value		$ 4,943		$ 2,453
Investment, Unaffiliated Issuer [Member] | Sonex Health, Inc. [Member] | Medical Device Sector [Member] | Term Loan, Prime Index, Five [Member]
Cash Rate				13.50%
Margin				6.50%
Floor				9.75%
Ceiling				0%
ETP				8%
Maturity Date				May 01, 2026
Principal Amount				$ 2,500
Investments at cost				2,455
Investments at fair value				$ 2,455
Investment, Unaffiliated Issuer [Member] | Kodiak Robotics, Inc. [Member] | Software Sector [Member] | Term Loan, Prime Index, One [Member]
Cash Rate		14%		13%
Margin		5.50%		5.50%
Floor		10.25%		10.25%
Ceiling		0%		0%
ETP		4%		4%
Maturity Date		Apr. 01, 2026		Apr. 01, 2026
Principal Amount		$ 10,000		$ 10,000
Investments at cost		9,877		9,826
Investments at fair value		$ 9,877		$ 9,826
Investment, Unaffiliated Issuer [Member] | Kodiak Robotics, Inc. [Member] | Software Sector [Member] | Term Loan, Prime Index Two [Member]
Cash Rate		14%		13%
Margin		5.50%		5.50%
Floor		10.25%		10.25%
Ceiling		0%		0%
ETP		4%		4%
Maturity Date		Apr. 01, 2026		Apr. 01, 2026
Principal Amount		$ 10,000		$ 10,000
Investments at cost		9,877		9,826
Investments at fair value		9,877		9,826
Investment, Unaffiliated Issuer [Member] | Kodiak Robotics, Inc. [Member] | Software Sector [Member] | Preferred Stock Warrants [Member]
Investments at cost		273		273
Investments at fair value		$ 124		$ 296
Number of Shares (in shares)		639,918		639,918
Investment, Unaffiliated Issuer [Member] | Kodiak Robotics, Inc. [Member] | Software Sector [Member] | Term Loan, Prime Index Three [Member]
Cash Rate		14%		13%
Margin		5.50%		5.50%
Floor		10.25%		10.25%
Ceiling		0%		0%
ETP		4%		4%
Maturity Date		Apr. 01, 2026		Apr. 01, 2026
Principal Amount		$ 5,000		$ 5,000
Investments at cost		4,939		4,913
Investments at fair value		$ 4,939		$ 4,913
Investment, Unaffiliated Issuer [Member] | Kodiak Robotics, Inc. [Member] | Software Sector [Member] | Term Loan, Prime Index, Four [Member]
Cash Rate		14%		13%
Margin		5.50%		5.50%
Floor		10.25%		10.25%
Ceiling		0%		0%
ETP		4%		4%
Maturity Date		Apr. 01, 2026		Apr. 01, 2026
Principal Amount		$ 5,000		$ 5,000
Investments at cost		4,939		4,913
Investments at fair value		$ 4,939		$ 4,913
Investment, Unaffiliated Issuer [Member] | KSQ Therapeutics, Inc. [Member] | Biotechnology Sector [Member] | Term Loan, Prime Index, One [Member]
Cash Rate		13.25%		12.25%
Margin		4.75%		4.75%
Floor		8.50%		8.50%
Ceiling		0%		0%
ETP		5.50%		5.50%
Maturity Date		May 01, 2027		May 01, 2027
Principal Amount		$ 6,250		$ 6,250
Investments at cost		6,193		6,077
Investments at fair value		$ 6,193		$ 6,077
Investment, Unaffiliated Issuer [Member] | KSQ Therapeutics, Inc. [Member] | Biotechnology Sector [Member] | Term Loan, Prime Index Two [Member]
Cash Rate		13.25%		12.25%
Margin		4.75%		4.75%
Floor		8.50%		8.50%
Ceiling		0%		0%
ETP		5.50%		5.50%
Maturity Date		May 01, 2027		May 01, 2027
Principal Amount		$ 6,250		$ 6,250
Investments at cost		6,193		6,177
Investments at fair value		6,193		6,177
Investment, Unaffiliated Issuer [Member] | KSQ Therapeutics, Inc. [Member] | Biotechnology Sector [Member] | Preferred Stock Warrants [Member]
Investments at cost		50		51
Investments at fair value		$ 60		$ 60
Number of Shares (in shares)		48,076		48,077
Investment, Unaffiliated Issuer [Member] | Temperpack Technologies, Inc [Member] | Other Sustainability Sector [Member] | Term Loan, Prime Index, One [Member]
Cash Rate		15.25%		14.25%
Margin		6.75%		6.75%
Floor		10%		10%
Ceiling		0%		0%
ETP		2.50%		2.50%
Maturity Date		Apr. 01, 2028		Jun. 01, 2025
Principal Amount		$ 3,750		$ 3,750
Investments at cost		3,678		3,697
Investments at fair value		$ 3,678		$ 3,697
Investment, Unaffiliated Issuer [Member] | Temperpack Technologies, Inc [Member] | Other Sustainability Sector [Member] | Term Loan, Prime Index Two [Member]
Cash Rate		15.25%		14.25%
Margin		6.75%		6.75%
Floor		10%		10%
Ceiling		0%		0%
ETP		2.50%		2.50%
Maturity Date		Apr. 01, 2028		Jun. 01, 2025
Principal Amount		$ 3,750		$ 3,750
Investments at cost		3,692		3,717
Investments at fair value		3,692		3,717
Investment, Unaffiliated Issuer [Member] | Temperpack Technologies, Inc [Member] | Other Sustainability Sector [Member] | Preferred Stock Warrants [Member]
Investments at cost		175		126
Investments at fair value		$ 322		$ 268
Number of Shares (in shares)		46,311		35,906
Investment, Unaffiliated Issuer [Member] | Temperpack Technologies, Inc [Member] | Other Sustainability Sector [Member] | Term Loan, Prime Index Three [Member]
Cash Rate		15.25%		14.25%
Margin		6.75%		6.75%
Floor		10%		10%
Ceiling		0%		0%
ETP		2.50%		2.50%
Maturity Date		Apr. 01, 2028		Oct. 01, 2025
Principal Amount		$ 7,500		$ 7,500
Investments at cost		7,374		7,424
Investments at fair value		$ 7,374		$ 7,424
Investment, Unaffiliated Issuer [Member] | Temperpack Technologies, Inc [Member] | Other Sustainability Sector [Member] | Term Loan, Prime Index, Four [Member]
Cash Rate		15.25%		14.25%
Margin		6.75%		6.75%
Floor		10%		10%
Ceiling		0%		0%
ETP		2.50%		2.50%
Maturity Date		Apr. 01, 2028		Oct. 01, 2025
Principal Amount		$ 3,750		$ 3,750
Investments at cost		3,687		3,712
Investments at fair value		$ 3,687		$ 3,712
Investment, Unaffiliated Issuer [Member] | Temperpack Technologies, Inc [Member] | Other Sustainability Sector [Member] | Term Loan, Prime Index, Five [Member]
Cash Rate		15.25%		14.25%
Margin		6.75%		6.75%
Floor		10%		10%
Ceiling		0%		0%
ETP		2.50%		2.50%
Maturity Date		Apr. 01, 2028		Oct. 01, 2025
Principal Amount		$ 3,750		$ 3,750
Investments at cost		3,687		3,712
Investments at fair value		3,687		3,712
Investment, Unaffiliated Issuer [Member] | Medsphere Systems Corporation [Member] | Software Sector [Member] | Preferred Stock Warrants [Member]
Investments at cost		61
Investments at fair value		$ 346
Number of Shares (in shares)		7,097,792
Investment, Unaffiliated Issuer [Member] | Medsphere Systems Corporation [Member] | Software, Healthcare Information and Service [Member] | Preferred Stock Warrants [Member]
Investments at cost				60
Investments at fair value				$ 359
Number of Shares (in shares)				7,097,792
Investment, Unaffiliated Issuer [Member] | Embody, Inc. [Member] | Medical Device Sector [Member] | Term Loan, Prime Index, One [Member]
Cash Rate				14%
Margin				6.50%
Floor				9.75%
Ceiling				0%
ETP				28%
Maturity Date				Aug. 01, 2026
Principal Amount				$ 2,500
Investments at cost				2,482
Investments at fair value				2,482
Investment, Unaffiliated Issuer [Member] | Aterian, Inc [Member] | Consumer-related Technologies [Member] | Common Stock Warrants [Member]
Investments at cost		$ 195		195
Investments at fair value		$ 0		$ 0
Number of Shares (in shares)		76,923		76,923
Investment, Unaffiliated Issuer [Member] | Mustang Bio, Inc [Member] | Biotechnology Sector [Member] | Common Stock Warrants [Member]
Investments at cost		$ 146		$ 146
Investments at fair value		$ 0		$ 0
Number of Shares (in shares)		16,611		252,161
Investment, Unaffiliated Issuer [Member] | SafelyYou, Inc [Member] | Software Sector [Member] | Term Loan, Prime Index, One [Member]
Cash Rate		11.75%
Margin		3.25%
Floor		11%
Ceiling		0%
ETP		5%
Maturity Date		Jun. 01, 2027
Principal Amount		$ 5,000
Investments at cost		4,642
Investments at fair value		$ 4,642
Investment, Unaffiliated Issuer [Member] | SafelyYou, Inc [Member] | Software Sector [Member] | Term Loan, Prime Index Two [Member]
Cash Rate		11.75%
Margin		3.25%
Floor		11%
Ceiling		0%
ETP		5%
Maturity Date		Jun. 01, 2027
Principal Amount		$ 5,000
Investments at cost		4,912
Investments at fair value		4,912
Investment, Unaffiliated Issuer [Member] | SafelyYou, Inc [Member] | Software Sector [Member] | Preferred Stock Warrants [Member]
Investments at cost		163
Investments at fair value		$ 167
Number of Shares (in shares)		150,353
Investment, Unaffiliated Issuer [Member] | InfoBionic, Inc [Member] | Medical Device Sector [Member] | Term Loan, Prime Index, One [Member]
Cash Rate		14.75%		13.25%
Margin		6.25%		6.25%
Floor		9.50%		9.50%
Ceiling		0%		0%
ETP		4%		4%
Maturity Date		Oct. 01, 2024		Oct. 01, 2024
Principal Amount		$ 2,771		$ 3,208
Investments at cost		2,733		3,143
Investments at fair value		$ 2,733		$ 3,143
Investment, Unaffiliated Issuer [Member] | InfoBionic, Inc [Member] | Medical Device Sector [Member] | Term Loan, Prime Index Two [Member]
Cash Rate		14.75%		13.25%
Margin		6.25%		6.25%
Floor		9.50%		9.50%
Ceiling		0%		0%
ETP		4%		4%
Maturity Date		Jun. 01, 2025		Jun. 01, 2025
Principal Amount		$ 1,000		$ 1,000
Investments at cost		982		974
Investments at fair value		982		974
Investment, Unaffiliated Issuer [Member] | InfoBionic, Inc [Member] | Medical Device Sector [Member] | Preferred Stock Warrants [Member]
Investments at cost		124		124
Investments at fair value		$ 59		$ 113
Number of Shares (in shares)		317,647		317,647
Investment, Unaffiliated Issuer [Member] | F-Star Therapeutics, Inc [Member] | Biotechnology Sector [Member] | Term Loan, Prime Index, One [Member]
Cash Rate				13.25%
Margin				6.25%
Floor				9.50%
Ceiling				0%
ETP				4%
Maturity Date				Apr. 01, 2025
Principal Amount				$ 2,500
Investments at cost				2,476
Investments at fair value				$ 2,476
Investment, Unaffiliated Issuer [Member] | F-Star Therapeutics, Inc [Member] | Biotechnology Sector [Member] | Term Loan, Prime Index Two [Member]
Cash Rate				13.25%
Margin				6.25%
Floor				9.50%
Ceiling				0%
ETP				4%
Maturity Date				Jul. 01, 2025
Principal Amount				$ 2,500
Investments at cost				2,473
Investments at fair value				2,473
Investment, Unaffiliated Issuer [Member] | F-Star Therapeutics, Inc [Member] | Biotechnology Sector [Member] | Common Stock Warrants [Member]
Investments at cost				35
Investments at fair value				$ 0
Number of Shares (in shares)				21,120
Investment, Unaffiliated Issuer [Member] | Native Microbials, Inc. [Member] | Biotechnology Sector [Member] | Term Loan, Prime Index, One [Member]
Cash Rate		13.75%		12.75%
Margin		5.25%		5.25%
Floor		8.50%		8.50%
Ceiling		0%		0%
ETP		5%		5%
Maturity Date		Nov. 01, 2026		Nov. 01, 2026
Principal Amount		$ 3,750		$ 3,750
Investments at cost		3,716		3,630
Investments at fair value		$ 3,716		$ 3,630
Investment, Unaffiliated Issuer [Member] | Native Microbials, Inc. [Member] | Biotechnology Sector [Member] | Term Loan, Prime Index Two [Member]
Cash Rate		13.75%		12.75%
Margin		5.25%		5.25%
Floor		8.50%		8.50%
Ceiling		0%		0%
ETP		5%		5%
Maturity Date		Nov. 01, 2026		Nov. 01, 2026
Principal Amount		$ 2,500		$ 2,500
Investments at cost		2,478		2,469
Investments at fair value		2,478		2,469
Investment, Unaffiliated Issuer [Member] | Native Microbials, Inc. [Member] | Biotechnology Sector [Member] | Preferred Stock Warrants [Member]
Investments at cost		64		64
Investments at fair value		$ 165		$ 162
Number of Shares (in shares)		103,679		103,679
Investment, Unaffiliated Issuer [Member] | Greenlight Biosciences, Inc [Member] | Biotechnology Sector [Member] | Term Loan, Prime Index, One [Member]
Cash Rate		14.25%		13.25%
Margin		5.75%		5.75%
Floor		9%		9%
Ceiling		0%		0%
ETP		3%		3%
Maturity Date		Jul. 01, 2025		Jul. 01, 2025
Principal Amount		$ 3,500		$ 5,000
Investments at cost		3,399		4,857
Investments at fair value		$ 3,365		$ 4,857
Investment, Unaffiliated Issuer [Member] | Greenlight Biosciences, Inc [Member] | Biotechnology Sector [Member] | Term Loan, Prime Index Two [Member]
Cash Rate		14.25%		13.25%
Margin		5.75%		5.75%
Floor		9%		9%
Ceiling		0%		0%
ETP		3%		3%
Maturity Date		Jul. 01, 2025		Jul. 01, 2025
Principal Amount		$ 1,750		$ 2,500
Investments at cost		1,699		2,430
Investments at fair value		1,684		2,430
Investment, Unaffiliated Issuer [Member] | Greenlight Biosciences, Inc [Member] | Biotechnology Sector [Member] | Common Stock Warrants [Member]
Investments at cost				366
Investments at fair value				$ 0
Number of Shares (in shares)				47,452
Investment, Unaffiliated Issuer [Member] | Caastle, Inc [Member] | Consumer-related Technologies [Member] | Preferred Stock Warrants [Member]
Investments at cost		68		$ 68
Investments at fair value		$ 1,060		$ 1,069
Number of Shares (in shares)		268,591		268,591
Investment, Unaffiliated Issuer [Member] | PDS Biotechnology Corporation [Member] | Biotechnology Sector [Member] | Term Loan, Prime Index, One [Member]
Cash Rate		14.25%		13.25%
Margin		5.75%		5.75%
Floor		9.75%		9.75%
Ceiling		0%		0%
ETP		3.75%		3.75%
Maturity Date		Sep. 01, 2026		Sep. 01, 2026
Principal Amount		$ 10,000		$ 10,000
Investments at cost		9,898		9,701
Investments at fair value		$ 9,898		$ 9,701
Investment, Unaffiliated Issuer [Member] | PDS Biotechnology Corporation [Member] | Biotechnology Sector [Member] | Term Loan, Prime Index Two [Member]
Cash Rate		14.25%		13.25%
Margin		5.75%		5.75%
Floor		9.75%		9.75%
Ceiling		0%		0%
ETP		3.75%		3.75%
Maturity Date		Sep. 01, 2026		Sep. 01, 2026
Principal Amount		$ 3,750		$ 3,750
Investments at cost		3,712		3,697
Investments at fair value		3,712		3,697
Investment, Unaffiliated Issuer [Member] | PDS Biotechnology Corporation [Member] | Biotechnology Sector [Member] | Common Stock Warrants [Member]
Investments at cost		162		160
Investments at fair value		$ 667		$ 3,024
Number of Shares (in shares)		299,848		299,848
Investment, Unaffiliated Issuer [Member] | PDS Biotechnology Corporation [Member] | Biotechnology Sector [Member] | Term Loan, Prime Index Three [Member]
Cash Rate		14.25%		13.25%
Margin		5.75%		5.75%
Floor		9.75%		9.75%
Ceiling		0%		0%
ETP		3.75%		3.75%
Maturity Date		Sep. 01, 2026		Sep. 01, 2026
Principal Amount		$ 3,750		$ 3,750
Investments at cost		3,712		3,697
Investments at fair value		3,712		$ 3,697
Investment, Unaffiliated Issuer [Member] | Magnolia Medical Technologies, Inc [Member] | Medical Device Sector [Member]
Investments at fair value		$ 4,934
Investment, Unaffiliated Issuer [Member] | Magnolia Medical Technologies, Inc [Member] | Medical Device Sector [Member] | Term Loan, Prime Index, One [Member]
Cash Rate		13.50%		12%
Margin		5%		5%
Floor		9.75%		9.75%
Ceiling		0%		0%
ETP		4%		4%
Maturity Date		Mar. 01, 2025		Mar. 01, 2025
Principal Amount		$ 5,000		$ 5,000
Investments at cost		4,960		4,939
Investments at fair value		$ 4,960		$ 4,939
Investment, Unaffiliated Issuer [Member] | Magnolia Medical Technologies, Inc [Member] | Medical Device Sector [Member] | Term Loan, Prime Index Two [Member]
Cash Rate		13.50%		12%
Margin		5%		5%
Floor		9.75%		9.75%
Ceiling		0%		0%
ETP		4%		4%
Maturity Date		Mar. 01, 2025		Mar. 01, 2025
Principal Amount		$ 5,000		$ 5,000
Investments at cost		4,960		4,939
Investments at fair value		4,960		4,939
Investment, Unaffiliated Issuer [Member] | Magnolia Medical Technologies, Inc [Member] | Medical Device Sector [Member] | Preferred Stock Warrants [Member]
Investments at cost		194		194
Investments at fair value		$ 395		$ 385
Number of Shares (in shares)		809,931		809,931
Investment, Unaffiliated Issuer [Member] | Magnolia Medical Technologies, Inc [Member] | Medical Device Sector [Member] | Term Loan, Prime Index Three [Member]
Cash Rate		13.50%		12%
Margin		5%		5%
Floor		9.75%		9.75%
Ceiling		0%		0%
ETP		4%		4%
Maturity Date		Mar. 01, 2025		Mar. 01, 2025
Principal Amount		$ 5,000		$ 5,000
Investments at cost		4,956		4,933
Investments at fair value		$ 4,956		$ 4,933
Investment, Unaffiliated Issuer [Member] | Magnolia Medical Technologies, Inc [Member] | Medical Device Sector [Member] | Term Loan, Prime Index, Four [Member]
Cash Rate		13.50%		12%
Margin		5%		5%
Floor		9.75%		9.75%
Ceiling		0%		0%
ETP		4%		4%
Maturity Date		Mar. 01, 2025		Mar. 01, 2025
Principal Amount		$ 5,000		$ 5,000
Investments at cost		4,956		4,933
Investments at fair value		$ 4,956		$ 4,933
Investment, Unaffiliated Issuer [Member] | Magnolia Medical Technologies, Inc [Member] | Medical Device Sector [Member] | Term Loan, Prime Index, Five [Member]
Cash Rate		13.50%		12.50%
Margin		5%		5%
Floor		9.75%		9.75%
Ceiling		0%		0%
ETP		4%		4%
Maturity Date		Jan. 01, 2027		Jan. 01, 2027
Principal Amount		$ 5,000		$ 5,000
Investments at cost		4,934		4,913
Investments at fair value		$ 4,934		$ 4,913
Investment, Unaffiliated Issuer [Member] | Magnolia Medical Technologies, Inc [Member] | Medical Device Sector [Member] | Term Loan, Prime Index, Six [Member]
Cash Rate		13.50%		12.50%
Margin		5%		5%
Floor		9.75%		9.75%
Ceiling		0%		0%
ETP		4%		4%
Maturity Date		Jan. 01, 2027		Jan. 01, 2027
Principal Amount		$ 5,000		$ 5,000
Investments at cost		$ 4,934		4,913
Investments at fair value				$ 4,913
Investment, Unaffiliated Issuer [Member] | Havenly, Inc. [Member] | Consumer-related Technologies [Member] | Term Loan, Prime Index, One [Member]
Cash Rate		13.50%		12.50%
Margin		5%		5%
Floor		5%		5%
Ceiling		0%		0%
ETP		4%		4%
Maturity Date		Mar. 01, 2027		Mar. 01, 2027
Principal Amount		$ 2,000		$ 2,000
Investments at cost		1,335		1,082
Investments at fair value		$ 1,335		$ 1,082
Investment, Unaffiliated Issuer [Member] | Havenly, Inc. [Member] | Consumer-related Technologies [Member] | Term Loan, Prime Index Two [Member]
Cash Rate		13.50%		12.50%
Margin		5%		5%
Floor		5%		5%
Ceiling		0%		0%
ETP		4%		4%
Maturity Date		Mar. 01, 2027		Mar. 01, 2027
Principal Amount		$ 3,000		$ 3,000
Investments at cost		2,003		1,623
Investments at fair value		2,003		1,623
Investment, Unaffiliated Issuer [Member] | Havenly, Inc. [Member] | Consumer-related Technologies [Member] | Common Stock Warrants [Member]
Investments at cost		2,945		2,947
Investments at fair value		$ 2,676		$ 2,947
Number of Shares (in shares)		1,312,500		1,312,500
Investment, Unaffiliated Issuer [Member] | Havenly, Inc. [Member] | Consumer-related Technologies [Member] | Term Loan, Prime Index Three [Member]
Cash Rate		12%		11%
Margin		3.50%		3.50%
Floor		10.50%		10.50%
Ceiling		0%		0%
ETP		7.78%		7.78%
Maturity Date		Feb. 01, 2028		Feb. 01, 2028
Principal Amount		$ 2,813		$ 2,813
Investments at cost		2,813		2,813
Investments at fair value		$ 2,813		$ 2,813
Investment, Unaffiliated Issuer [Member] | Havenly, Inc. [Member] | Consumer-related Technologies [Member] | Term Loan, Prime Index, Four [Member]
Cash Rate		12%		11%
Margin		3.50%		3.50%
Floor		10.50%		10.50%
Ceiling		0%		0%
ETP		7.78%		7.78%
Maturity Date		Feb. 01, 2028		Feb. 01, 2028
Principal Amount		$ 2,813		$ 2,813
Investments at cost		2,813		2,813
Investments at fair value		$ 2,813		$ 2,813
Investment, Unaffiliated Issuer [Member] | Spineology, Inc [Member] | Medical Device Sector [Member] | Term Loan, Prime Index, One [Member]
Cash Rate		15.50%		14.50%
Margin		7%		7%
Floor		10.25%		10.25%
Ceiling		0%		0%
ETP		1%		1%
Maturity Date		Oct. 01, 2025		Oct. 01, 2025
Principal Amount		$ 5,000		$ 5,000
Investments at cost		4,975		4,966
Investments at fair value		$ 4,975		$ 4,966
Investment, Unaffiliated Issuer [Member] | Spineology, Inc [Member] | Medical Device Sector [Member] | Term Loan, Prime Index Two [Member]
Cash Rate		15.50%		14.50%
Margin		7%		7%
Floor		10.25%		10.25%
Ceiling		0%		0%
ETP		1%		1%
Maturity Date		Apr. 01, 2026		Apr. 01, 2026
Principal Amount		$ 2,500		$ 2,500
Investments at cost		2,487		2,481
Investments at fair value		$ 2,487		$ 2,481
Investment, Unaffiliated Issuer [Member] | Lemongrass Holdings, Inc [Member] | Software Sector [Member] | Term Loan, Prime Index, One [Member]
Cash Rate		15%		14%
Margin		6.50%		6.50%
Floor		9.75%		9.75%
Ceiling		0%		0%
ETP		2.50%		2.50%
Maturity Date		Mar. 01, 2026		Mar. 01, 2026
Principal Amount		$ 5,000		$ 5,000
Investments at cost		4,965		4,947
Investments at fair value		$ 4,965		$ 4,947
Investment, Unaffiliated Issuer [Member] | Lemongrass Holdings, Inc [Member] | Software Sector [Member] | Term Loan, Prime Index Two [Member]
Cash Rate		15%		14%
Margin		6.50%		6.50%
Floor		9.75%		9.75%
Ceiling		0%		0%
ETP		2.50%		2.50%
Maturity Date		Mar. 01, 2026		Mar. 01, 2026
Principal Amount		$ 2,500		$ 2,500
Investments at cost		2,483		2,474
Investments at fair value		2,483		2,474
Investment, Unaffiliated Issuer [Member] | Lemongrass Holdings, Inc [Member] | Software Sector [Member] | Preferred Stock Warrants [Member]
Investments at cost		32		34
Investments at fair value		$ 43		$ 41
Number of Shares (in shares)		101,308		101,308
Investment, Unaffiliated Issuer [Member] | Provivi, Inc. [Member] | Biotechnology Sector [Member] | Term Loan, Prime Index, One [Member]
Cash Rate		13.86%
Margin		5.36%
Floor		9.50%
Ceiling		0%
ETP		5.50%
Maturity Date		Dec. 01, 2024
Principal Amount		$ 4,667
Investments at cost		4,594
Investments at fair value		$ 4,594
Investment, Unaffiliated Issuer [Member] | Provivi, Inc. [Member] | Biotechnology Sector [Member] | Term Loan, Prime Index Two [Member]
Cash Rate		13.86%
Margin		5.36%
Floor		9.50%
Ceiling		0%
ETP		5.50%
Maturity Date		Dec. 01, 2024
Principal Amount		$ 4,667
Investments at cost		4,594
Investments at fair value		4,594
Investment, Unaffiliated Issuer [Member] | Provivi, Inc. [Member] | Biotechnology Sector [Member] | Preferred Stock Warrants [Member]
Investments at cost		487		$ 399
Investments at fair value		$ 205		$ 648
Number of Shares (in shares)		345,327		203,017
Investment, Unaffiliated Issuer [Member] | Provivi, Inc. [Member] | Biotechnology Sector [Member] | Term Loan, Prime Index Three [Member]
Cash Rate		13.86%
Margin		5.36%
Floor		9.50%
Ceiling		0%
ETP		5.50%
Maturity Date		Dec. 01, 2024
Principal Amount		$ 2,333
Investments at cost		2,286
Investments at fair value		$ 2,286
Investment, Unaffiliated Issuer [Member] | Provivi, Inc. [Member] | Biotechnology Sector [Member] | Term Loan, LIBOR Index, One [Member]
Cash Rate				12.67%
Margin				8.50%
Floor				9.50%
Ceiling				0%
ETP				5.50%
Maturity Date				Dec. 01, 2024
Principal Amount				$ 4,667
Investments at cost				4,597
Investments at fair value				$ 4,597
Investment, Unaffiliated Issuer [Member] | Provivi, Inc. [Member] | Biotechnology Sector [Member] | Term Loan, Prime Index, Four [Member]
Cash Rate		13.86%
Margin		5.36%
Floor		9.50%
Ceiling		0%
ETP		5.50%
Maturity Date		Dec. 01, 2024
Principal Amount		$ 2,333
Investments at cost		2,286
Investments at fair value		$ 2,286
Investment, Unaffiliated Issuer [Member] | Provivi, Inc. [Member] | Biotechnology Sector [Member] | Term Loan, LIBOR Index, Two [Member]
Cash Rate				12.67%
Margin				8.50%
Floor				9.50%
Ceiling				0%
ETP				5.50%
Maturity Date				Dec. 01, 2024
Principal Amount				$ 4,667
Investments at cost				4,597
Investments at fair value				$ 4,597
Investment, Unaffiliated Issuer [Member] | Provivi, Inc. [Member] | Biotechnology Sector [Member] | Term Loan, Prime Index, Five [Member]
Cash Rate		13.86%
Margin		5.36%
Floor		9.50%
Ceiling		0%
ETP		5.50%
Maturity Date		Dec. 01, 2024
Principal Amount		$ 2,333
Investments at cost		2,282
Investments at fair value		$ 2,282
Investment, Unaffiliated Issuer [Member] | Provivi, Inc. [Member] | Biotechnology Sector [Member] | Term Loan, LIBOR Index, Three [Member]
Cash Rate				12.67%
Margin				8.50%
Floor				9.50%
Ceiling				0%
ETP				5.50%
Maturity Date				Dec. 01, 2024
Principal Amount				$ 2,333
Investments at cost				2,280
Investments at fair value				$ 2,280
Investment, Unaffiliated Issuer [Member] | Provivi, Inc. [Member] | Biotechnology Sector [Member] | Term Loan, Prime Index, Six [Member]
Cash Rate		13.86%
Margin		5.36%
Floor		9.50%
Ceiling		0%
ETP		5.50%
Maturity Date		Dec. 01, 2024
Principal Amount		$ 2,333
Investments at cost		2,282
Investments at fair value		2,282
Investment, Unaffiliated Issuer [Member] | Provivi, Inc. [Member] | Biotechnology Sector [Member] | Term Loan, LIBOR Index, Four [Member]
Cash Rate				12.67%
Margin				8.50%
Floor				9.50%
Ceiling				0%
ETP				5.50%
Maturity Date				Dec. 01, 2024
Principal Amount				$ 2,333
Investments at cost				2,280
Investments at fair value				$ 2,280
Investment, Unaffiliated Issuer [Member] | Provivi, Inc. [Member] | Biotechnology Sector [Member] | Term Loan, LIBOR Index, Five [Member]
Cash Rate				12.67%
Margin				8.50%
Floor				9.50%
Ceiling				0%
ETP				5.50%
Maturity Date				Dec. 01, 2024
Principal Amount				$ 2,333
Investments at cost				2,274
Investments at fair value				$ 2,274
Investment, Unaffiliated Issuer [Member] | Provivi, Inc. [Member] | Biotechnology Sector [Member] | Term Loan, LIBOR Index, Six [Member]
Cash Rate				12.67%
Margin				8.50%
Floor				9.50%
Ceiling				0%
ETP				5.50%
Maturity Date				Dec. 01, 2024
Principal Amount				$ 2,333
Investments at cost				2,274
Investments at fair value				2,274
Investment, Unaffiliated Issuer [Member] | Lumithera, Inc. [Member] | Medical Device Sector [Member] | Common Stock [Member]
Investments at cost		2,000		2,000
Investments at fair value		$ 1,700		$ 1,700
Number of Shares (in shares)		392,651		392,651
Investment, Unaffiliated Issuer [Member] | Lumithera, Inc. [Member] | Medical Device Sector [Member] | Royalty Agreement [Member]
Investments at cost		$ 1,200		$ 1,200
Investments at fair value		$ 1,100		$ 1,100
Investment, Unaffiliated Issuer [Member] | IMV Inc [Member] | Biotechnology Sector [Member] | Term Loan, Prime Index, One [Member]
Cash Rate				13.25%
Margin				5.75%
Floor				9%
Ceiling				0%
ETP				5%
Maturity Date				Jul. 01, 2025
Principal Amount				$ 5,000
Investments at cost				4,946
Investments at fair value				$ 4,946
Investment, Unaffiliated Issuer [Member] | IMV Inc [Member] | Biotechnology Sector [Member] | Term Loan, Prime Index Two [Member]
Cash Rate				13.25%
Margin				5.75%
Floor				9%
Ceiling				0%
ETP				5%
Maturity Date				Jul. 01, 2025
Principal Amount				$ 2,500
Investments at cost				2,473
Investments at fair value				2,473
Investment, Unaffiliated Issuer [Member] | IMV Inc [Member] | Biotechnology Sector [Member] | Common Stock Warrants [Member]
Investments at cost				67
Investments at fair value				$ 0
Number of Shares (in shares)				39,774
Investment, Unaffiliated Issuer [Member] | IMV Inc [Member] | Biotechnology Sector [Member] | Term Loan, Prime Index Three [Member]
Cash Rate				13.25%
Margin				5.75%
Floor				9%
Ceiling				0%
ETP				5%
Maturity Date				Jan. 01, 2026
Principal Amount				$ 5,000
Investments at cost				4,947
Investments at fair value				$ 4,947
Investment, Unaffiliated Issuer [Member] | IMV Inc [Member] | Biotechnology Sector [Member] | Term Loan, Prime Index, Four [Member]
Cash Rate				13.25%
Margin				5.75%
Floor				9%
Ceiling				0%
ETP				5%
Maturity Date				Jan. 01, 2026
Principal Amount				$ 5,000
Investments at cost				4,947
Investments at fair value				$ 4,947
Investment, Unaffiliated Issuer [Member] | Stealth BioTherapeutics Inc. [Member] | Biotechnology Sector [Member] | Term Loan, Prime Index, One [Member]
Cash Rate		14%		13%
Margin		5.50%		5.50%
Floor		8.75%		8.75%
Ceiling		0%		0%
ETP		6%		6%
Maturity Date		Oct. 01, 2025		Oct. 01, 2025
Principal Amount		$ 4,500		$ 5,000
Investments at cost		4,434		4,914
Investments at fair value		$ 4,434		$ 4,914
Investment, Unaffiliated Issuer [Member] | Stealth BioTherapeutics Inc. [Member] | Biotechnology Sector [Member] | Term Loan, Prime Index Two [Member]
Cash Rate		14%		13%
Margin		5.50%		5.50%
Floor		8.75%		8.75%
Ceiling		0%		0%
ETP		6%		6%
Maturity Date		Oct. 01, 2025		Oct. 01, 2025
Principal Amount		$ 2,250		$ 2,500
Investments at cost		2,217		2,457
Investments at fair value		2,217		2,457
Investment, Unaffiliated Issuer [Member] | Stealth BioTherapeutics Inc. [Member] | Biotechnology Sector [Member] | Common Stock Warrants [Member]
Investments at cost		264		264
Investments at fair value		$ 127		$ 37
Number of Shares (in shares)		318,181		318,181
Investment, Unaffiliated Issuer [Member] | ZetrOZ, Inc [Member] | Medical Device Sector [Member] | Royalty Agreement [Member]
Investments at cost		$ 0		$ 0
Investments at fair value		$ 0		$ 200
Investment, Unaffiliated Issuer [Member] | Swift Health Systems Inc. [Member] | Medical Device Sector [Member] | Term Loan, Prime Index, One [Member]
Cash Rate		13.75%		12.25%
Margin		5.25%		5.25%
Floor		9%		9%
Ceiling		0%		0%
ETP		5%		5%
Maturity Date		Jul. 01, 2027		Jul. 01, 2027
Principal Amount		$ 3,500		$ 3,500
Investments at cost		3,464		3,349
Investments at fair value		$ 3,464		$ 3,349
Investment, Unaffiliated Issuer [Member] | Swift Health Systems Inc. [Member] | Medical Device Sector [Member] | Term Loan, Prime Index Two [Member]
Cash Rate		13.75%		12.25%
Margin		5.25%		5.25%
Floor		9%		9%
Ceiling		0%		0%
ETP		5%		5%
Maturity Date		Jul. 01, 2027		Jul. 01, 2027
Principal Amount		$ 3,500		$ 3,500
Investments at cost		3,464		3,454
Investments at fair value		3,464		3,454
Investment, Unaffiliated Issuer [Member] | Swift Health Systems Inc. [Member] | Medical Device Sector [Member] | Preferred Stock Warrants [Member]
Investments at cost		71		71
Investments at fair value		$ 40		$ 83
Number of Shares (in shares)		135,484		135,484
Investment, Unaffiliated Issuer [Member] | Swift Health Systems Inc. [Member] | Medical Device Sector [Member] | Term Loan, Prime Index Three [Member]
Cash Rate		13.75%
Margin		5.25%
Floor		9%
Ceiling		0%
ETP		5%
Maturity Date		Jul. 01, 2027
Principal Amount		$ 3,500
Investments at cost		3,453
Investments at fair value		$ 3,453
Investment, Unaffiliated Issuer [Member] | Swift Health Systems Inc. [Member] | Medical Device Sector [Member] | Term Loan, Prime Index, Four [Member]
Cash Rate		13.75%
Margin		5.25%
Floor		9%
Ceiling		0%
ETP		5%
Maturity Date		Jul. 01, 2027
Principal Amount		$ 3,500
Investments at cost		3,453
Investments at fair value		$ 3,453
Investment, Unaffiliated Issuer [Member] | Lytics, Inc. [Member] | Software Sector [Member] | Term Loan, Prime Index, One [Member]
Cash Rate		14.50%		13%
Margin		6%		6%
Floor		14.25%		9.25%
Ceiling		0%		0%
ETP		4%		3%
Maturity Date		Nov. 01, 2026		Jul. 01, 2025
Principal Amount		$ 2,500		$ 2,500
Investments at cost		2,418		2,396
Investments at fair value		$ 2,350		$ 2,396
Investment, Unaffiliated Issuer [Member] | Lytics, Inc. [Member] | Software Sector [Member] | Term Loan, Prime Index Two [Member]
Cash Rate		14.50%		13%
Margin		6%		6%
Floor		14.25%		12.25%
Ceiling		0%		0%
ETP		4%		3%
Maturity Date		Dec. 01, 2026		Dec. 01, 2026
Principal Amount		$ 1,250		$ 1,250
Investments at cost		1,236		1,231
Investments at fair value		1,201		1,231
Investment, Unaffiliated Issuer [Member] | Lytics, Inc. [Member] | Software Sector [Member] | Preferred Stock Warrants [Member]
Investments at cost		43		40
Investments at fair value		$ 1		$ 44
Number of Shares (in shares)		85,543		80,197
Investment, Unaffiliated Issuer [Member] | Lytics, Inc. [Member] | Software Sector [Member] | Term Loan, Prime Index Three [Member]
Cash Rate		14.50%
Margin		6%
Floor		14.25%
Ceiling		0%
ETP		4%
Maturity Date		Apr. 01, 2027
Principal Amount		$ 1,000
Investments at cost		993
Investments at fair value		$ 966
Investment, Unaffiliated Issuer [Member] | Tallac Therapeutics, Inc [Member] | Biotechnology Sector [Member] | Term Loan, Prime Index, One [Member]
Cash Rate		12.75%
Margin		4.25%
Floor		12.25%
Ceiling		0%
ETP		4%
Maturity Date		Aug. 01, 2027
Principal Amount		$ 2,500
Investments at cost		2,226
Investments at fair value		$ 2,226
Investment, Unaffiliated Issuer [Member] | Tallac Therapeutics, Inc [Member] | Biotechnology Sector [Member] | Term Loan, Prime Index Two [Member]
Cash Rate		12.75%
Margin		4.25%
Floor		12.25%
Ceiling		0%
ETP		4%
Maturity Date		Aug. 01, 2027
Principal Amount		$ 2,500
Investments at cost		2,455
Investments at fair value		2,455
Investment, Unaffiliated Issuer [Member] | Tallac Therapeutics, Inc [Member] | Biotechnology Sector [Member] | Preferred Stock Warrants [Member]
Investments at cost		194
Investments at fair value		$ 194
Number of Shares (in shares)		1,600,002
Investment, Unaffiliated Issuer [Member] | vTv Therapeutics Inc [Member] | Biotechnology Sector [Member] | Common Stock Warrants [Member]
Investments at cost		$ 44		$ 44
Investments at fair value		$ 0		$ 0
Number of Shares (in shares)		95,293		95,293
Investment, Unaffiliated Issuer [Member] | Interior Define, Inc. [Member] | Consumer-related Technologies [Member] | Term Loan, Prime Index, One [Member]
Cash Rate				13.50%
Margin				6.50%
Floor				9.75%
Ceiling				0%
ETP				4%
Maturity Date				Jan. 01, 2026
Principal Amount				$ 3,210
Investments at cost				3,151
Investments at fair value				$ 0
Investment, Unaffiliated Issuer [Member] | Interior Define, Inc. [Member] | Consumer-related Technologies [Member] | Term Loan, Prime Index Two [Member]
Cash Rate				13.50%
Margin				6.50%
Floor				9.75%
Ceiling				0%
ETP				4%
Maturity Date				Jan. 01, 2026
Principal Amount				$ 2,963
Investments at cost				2,886
Investments at fair value				0
Investment, Unaffiliated Issuer [Member] | Interior Define, Inc. [Member] | Consumer-related Technologies [Member] | Preferred Stock Warrants [Member]
Investments at cost				103
Investments at fair value				$ 0
Number of Shares (in shares)				553,710
Investment, Unaffiliated Issuer [Member] | Xeris Pharmaceuticals, Inc [Member] | Biotechnology Sector [Member] | Common Stock Warrants [Member]
Investments at cost		$ 72		$ 72
Investments at fair value		$ 17		$ 3
Number of Shares (in shares)		126,000		126,000
Investment, Unaffiliated Issuer [Member] | MyForest Foods Co [Member] | Consumer-related Technologies [Member] | Term Loan, Prime Index, One [Member]
Cash Rate		15.25%		14.25%
Margin		6.75%		6.75%
Floor		10%		10%
Ceiling		0%		0%
ETP		3%		3%
Maturity Date		Oct. 01, 2025		Oct. 01, 2025
Principal Amount		$ 4,000		$ 5,000
Investments at cost		3,975		4,954
Investments at fair value		$ 3,975		$ 4,954
Investment, Unaffiliated Issuer [Member] | MyForest Foods Co [Member] | Consumer-related Technologies [Member] | Term Loan, Prime Index Two [Member]
Cash Rate		15.25%		14.25%
Margin		6.75%		6.75%
Floor		10%		10%
Ceiling		0%		0%
ETP		3%		3%
Maturity Date		Oct. 01, 2025		Oct. 01, 2025
Principal Amount		$ 2,000		$ 2,500
Investments at cost		1,987		2,477
Investments at fair value		1,987		2,477
Investment, Unaffiliated Issuer [Member] | MyForest Foods Co [Member] | Consumer-related Technologies [Member] | Preferred Stock Warrants [Member]
Investments at cost		29		29
Investments at fair value		$ 63		$ 37
Number of Shares (in shares)		250		143
Investment, Unaffiliated Issuer [Member] | Mirantis, Inc [Member] | Software Sector [Member] | Term Loan, Prime Index, One [Member]
Cash Rate		12%
Margin		3.50%
Floor		11.75%
Ceiling		0%
ETP		4%
Maturity Date		Oct. 01, 2028
Principal Amount		$ 5,000
Investments at cost		4,774
Investments at fair value		$ 4,774
Investment, Unaffiliated Issuer [Member] | Mirantis, Inc [Member] | Software Sector [Member] | Term Loan, Prime Index Two [Member]
Cash Rate		12%
Margin		3.50%
Floor		11.75%
Ceiling		0%
ETP		4%
Maturity Date		Oct. 01, 2028
Principal Amount		$ 5,000
Investments at cost		4,910
Investments at fair value		4,910
Investment, Unaffiliated Issuer [Member] | Mirantis, Inc [Member] | Software Sector [Member] | Common Stock Warrants [Member]
Investments at cost		223
Investments at fair value		$ 223
Number of Shares (in shares)		948,275
Investment, Unaffiliated Issuer [Member] | Mirantis, Inc [Member] | Software Sector [Member] | Term Loan, Prime Index Three [Member]
Cash Rate		12%
Margin		3.50%
Floor		11.75%
Ceiling		0%
ETP		4%
Maturity Date		Oct. 01, 2028
Principal Amount		$ 5,000
Investments at cost		4,910
Investments at fair value		$ 4,910
Investment, Unaffiliated Issuer [Member] | Mirantis, Inc [Member] | Software Sector [Member] | Term Loan, Prime Index, Four [Member]
Cash Rate		12%
Margin		3.50%
Floor		11.75%
Ceiling		0%
ETP		4%
Maturity Date		Oct. 01, 2028
Principal Amount		$ 5,000
Investments at cost		4,910
Investments at fair value		4,910
Investment, Unaffiliated Issuer [Member] | AccuVein Inc [Member] | Medical Device Sector [Member] | Common Stock Warrants [Member]
Investments at cost		24		$ 24
Investments at fair value		$ 0		$ 0
Number of Shares (in shares)		1,175		1,175
Investment, Unaffiliated Issuer [Member] | Lyrical Foods, Inc [Member] | Consumer-related Technologies [Member] | Term Loan, Prime Index, One [Member]
Cash Rate		11%		10%
Margin		2.50%		6.75%
Floor		8%		10%
Ceiling		0%		0%
ETP		0%		0%
Maturity Date		Sep. 01, 2027		Sep. 01, 2027
Principal Amount		$ 2,598		$ 2,500
Investments at cost		2,589		2,588
Investments at fair value		$ 2,351		$ 2,279
Investment, Unaffiliated Issuer [Member] | NextCar Holding Company, Inc [Member] | Consumer-related Technologies [Member] | Term Loan, Prime Index, One [Member]
Cash Rate		14.25%		12.75%
Margin		5.75%		5.75%
Floor		9%		9%
Ceiling		0%		0%
ETP		5.25%		2%
Maturity Date		Oct. 31, 2023		Dec. 30, 2022
Principal Amount		$ 5,547		$ 5,000
Investments at cost		5,505		4,943
Investments at fair value		$ 4,894		$ 4,715
Investment, Unaffiliated Issuer [Member] | NextCar Holding Company, Inc [Member] | Consumer-related Technologies [Member] | Term Loan, Prime Index Two [Member]
Cash Rate		14.25%		12.75%
Margin		5.75%		5.75%
Floor		9%		9%
Ceiling		0%		0%
ETP		5.25%		2%
Maturity Date		Oct. 31, 2023		Dec. 30, 2022
Principal Amount		$ 2,219		$ 2,000
Investments at cost		2,204		1,981
Investments at fair value		1,960		1,890
Investment, Unaffiliated Issuer [Member] | NextCar Holding Company, Inc [Member] | Consumer-related Technologies [Member] | Preferred Stock Warrants [Member]
Investments at cost				197
Investments at fair value				$ 17
Number of Shares (in shares)				1,261,253
Investment, Unaffiliated Issuer [Member] | NextCar Holding Company, Inc [Member] | Consumer-related Technologies [Member] | Preferred and Common Stock [Member]
Investments at cost		197
Investments at fair value		$ 0
Number of Shares (in shares)		1,237,370
Investment, Unaffiliated Issuer [Member] | NextCar Holding Company, Inc [Member] | Consumer-related Technologies [Member] | Term Loan, Prime Index Three [Member]
Cash Rate		14.25%		12.75%
Margin		5.75%		5.75%
Floor		9%		9%
Ceiling		0%		0%
ETP		5.25%		2%
Maturity Date		Oct. 31, 2023		Dec. 30, 2022
Principal Amount		$ 2,774		$ 2,500
Investments at cost		2,759		2,477
Investments at fair value		$ 2,453		$ 2,363
Investment, Unaffiliated Issuer [Member] | NextCar Holding Company, Inc [Member] | Consumer-related Technologies [Member] | Term Loan, Prime Index, Four [Member]
Cash Rate		14.25%		12.75%
Margin		5.75%		5.75%
Floor		9%		9%
Ceiling		0%		0%
ETP		5.25%		2%
Maturity Date		Oct. 31, 2023		Dec. 30, 2022
Principal Amount		$ 3,328		$ 3,000
Investments at cost		3,310		2,971
Investments at fair value		$ 2,943		$ 2,835
Investment, Unaffiliated Issuer [Member] | NextCar Holding Company, Inc [Member] | Consumer-related Technologies [Member] | Term Loan, Prime Index, Five [Member]
Cash Rate		14.25%		12.75%
Margin		5.75%		5.75%
Floor		9%		9%
Ceiling		0%		0%
ETP		5.25%		2%
Maturity Date		Oct. 31, 2023		Dec. 30, 2022
Principal Amount		$ 2,774		$ 2,500
Investments at cost		2,747		2,459
Investments at fair value		$ 2,443		$ 2,345
Investment, Unaffiliated Issuer [Member] | NextCar Holding Company, Inc [Member] | Consumer-related Technologies [Member] | Term Loan, Prime Index, Six [Member]
Cash Rate		14.25%		12.75%
Margin		5.75%		5.75%
Floor		9%		9%
Ceiling		0%		0%
ETP		5.25%		2%
Maturity Date		Oct. 31, 2023		Dec. 30, 2022
Principal Amount		$ 2,774		$ 2,500
Investments at cost		2,747		2,459
Investments at fair value		$ 2,443		$ 2,345
Investment, Unaffiliated Issuer [Member] | NextCar Holding Company, Inc [Member] | Consumer-related Technologies [Member] | Term Loan, Prime Index, Seven [Member]
Cash Rate		14.25%		12.75%
Margin		5.75%		5.75%
Floor		9%		9%
Ceiling		0%		0%
ETP		5.25%		2%
Maturity Date		Oct. 31, 2023		Dec. 30, 2022
Principal Amount		$ 5,547		$ 5,000
Investments at cost		5,493		4,914
Investments at fair value		$ 4,884		$ 4,688
Investment, Unaffiliated Issuer [Member] | NextCar Holding Company, Inc [Member] | Consumer-related Technologies [Member] | Term Loan, Prime Index, Eight [Member]
Cash Rate		14.25%		12.75%
Margin		5.75%		5.75%
Floor		9%		9%
Ceiling		0%		0%
ETP		5.25%		2%
Maturity Date		Oct. 31, 2023		Dec. 30, 2022
Principal Amount		$ 2,774		$ 2,500
Investments at cost		2,746		2,456
Investments at fair value		2,441		2,342
Investment, Unaffiliated Issuer [Member] | NextCar Holding Company, Inc [Member] | Technology Sector [Member] | Preferred Stock [Member]
Investments at cost		89
Investments at fair value		$ 89
Number of Shares (in shares)		2,688,971
Investment, Unaffiliated Issuer [Member] | Aerin Medical, Inc [Member] | Medical Device Sector [Member] | Preferred Stock Warrants [Member]
Investments at cost		$ 66		64
Investments at fair value		$ 1,210		$ 1,200
Number of Shares (in shares)		1,818,183		1,818,183
Investment, Unaffiliated Issuer [Member] | CZV, Inc [Member] | Consumer-related Technologies [Member] | Common Stock Warrants [Member]
Investments at cost		$ 81
Investments at fair value		$ 81
Number of Shares (in shares)		65,569
Investment, Unaffiliated Issuer [Member] | Getaround, Inc [Member] | Consumer-related Technologies [Member] | Common Stock [Member]
Investments at cost		$ 253		$ 253
Investments at fair value		$ 30		$ 57
Number of Shares (in shares)		87,082		87,082
Investment, Unaffiliated Issuer [Member] | Rocket Pharmaceuticals Corporation [Member] | Biotechnology Sector [Member] | Common Stock Warrants [Member]
Investments at cost				$ 17
Investments at fair value				$ 14
Number of Shares (in shares)				7,051
Investment, Unaffiliated Issuer [Member] | Optoro, Inc. [Member] | Consumer-related Technologies [Member] | Term Loan, Prime Index, One [Member]
Cash Rate		14.75%		13.25%
Margin		6.25%		6.25%
Floor		9.50%		9.50%
Ceiling		0%		0%
ETP		4%		4%
Maturity Date		Aug. 01, 2027		Aug. 01, 2027
Principal Amount		$ 2,500		$ 2,500
Investments at cost		2,408		2,347
Investments at fair value		$ 2,408		2,347
Investment, Unaffiliated Issuer [Member] | Optoro, Inc. [Member] | Consumer-related Technologies [Member] | Term Loan, Prime Index Two [Member]
Cash Rate		14.75%
Margin		6.25%
Floor		9.50%
Ceiling		0%
ETP		4%
Maturity Date		Jul. 01, 2028
Principal Amount		$ 1,875
Investments at cost		1,783
Investments at fair value		1,783
Investment, Unaffiliated Issuer [Member] | Optoro, Inc. [Member] | Consumer-related Technologies [Member] | Preferred Stock Warrants [Member]
Investments at cost		182		104
Investments at fair value		$ 182		$ 104
Number of Shares (in shares)		11,550		6,600
Investment, Unaffiliated Issuer [Member] | Aerobiotix, LLC [Member] | Medical Device Sector [Member] | Term Loan, Prime Index, One [Member]
Cash Rate				13.75%
Margin				6.25%
Floor				9.50%
Ceiling				0%
ETP				6%
Maturity Date				Apr. 01, 2026
Principal Amount				$ 2,500
Investments at cost				2,463
Investments at fair value				$ 2,364
Investment, Unaffiliated Issuer [Member] | Aerobiotix, LLC [Member] | Medical Device Sector [Member] | Term Loan, Prime Index Two [Member]
Cash Rate				13.75%
Margin				6.25%
Floor				9.50%
Ceiling				0%
ETP				6%
Maturity Date				Apr. 01, 2026
Principal Amount				$ 2,500
Investments at cost				2,463
Investments at fair value				2,364
Investment, Unaffiliated Issuer [Member] | Aerobiotix, LLC [Member] | Medical Device Sector [Member] | Preferred Stock Warrants [Member]
Investments at cost		$ 48		48
Investments at fair value		$ 10		$ 31
Number of Shares (in shares)		8,800		27,330
Investment, Unaffiliated Issuer [Member] | Aerobiotix, LLC [Member] | Medical Device Sector [Member] | Term Loan, Fixed Index One [Member]
Cash Rate		9%
Margin		0%
Floor		0%
Ceiling		0%
ETP		18%
Maturity Date		Apr. 01, 2028
Principal Amount		$ 2,500
Investments at cost		2,466
Investments at fair value		$ 2,344
Investment, Unaffiliated Issuer [Member] | Aerobiotix, LLC [Member] | Medical Device Sector [Member] | Term Loan, Fixed Index Two [Member]
Cash Rate		9%
Margin		0%
Floor		0%
Ceiling		0%
ETP		18%
Maturity Date		Apr. 01, 2028
Principal Amount		$ 2,500
Investments at cost		2,466
Investments at fair value		$ 2,344
Investment, Unaffiliated Issuer [Member] | Aerobiotix, LLC [Member] | Medical Device Sector [Member] | Term Loan, Fixed Index Three [Member]
Cash Rate		9%
Margin		0%
Floor		0%
Ceiling		0%
ETP		18%
Maturity Date		Jun. 30, 2024
Principal Amount		$ 200
Investments at cost		200
Investments at fair value		$ 190
Investment, Unaffiliated Issuer [Member] | Primary Kids, Inc [Member] | Consumer-related Technologies [Member] | Term Loan, Prime Index, One [Member]
Cash Rate		15.75%		14.25%
Margin		7.25%		7.25%
Floor		10.50%		10.50%
Ceiling		0%		0%
ETP		3%		3%
Maturity Date		Mar. 01, 2025		Mar. 01, 2025
Principal Amount		$ 1,700		$ 2,700
Investments at cost		1,683		2,673
Investments at fair value		$ 1,683		$ 2,673
Investment, Unaffiliated Issuer [Member] | Primary Kids, Inc [Member] | Consumer-related Technologies [Member] | Term Loan, Prime Index Two [Member]
Cash Rate		15.75%		14.25%
Margin		7.25%		7.25%
Floor		10.50%		10.50%
Ceiling		0%		0%
ETP		3%		3%
Maturity Date		Mar. 01, 2025		Mar. 01, 2025
Principal Amount		$ 1,700		$ 2,700
Investments at cost		1,683		2,673
Investments at fair value		1,683		2,673
Investment, Unaffiliated Issuer [Member] | Primary Kids, Inc [Member] | Consumer-related Technologies [Member] | Preferred Stock Warrants [Member]
Investments at cost		57		57
Investments at fair value		$ 596		$ 429
Number of Shares (in shares)		553,778		553,778
Investment, Unaffiliated Issuer [Member] | Primary Kids, Inc [Member] | Consumer-related Technologies [Member] | Term Loan, Prime Index Three [Member]
Cash Rate		15.75%		14.25%
Margin		7.25%		7.25%
Floor		10.50%		10.50%
Ceiling		0%		0%
ETP		3%		3%
Maturity Date		Sep. 01, 2025		Sep. 01, 2025
Principal Amount		$ 2,300		$ 3,000
Investments at cost		2,277		2,967
Investments at fair value		2,277		$ 2,967
Investment, Unaffiliated Issuer [Member] | Canary Medical Inc. [Member] | Medical Device Sector [Member] | Term Loan, Prime Index, One [Member]
Cash Rate				12.75%
Margin				5.75%
Floor				9%
Ceiling				0%
ETP				7%
Maturity Date				Nov. 01, 2024
Principal Amount				$ 2,500
Investments at cost				2,475
Investments at fair value				$ 2,475
Investment, Unaffiliated Issuer [Member] | Canary Medical Inc. [Member] | Medical Device Sector [Member] | Term Loan, Prime Index Two [Member]
Cash Rate				12.75%
Margin				5.75%
Floor				9%
Ceiling				0%
ETP				7%
Maturity Date				Nov. 01, 2024
Principal Amount				$ 2,500
Investments at cost				2,489
Investments at fair value				2,489
Investment, Unaffiliated Issuer [Member] | Canary Medical Inc. [Member] | Medical Device Sector [Member] | Preferred Stock Warrants [Member]
Investments at cost		86		84
Investments at fair value		$ 1,307		$ 1,864
Number of Shares (in shares)		12,153		12,153
Investment, Unaffiliated Issuer [Member] | Canary Medical Inc. [Member] | Medical Device Sector [Member] | Term Loan, Prime Index Three [Member]
Cash Rate				12.75%
Margin				5.75%
Floor				9%
Ceiling				0%
ETP				7%
Maturity Date				Nov. 01, 2024
Principal Amount				$ 2,500
Investments at cost				2,473
Investments at fair value				2,473
Investment, Unaffiliated Issuer [Member] | SnagAJob.com, Inc [Member] | Consumer-related Technologies [Member] | Common Stock [Member]
Investments at cost		$ 9		8
Investments at fair value		$ 83		$ 83
Number of Shares (in shares)		82,974		82,974
Investment, Unaffiliated Issuer [Member] | Quip NYC Inc [Member] | Consumer-related Technologies [Member] | Preferred Stock Warrants [Member]
Investments at cost		$ 325		$ 325
Investments at fair value		$ 538		$ 534
Number of Shares (in shares)		6,191		6,191
Investment, Unaffiliated Issuer [Member] | Nexii Building Solutions, Inc1 [Member] | Other Sustainability Sector [Member] | Term Loan, Prime Index, One [Member]
Cash Rate		15.50%		14.50%
Margin		7%		7%
Floor		10.25%		10.25%
Ceiling		0%		0%
ETP		2.50%		2.50%
Maturity Date		Sep. 01, 2025		Sep. 01, 2025
Principal Amount		$ 8,102		$ 7,500
Investments at cost		8,009		7,371
Investments at fair value		$ 6,754		$ 7,371
Investment, Unaffiliated Issuer [Member] | Nexii Building Solutions, Inc1 [Member] | Other Sustainability Sector [Member] | Term Loan, Prime Index Two [Member]
Cash Rate		15.50%		14.50%
Margin		7%		7%
Floor		10.25%		10.25%
Ceiling		0%		0%
ETP		2.50%		2.50%
Maturity Date		Sep. 01, 2025		Sep. 01, 2025
Principal Amount		$ 8,102		$ 7,500
Investments at cost		8,009		7,371
Investments at fair value		$ 6,754		7,371
Investment, Unaffiliated Issuer [Member] | Nexii Building Solutions, Inc1 [Member] | Other Sustainability Sector [Member] | Common Stock Warrants [Member]
Investments at cost				488
Investments at fair value				$ 1,061
Number of Shares (in shares)				204,832
Investment, Unaffiliated Issuer [Member] | Nexii Building Solutions, Inc1 [Member] | Other Sustainability Sector [Member] | Term Loan, Prime Index Three [Member]
Cash Rate		15.50%		14.50%
Margin		7%		7%
Floor		10.25%		10.25%
Ceiling		0%		0%
ETP		2.50%		2.50%
Maturity Date		Sep. 01, 2025		Sep. 01, 2025
Principal Amount		$ 8,102		$ 7,500
Investments at cost		8,009		7,371
Investments at fair value		$ 6,754		$ 7,371
Investment, Unaffiliated Issuer [Member] | Nexii Building Solutions, Inc1 [Member] | Other Sustainability Sector [Member] | Term Loan, Prime Index, Four [Member]
Cash Rate		15.50%		14.50%
Margin		7%		7%
Floor		10.25%		10.25%
Ceiling		0%		0%
ETP		2.50%		2.50%
Maturity Date		Jul. 01, 2026		Jul. 01, 2026
Principal Amount		$ 5,402		$ 5,000
Investments at cost		5,332		4,903
Investments at fair value		$ 4,496		$ 4,903
Investment, Unaffiliated Issuer [Member] | Nexii Building Solutions, Inc1 [Member] | Other Sustainability Sector [Member] | Term Loan, Prime Index, Five [Member]
Cash Rate		15.50%		14.50%
Margin		7%		7%
Floor		10.25%		10.25%
Ceiling		0%		0%
ETP		2.50%		2.50%
Maturity Date		Jul. 01, 2026		Jul. 01, 2026
Principal Amount		$ 5,402		$ 5,000
Investments at cost		5,332		4,903
Investments at fair value		$ 4,496		$ 4,903
Investment, Unaffiliated Issuer [Member] | Nexii Building Solutions, Inc1 [Member] | Other Sustainability Sector [Member] | Term Loan, Prime Index, Six [Member]
Cash Rate		15.50%
Margin		7%
Floor		10.25%
Ceiling		0%
ETP		2.50%
Maturity Date		Sep. 30, 2023
Principal Amount		$ 707
Investments at cost		707
Investments at fair value		$ 596
Investment, Unaffiliated Issuer [Member] | Nexii Building Solutions, Inc1 [Member] | Other Sustainability Sector [Member] | Term Loan, Prime Index, Seven [Member]
Cash Rate		15.50%
Margin		7%
Floor		10.25%
Ceiling		0%
ETP		2.50%
Maturity Date		Sep. 30, 2023
Principal Amount		$ 564
Investments at cost		564
Investments at fair value		$ 475
Investment, Unaffiliated Issuer [Member] | Nexii Building Solutions, Inc1 [Member] | Other Sustainability Sector [Member] | Term Loan, Prime Index, Eight [Member]
Cash Rate		15.50%
Margin		7%
Floor		10.25%
Ceiling		0%
ETP		2.50%
Maturity Date		Sep. 30, 2023
Principal Amount		$ 281
Investments at cost		281
Investments at fair value		$ 237
Investment, Unaffiliated Issuer [Member] | Nexii Building Solutions, Inc1 [Member] | Other Sustainability Sector [Member] | Term Loan, Prime Index, Nine [Member]
Cash Rate		15.50%
Margin		7%
Floor		10.25%
Ceiling		0%
ETP		2.50%
Maturity Date		Sep. 30, 2023
Principal Amount		$ 279
Investments at cost		279
Investments at fair value		$ 235
Investment, Unaffiliated Issuer [Member] | Nexii Building Solutions, Inc1 [Member] | Other Sustainability Sector [Member] | Term Loan, Prime Index, Ten [Member]
Cash Rate		15.50%
Margin		7%
Floor		10.25%
Ceiling		0%
ETP		2.50%
Maturity Date		Sep. 30, 2023
Principal Amount		$ 167
Investments at cost		167
Investments at fair value		$ 141
Investment, Unaffiliated Issuer [Member] | Noodle Partners, Inc. [Member] | Software Sector [Member] | Term Loan, Prime Index, One [Member]
Cash Rate		13.50%
Margin		5%
Floor		12%
Ceiling		0%
ETP		3%
Maturity Date		Mar. 01, 2027
Principal Amount		$ 10,000
Investments at cost		9,814
Investments at fair value		$ 9,814
Investment, Unaffiliated Issuer [Member] | Noodle Partners, Inc. [Member] | Software Sector [Member] | Term Loan, Prime Index Two [Member]
Cash Rate		13.50%
Margin		5%
Floor		12%
Ceiling		0%
ETP		3%
Maturity Date		Mar. 01, 2027
Principal Amount		$ 5,000
Investments at cost		4,938
Investments at fair value		4,938
Investment, Unaffiliated Issuer [Member] | Noodle Partners, Inc. [Member] | Software Sector [Member] | Preferred Stock Warrants [Member]
Investments at cost		115
Investments at fair value		$ 79
Number of Shares (in shares)		84,037
Investment, Unaffiliated Issuer [Member] | Noodle Partners, Inc. [Member] | Software Sector [Member] | Term Loan, Prime Index Three [Member]
Cash Rate		13.50%
Margin		5%
Floor		12%
Ceiling		0%
ETP		3%
Maturity Date		Mar. 01, 2027
Principal Amount		$ 5,000
Investments at cost		4,939
Investments at fair value		$ 4,939
Investment, Unaffiliated Issuer [Member] | Candesant Biomedical, Inc. [Member] | Medical Device Sector [Member] | Term Loan, Prime Index, One [Member]
Cash Rate		12%
Margin		3.50%
Floor		11.50%
Ceiling		0%
ETP		5%
Maturity Date		Sep. 01, 2027
Principal Amount		$ 5,000
Investments at cost		4,751
Investments at fair value		$ 4,751
Investment, Unaffiliated Issuer [Member] | Candesant Biomedical, Inc. [Member] | Medical Device Sector [Member] | Term Loan, Prime Index Two [Member]
Cash Rate		12%
Margin		3.50%
Floor		11.50%
Ceiling		0%
ETP		5%
Maturity Date		Sep. 01, 2027
Principal Amount		$ 2,500
Investments at cost		2,451
Investment, Unaffiliated Issuer [Member] | Candesant Biomedical, Inc. [Member] | Medical Device Sector [Member] | Preferred Stock Warrants [Member]
Investments at cost		152
Investments at fair value		$ 152
Number of Shares (in shares)		93,336
Investment, Unaffiliated Issuer [Member] | Candesant Biomedical, Inc. [Member] | Medical Device Sector [Member] | Term Loan, Prime Index Three [Member]
Cash Rate		12%
Margin		3.50%
Floor		11.50%
Ceiling		0%
ETP		5%
Maturity Date		Sep. 01, 2027
Principal Amount		$ 2,500
Investments at cost		2,451
Investments at fair value		$ 2,451
Investment, Unaffiliated Issuer [Member] | Unagi, Inc [Member] | Consumer-related Technologies [Member] | Term Loan, Prime Index, One [Member]
Cash Rate		16.25%		15.25%
Margin		7.75%		7.75%
Floor		11%		11%
Ceiling		0%		0%
ETP		0%		0%
Maturity Date		May 01, 2027		Jul. 01, 2025
Principal Amount		$ 1,108		$ 2,500
Investments at cost		1,086		2,473
Investments at fair value		$ 872		$ 2,473
Investment, Unaffiliated Issuer [Member] | Unagi, Inc [Member] | Consumer-related Technologies [Member] | Term Loan, Prime Index Two [Member]
Cash Rate		16.25%		15.25%
Margin		7.75%		7.75%
Floor		11%		11%
Ceiling		0%		0%
ETP		0%		0%
Maturity Date		May 01, 2027		Jul. 01, 2025
Principal Amount		$ 554		$ 1,250
Investments at cost		543		1,236
Investments at fair value		436		1,236
Investment, Unaffiliated Issuer [Member] | Unagi, Inc [Member] | Consumer-related Technologies [Member] | Preferred Stock Warrants [Member]
Investments at cost		32		32
Investments at fair value		$ 0		$ 22
Number of Shares (in shares)		171,081		171,081
Investment, Unaffiliated Issuer [Member] | Unagi, Inc [Member] | Consumer-related Technologies [Member] | Term Loan, Prime Index Three [Member]
Cash Rate		16.25%		15.25%
Margin		7.75%		7.75%
Floor		11%		11%
Ceiling		0%		0%
ETP		0%		0%
Maturity Date		May 01, 2027		Jul. 01, 2025
Principal Amount		$ 554		$ 1,250
Investments at cost		543		1,236
Investments at fair value		$ 436		$ 1,236
Investment, Unaffiliated Issuer [Member] | Ceribell, Inc. [Member] | Medical Device Sector [Member] | Term Loan, Prime Index, One [Member]
Cash Rate		12%		10.50%
Margin		3.50%		3.50%
Floor		8.25%		8.25%
Ceiling		0%		0%
ETP		5.50%		5.50%
Maturity Date		Oct. 01, 2024		Oct. 01, 2024
Principal Amount		$ 5,000		$ 5,000
Investments at cost		4,985		4,973
Investments at fair value		$ 4,985		$ 4,973
Investment, Unaffiliated Issuer [Member] | Ceribell, Inc. [Member] | Medical Device Sector [Member] | Term Loan, Prime Index Two [Member]
Cash Rate		12%		10.50%
Margin		3.50%		3.50%
Floor		8.25%		8.25%
Ceiling		0%		0%
ETP		5.50%		5.50%
Maturity Date		Oct. 01, 2024		Oct. 01, 2024
Principal Amount		$ 5,000		$ 5,000
Investments at cost		4,985		4,973
Investments at fair value		4,985		4,973
Investment, Unaffiliated Issuer [Member] | Ceribell, Inc. [Member] | Medical Device Sector [Member] | Preferred Stock Warrants [Member]
Investments at cost		69		69
Investments at fair value		$ 213		$ 209
Number of Shares (in shares)		145,483		145,483
Investment, Unaffiliated Issuer [Member] | Ceribell, Inc. [Member] | Medical Device Sector [Member] | Term Loan, Prime Index Three [Member]
Cash Rate		12%		10.50%
Margin		3.50%		3.50%
Floor		8.25%		8.25%
Ceiling		0%		0%
ETP		5.50%		5.50%
Maturity Date		Oct. 01, 2024		Oct. 01, 2024
Principal Amount		$ 2,500		$ 2,500
Investments at cost		2,488		2,478
Investments at fair value		$ 2,488		$ 2,478
Investment, Unaffiliated Issuer [Member] | Ceribell, Inc. [Member] | Medical Device Sector [Member] | Term Loan, Prime Index, Four [Member]
Cash Rate		12%		10.50%
Margin		3.50%		3.50%
Floor		8.25%		8.25%
Ceiling		0%		0%
ETP		5.50%		5.50%
Maturity Date		Oct. 01, 2024		Oct. 01, 2024
Principal Amount		$ 2,500		$ 2,500
Investments at cost		2,488		2,478
Investments at fair value		2,488		2,478
Investment, Unaffiliated Issuer [Member] | Tigo Energy, Inc. [Member] | Other Sustainability Sector [Member] | Common Stock [Member]
Investments at cost		111
Investments at fair value		$ 36
Number of Shares (in shares)		5,205
Investment, Unaffiliated Issuer [Member] | Tigo Energy, Inc. [Member] | Other Sustainability Sector [Member] | Preferred Stock [Member]
Investments at cost				8
Investments at fair value				$ 27
Number of Shares (in shares)				22,313
Investment, Unaffiliated Issuer [Member] | Updater, Inc [Member] | Consumer-related Technologies [Member] | Common Stock Warrants [Member]
Investments at cost		$ 34		$ 34
Investments at fair value		$ 0		$ 42
Number of Shares (in shares)		108,333		108,333
Investment, Unaffiliated Issuer [Member] | Cognoa, Inc. [Member] | Medical Device Sector [Member] | Term Loan, Prime Index, One [Member]
Cash Rate		14%		13%
Margin		5.50%		5.50%
Floor		8.75%		8.75%
Ceiling		0%		0%
ETP		6%		6%
Maturity Date		Aug. 01, 2026		Aug. 01, 2026
Principal Amount		$ 4,722		$ 2,500
Investments at cost		4,678		2,466
Investments at fair value		$ 4,678		$ 2,466
Investment, Unaffiliated Issuer [Member] | Cognoa, Inc. [Member] | Medical Device Sector [Member] | Term Loan, Prime Index Two [Member]
Cash Rate		14%		13%
Margin		5.50%		5.50%
Floor		8.75%		8.75%
Ceiling		0%		0%
ETP		6%		6%
Maturity Date		Aug. 01, 2026		Aug. 01, 2026
Principal Amount		$ 2,361		$ 5,000
Investments at cost		2,339		4,932
Investments at fair value		2,339		4,932
Investment, Unaffiliated Issuer [Member] | Cognoa, Inc. [Member] | Medical Device Sector [Member] | Preferred Stock Warrants [Member]
Investments at cost		148		148
Investments at fair value		$ 184		$ 179
Number of Shares (in shares)		4,106,174		775,000
Investment, Unaffiliated Issuer [Member] | Branded Online, Inc [Member] | Software Sector [Member] | Common Stock [Member]
Investments at cost		$ 1,079		$ 1,079
Investments at fair value		$ 3		$ 83
Number of Shares (in shares)		5,398		108,004
Investment, Unaffiliated Issuer [Member] | CPG Beyond, Inc [Member] | Data Storage Sector [Member] | Preferred Stock Warrants [Member]
Investments at cost		$ 242		$ 242
Investments at fair value		$ 917		$ 909
Number of Shares (in shares)		500,000		500,000
Investment, Unaffiliated Issuer [Member] | Reputation Institute, Inc [Member] | Software Sector [Member] | Term Loan, Prime Index, One [Member]
Cash Rate		15.75%		14.25%
Margin		7.25%		7.25%
Floor		10.50%		10.50%
Ceiling		0%		0%
ETP		3%		3%
Maturity Date		Aug. 01, 2025		Aug. 01, 2025
Principal Amount		$ 3,833		$ 5,000
Investments at cost		3,785		4,932
Investments at fair value		3,785		4,932
Investment, Unaffiliated Issuer [Member] | Reputation Institute, Inc [Member] | Software Sector [Member] | Preferred Stock Warrants [Member]
Investments at cost		56		56
Investments at fair value		$ 48		$ 39
Number of Shares (in shares)		3,731		3,731
Investment, Unaffiliated Issuer [Member] | Conventus Orthopaedics, Inc [Member] | Medical Device Sector [Member] | Term Loan, Prime Index Two [Member]
Cash Rate		13.32%
Margin		4.82%
Floor		9.25%
Ceiling		0%
ETP		10.36%
Maturity Date		Jul. 01, 2025
Principal Amount		$ 3,960
Investments at cost		3,916
Investments at fair value		3,916
Investment, Unaffiliated Issuer [Member] | Conventus Orthopaedics, Inc [Member] | Medical Device Sector [Member] | Preferred Stock Warrants [Member]
Investments at cost		218		$ 221
Investments at fair value		$ 236		$ 226
Number of Shares (in shares)		7,972,222		7,972,222
Investment, Unaffiliated Issuer [Member] | Conventus Orthopaedics, Inc [Member] | Medical Device Sector [Member] | Term Loan, LIBOR Index, One [Member]
Cash Rate				12.17%
Margin				8%
Floor				9.25%
Ceiling				0%
ETP				10.36%
Maturity Date				Jul. 01, 2025
Principal Amount				$ 3,960
Investments at cost				3,898
Investments at fair value				$ 3,898
Investment, Unaffiliated Issuer [Member] | Conventus Orthopaedics, Inc [Member] | Medical Device Sector [Member] | Term Loan, LIBOR Index, Two [Member]
Cash Rate				12.17%
Margin				8%
Floor				9.25%
Ceiling				0%
ETP				10.36%
Maturity Date				Jul. 01, 2025
Principal Amount				$ 3,960
Investments at cost				3,898
Investments at fair value				$ 3,898
Investment, Unaffiliated Issuer [Member] | Decisyon, Inc [Member] | Software Sector [Member] | Term Loan, Prime Index, One [Member]
Cash Rate				16.93%
Margin				9.43%
Floor				12.68%
Ceiling				0%
ETP				50.43%
Maturity Date				Dec. 31, 2022
Principal Amount				$ 3,295
Investments at cost				3,295
Investments at fair value				3,295
Investment, Unaffiliated Issuer [Member] | Decisyon, Inc [Member] | Software Sector [Member] | Common Stock Warrants [Member]
Investments at cost				46
Investments at fair value				$ 0
Number of Shares (in shares)				82,967
Investment, Unaffiliated Issuer [Member] | Decisyon, Inc [Member] | Software Sector [Member] | Equity Securities [Member]
Investments at cost				$ 230
Investments at fair value				$ 0
Number of Shares (in shares)				72,638,663
Investment, Unaffiliated Issuer [Member] | Decisyon, Inc [Member] | Software Sector [Member] | Preferred Stock [Member]
Investments at cost		$ 2,800
Investments at fair value		$ 1,281
Number of Shares (in shares)		280,000
Investment, Unaffiliated Issuer [Member] | Silk, Inc [Member] | Data Storage Sector [Member] | Preferred Stock Warrants [Member]
Investments at cost		$ 175		$ 234
Investments at fair value		$ 153		$ 407
Number of Shares (in shares)		394,110		442,110
Investment, Unaffiliated Issuer [Member] | Slingshot Aerospace, Inc. [Member] | Software Sector [Member] | Term Loan, Prime Index, One [Member]
Cash Rate		14.25%		13.25%
Margin		5.75%		5.75%
Floor		9.75%		9.75%
Ceiling		0%		0%
ETP		5%		5%
Maturity Date		Aug. 01, 2026		Aug. 01, 2026
Principal Amount		$ 5,000		$ 5,000
Investments at cost		4,952		4,870
Investments at fair value		$ 4,952		$ 4,870
Investment, Unaffiliated Issuer [Member] | Slingshot Aerospace, Inc. [Member] | Software Sector [Member] | Term Loan, Prime Index Two [Member]
Cash Rate		14.25%		13.25%
Margin		5.75%		5.75%
Floor		9.75%		9.75%
Ceiling		0%		0%
ETP		5%		5%
Maturity Date		Aug. 01, 2026		Aug. 01, 2026
Principal Amount		$ 5,000		$ 5,000
Investments at cost		4,952		4,933
Investments at fair value		4,952		4,933
Investment, Unaffiliated Issuer [Member] | Slingshot Aerospace, Inc. [Member] | Software Sector [Member] | Preferred Stock Warrants [Member]
Investments at cost		123		123
Investments at fair value		$ 135		$ 133
Number of Shares (in shares)		309,208		309,208
Investment, Unaffiliated Issuer [Member] | Slingshot Aerospace, Inc. [Member] | Software Sector [Member] | Term Loan, Prime Index Three [Member]
Cash Rate		14.25%		13.25%
Margin		5.75%		5.75%
Floor		9.75%		9.75%
Ceiling		0%		0%
ETP		5%		5%
Maturity Date		Aug. 01, 2026		Aug. 01, 2026
Principal Amount		$ 5,000		$ 5,000
Investments at cost		4,952		4,933
Investments at fair value		$ 4,952		$ 4,933
Investment, Unaffiliated Issuer [Member] | Slingshot Aerospace, Inc. [Member] | Software Sector [Member] | Term Loan, Prime Index, Four [Member]
Cash Rate		14.25%		13.25%
Margin		5.75%		5.75%
Floor		9.75%		9.75%
Ceiling		0%		0%
ETP		5%		5%
Maturity Date		Aug. 01, 2026		Aug. 01, 2026
Principal Amount		$ 5,000		$ 5,000
Investments at cost		4,952		4,933
Investments at fair value		4,952		4,933
Investment, Unaffiliated Issuer [Member] | Lotame Solutions, Inc. [Member] | Software Sector [Member] | Preferred Stock Warrants [Member]
Investments at cost		18		22
Investments at fair value		$ 44		$ 312
Number of Shares (in shares)		71,305		288,115
Investment, Unaffiliated Issuer [Member] | Lotame Solutions, Inc. [Member] | Software Sector [Member] | Preferred Stock [Member]
Investments at cost		$ 4
Investments at fair value		$ 193
Number of Shares (in shares)		66,127
Investment, Unaffiliated Issuer [Member] | Global Worldwide LLC [Member] | Internet and Media Sector [Member] | Preferred Stock Warrants [Member]
Investments at cost		$ 75		$ 75
Investments at fair value		$ 63		$ 0
Number of Shares (in shares)		245,810		245,810
Investment, Unaffiliated Issuer [Member] | CVRx, Inc [Member] | Medical Device Sector [Member] | Common Stock Warrants [Member]
Investments at cost		$ 76		$ 76
Investments at fair value		$ 272		$ 394
Number of Shares (in shares)		47,410		47,410
Investment, Unaffiliated Issuer [Member] | Rocket Lawyer Incorporated [Member] | Internet and Media Sector [Member] | Preferred Stock Warrants [Member]
Investments at cost		$ 92		$ 92
Investments at fair value		$ 336		$ 357
Number of Shares (in shares)		261,721		261,721
Investment, Unaffiliated Issuer [Member] | Skillshare, Inc [Member] | Internet and Media Sector [Member] | Preferred Stock Warrants [Member]
Investments at cost		$ 162		$ 162
Investments at fair value		$ 1,216		$ 802
Number of Shares (in shares)		139,074		139,074
Investment, Unaffiliated Issuer [Member] | Liqid, Inc [Member] | Software Sector [Member] | Term Loan, Prime Index, Five [Member]
Cash Rate		14.75%
Margin		6.25%
Floor		9.50%
Ceiling		0%
ETP		4%
Maturity Date		Sep. 01, 2024
Principal Amount		$ 917
Investments at cost		887
Investments at fair value		$ 887
Investment, Unaffiliated Issuer [Member] | Liqid, Inc [Member] | Networking Sector [Member] | Term Loan, Prime Index, One [Member]
Cash Rate		14.75%		13.25%
Margin		6.25%		6.25%
Floor		9.50%		9.50%
Ceiling		0%		0%
ETP		4%		4%
Maturity Date		Sep. 01, 2024		Sep. 01, 2024
Principal Amount		$ 1,833		$ 3,333
Investments at cost		1,807		3,286
Investments at fair value		$ 1,807		$ 3,286
Investment, Unaffiliated Issuer [Member] | Liqid, Inc [Member] | Networking Sector [Member] | Term Loan, Prime Index Two [Member]
Cash Rate		14.75%		13.25%
Margin		6.25%		6.25%
Floor		9.50%		9.50%
Ceiling		0%		0%
ETP		4%		4%
Maturity Date		Sep. 01, 2024		Sep. 01, 2024
Principal Amount		$ 1,833		$ 3,333
Investments at cost		1,807		3,286
Investments at fair value		1,807		3,286
Investment, Unaffiliated Issuer [Member] | Liqid, Inc [Member] | Networking Sector [Member] | Preferred Stock Warrants [Member]
Investments at cost		364		364
Investments at fair value		$ 251		$ 243
Number of Shares (in shares)		344,102		344,102
Investment, Unaffiliated Issuer [Member] | Liqid, Inc [Member] | Networking Sector [Member] | Term Loan, Prime Index Three [Member]
Cash Rate		14.75%		13.25%
Margin		6.25%		6.25%
Floor		9.50%		9.50%
Ceiling		0%		0%
ETP		4%		4%
Maturity Date		Sep. 01, 2024		Sep. 01, 2024
Principal Amount		$ 917		$ 1,667
Investments at cost		903		1,641
Investments at fair value		$ 903		$ 1,641
Investment, Unaffiliated Issuer [Member] | Liqid, Inc [Member] | Networking Sector [Member] | Term Loan, Prime Index, Four [Member]
Cash Rate		14.75%		13.25%
Margin		6.25%		6.25%
Floor		9.50%		9.50%
Ceiling		0%		0%
ETP		4%		4%
Maturity Date		Sep. 01, 2024		Sep. 01, 2024
Principal Amount		$ 917		$ 1,667
Investments at cost		903		1,641
Investments at fair value		$ 903		$ 1,641
Investment, Unaffiliated Issuer [Member] | Liqid, Inc [Member] | Networking Sector [Member] | Term Loan, Prime Index, Five [Member]
Cash Rate				13.25%
Margin				6.25%
Floor				9.50%
Ceiling				0%
ETP				4%
Maturity Date				Sep. 01, 2024
Principal Amount				$ 1,667
Investments at cost				1,613
Investments at fair value				$ 1,613
Investment, Unaffiliated Issuer [Member] | Supply Network Visibility Holdings, LLC [Member] | Software Sector [Member] | Term Loan, Prime Index, One [Member]
Cash Rate		12.75%		13.50%
Margin		4.25%		6.50%
Floor		12%		9.75%
Ceiling		0%		0%
ETP		2.50%		4%
Maturity Date		Jun. 01, 2028		Feb. 01, 2025
Principal Amount		$ 2,500		$ 3,500
Investments at cost		2,457		3,472
Investments at fair value		$ 2,457		$ 3,472
Investment, Unaffiliated Issuer [Member] | Supply Network Visibility Holdings, LLC [Member] | Software Sector [Member] | Term Loan, Prime Index Two [Member]
Cash Rate		12.75%		13.50%
Margin		4.25%		6.50%
Floor		12%		9.75%
Ceiling		0%		0%
ETP		2.50%		4%
Maturity Date		Jun. 01, 2028		Feb. 01, 2025
Principal Amount		$ 3,500		$ 3,500
Investments at cost		3,489		3,472
Investments at fair value		3,489		$ 3,472
Investment, Unaffiliated Issuer [Member] | Supply Network Visibility Holdings, LLC [Member] | Software Sector [Member] | Preferred Stock Warrants [Member]
Investments at cost		64
Investments at fair value		$ 146
Number of Shares (in shares)		682
Investment, Unaffiliated Issuer [Member] | Supply Network Visibility Holdings, LLC [Member] | Software Sector [Member] | Term Loan, Prime Index Three [Member]
Cash Rate		12.75%		13.50%
Margin		4.25%		6.50%
Floor		12%		9.75%
Ceiling		0%		0%
ETP		2.50%		4%
Maturity Date		Jun. 01, 2028		Dec. 01, 2025
Principal Amount		$ 2,500		$ 2,500
Investments at cost		2,492		2,472
Investments at fair value		$ 2,492		$ 2,472
Investment, Unaffiliated Issuer [Member] | Supply Network Visibility Holdings, LLC [Member] | Software Sector [Member] | Term Loan, Prime Index, Four [Member]
Cash Rate		12.75%		13.50%
Margin		4.25%		6.50%
Floor		12%		9.75%
Ceiling		0%		0%
ETP		2.50%		4%
Maturity Date		Jun. 01, 2028		Dec. 01, 2025
Principal Amount		$ 1,500		$ 2,500
Investments at cost		1,495		2,472
Investments at fair value		1,495		2,472
Investment, Unaffiliated Issuer [Member] | Meditrina, Inc [Member] | Medical Device Sector [Member] | Preferred Stock Warrants [Member]
Investments at cost		83		83
Investments at fair value		$ 104		$ 101
Number of Shares (in shares)		233,993		233,993
Investment, Unaffiliated Issuer [Member] | Halio, Inc [Member] | Power Management Sector [Member] | Preferred Stock Warrants [Member]
Investments at cost		$ 1,585		$ 1,585
Investments at fair value		$ 2,901		$ 2,610
Number of Shares (in shares)		5,002,574		5,002,574
Investment, Unaffiliated Issuer [Member] | Avalanche Technology, Inc [Member] | Semiconductor Sector [Member] | Preferred and Common Stock [Member]
Investments at cost		$ 56
Investments at fair value		$ 0
Number of Shares (in shares)		6,081
Investment, Unaffiliated Issuer [Member] | Avalanche Technology, Inc [Member] | Semiconductor Sector [Member] | Warrant [Member]
Investments at cost				$ 56
Investments at fair value				$ 0
Number of Shares (in shares)				6,081
Investment, Unaffiliated Issuer [Member] | Aerofarms, Inc. [Member] | Other Sustainability Sector [Member] | Term Loan, Prime Index, One [Member]
Cash Rate				14.25%
Margin				6.75%
Floor				10%
Ceiling				0%
ETP				3%
Maturity Date				Apr. 01, 2026
Principal Amount				$ 3,750
Investments at cost				3,699
Investments at fair value				$ 3,699
Investment, Unaffiliated Issuer [Member] | Aerofarms, Inc. [Member] | Other Sustainability Sector [Member] | Term Loan, Prime Index Two [Member]
Cash Rate				14.25%
Margin				6.75%
Floor				10%
Ceiling				0%
ETP				3%
Maturity Date				Apr. 01, 2026
Principal Amount				$ 3,750
Investments at cost				3,699
Investments at fair value				3,699
Investment, Unaffiliated Issuer [Member] | Aerofarms, Inc. [Member] | Other Sustainability Sector [Member] | Preferred Stock Warrants [Member]
Investments at cost				61
Investments at fair value				$ 74
Number of Shares (in shares)				201,537
Investment, Unaffiliated Issuer [Member] | Britecore Holdings, Inc. [Member] | Software Sector [Member] | Term Loan, Prime Index, One [Member]
Cash Rate		14%		13.75%
Margin		5.50%		6.75%
Floor		14%		10%
Ceiling		0%		0%
ETP		3%		5%
Maturity Date		Oct. 01, 2028		Mar. 01, 2026
Principal Amount		$ 5,000		$ 2,500
Investments at cost		4,857		2,421
Investments at fair value		$ 4,857		$ 2,421
Investment, Unaffiliated Issuer [Member] | Britecore Holdings, Inc. [Member] | Software Sector [Member] | Term Loan, Prime Index Two [Member]
Cash Rate		14%		13.75%
Margin		5.50%		6.75%
Floor		14%		10%
Ceiling		0%		0%
ETP		3%		5%
Maturity Date		Oct. 01, 2028		Mar. 01, 2026
Principal Amount		$ 2,500		$ 2,500
Investments at cost		2,464		2,487
Investments at fair value		2,464		2,487
Investment, Unaffiliated Issuer [Member] | Britecore Holdings, Inc. [Member] | Software Sector [Member] | Preferred Stock Warrants [Member]
Investments at cost		98		21
Investments at fair value		$ 147		$ 69
Number of Shares (in shares)		161,215		77,828
Investment, Unaffiliated Issuer [Member] | Britecore Holdings, Inc. [Member] | Software Sector [Member] | Term Loan, Prime Index Three [Member]
Cash Rate		14%
Margin		5.50%
Floor		14%
Ceiling		0%
ETP		3%
Maturity Date		Oct. 01, 2028
Principal Amount		$ 2,500
Investments at cost		2,464
Investments at fair value		$ 2,464
Investment, Unaffiliated Issuer [Member] | Britecore Holdings, Inc. [Member] | Software Sector [Member] | Term Loan, Prime Index, Four [Member]
Cash Rate		14%
Margin		5.50%
Floor		14%
Ceiling		0%
ETP		3%
Maturity Date		Oct. 01, 2028
Principal Amount		$ 2,500
Investments at cost		2,464
Investments at fair value		$ 2,464
Investment, Unaffiliated Issuer [Member] | Viken Detection Corporation [Member] | Software Sector [Member] | Term Loan, Prime Index, One [Member]
Cash Rate		12.50%
Margin		4%
Floor		11.75%
Ceiling		0%
ETP		3.50%
Maturity Date		Jun. 01, 2027
Principal Amount		$ 5,000
Investments at cost		4,768
Investments at fair value		$ 4,768
Investment, Unaffiliated Issuer [Member] | Viken Detection Corporation [Member] | Software Sector [Member] | Term Loan, Prime Index Two [Member]
Cash Rate		12.50%
Margin		4%
Floor		11.75%
Ceiling		0%
ETP		3.50%
Maturity Date		Jun. 01, 2027
Principal Amount		$ 2,500
Investments at cost		2,464
Investments at fair value		2,464
Investment, Unaffiliated Issuer [Member] | Viken Detection Corporation [Member] | Software Sector [Member] | Preferred Stock Warrants [Member]
Investments at cost		120
Investments at fair value		$ 122
Number of Shares (in shares)		345,443
Investment, Unaffiliated Issuer [Member] | Viken Detection Corporation [Member] | Software Sector [Member] | Term Loan, Prime Index Three [Member]
Cash Rate		12.50%
Margin		4%
Floor		11.75%
Ceiling		0%
ETP		3.50%
Maturity Date		Jun. 01, 2027
Principal Amount		$ 2,500
Investments at cost		2,464
Investments at fair value		2,464
Investment, Unaffiliated Issuer [Member] | VERO Biotech LLC [Member] | Medical Device Sector [Member] | Preferred Stock Warrants [Member]
Investments at cost		53		$ 53
Investments at fair value		$ 1		$ 1
Number of Shares (in shares)		408		408
Investment, Unaffiliated Issuer [Member] | E La Carte, Inc [Member] | Software Sector [Member] | Common Stock Warrants [Member]
Investments at cost		$ 60		$ 60
Investments at fair value		$ 0		$ 3
Number of Shares (in shares)		147,361		147,361
Investment, Unaffiliated Issuer [Member] | Groundspeed Analytics, Inc. [Member] | Software Sector [Member] | Term Loan, Prime Index, One [Member]
Cash Rate				13%
Margin				5.50%
Floor				11%
Ceiling				18%
ETP				3%
Maturity Date				Dec. 01, 2026
Principal Amount				$ 5,000
Investments at cost				4,798
Investments at fair value				$ 4,798
Investment, Unaffiliated Issuer [Member] | Groundspeed Analytics, Inc. [Member] | Software Sector [Member] | Term Loan, Prime Index Two [Member]
Cash Rate				13%
Margin				5.50%
Floor				11%
Ceiling				18%
ETP				3%
Maturity Date				Dec. 01, 2026
Principal Amount				$ 5,000
Investments at cost				4,948
Investments at fair value				4,948
Investment, Unaffiliated Issuer [Member] | Groundspeed Analytics, Inc. [Member] | Software Sector [Member] | Preferred Stock Warrants [Member]
Investments at cost				6
Investments at fair value				$ 6
Number of Shares (in shares)				86,300
Investment, Unaffiliated Issuer [Member] | Everstream Holdings, LLC [Member] | Software Sector [Member] | Preferred Stock Warrants [Member]
Investments at cost		$ 70
Investments at fair value		$ 71
Number of Shares (in shares)		350,000
Investment, Unaffiliated Issuer [Member] | Revinate Holdings, Inc [Member] | Software Sector [Member] | Preferred Stock Warrants [Member]
Investments at cost		$ 44		$ 46
Investments at fair value		$ 103		$ 99
Number of Shares (in shares)		682,034		682,034
Investment, Unaffiliated Issuer [Member] | Riv Data Corp [Member] | Software Sector [Member] | Preferred Stock Warrants [Member]
Investments at cost				$ 12
Investments at fair value				$ 296
Number of Shares (in shares)				321,428
Investment, Unaffiliated Issuer [Member] | SIGNiX, Inc [Member] | Software Sector [Member] | Preferred Stock Warrants [Member]
Investments at cost		$ 225		$ 225
Investments at fair value		$ 0		$ 0
Number of Shares (in shares)		186,235		186,235
Investment, Unaffiliated Issuer [Member] | Skyword, Inc [Member] | Software Sector [Member] | Warrant [Member]
Investments at cost				$ 48
Investments at fair value				$ 1
Number of Shares (in shares)				301,055
Investment, Unaffiliated Issuer [Member] | Supply Network Visiblity Holdings LLC [Member] | Software Sector [Member] | Preferred Stock Warrants [Member]
Investments at cost				$ 64
Investments at fair value				$ 83
Number of Shares (in shares)				682
Investment, Unaffiliated Issuer [Member] | Topia Mobility, Inc [Member] | Software Sector [Member] | Preferred Stock Warrants [Member]
Investments at cost		$ 138		$ 138
Investments at fair value		$ 0		$ 0
Number of Shares (in shares)		3,049,607		3,049,607
Investment, Unaffiliated Issuer [Member] | xAd, Inc [Member] | Software Sector [Member] | Preferred Stock Warrants [Member]
Investments at cost		$ 177		$ 177
Investments at fair value		$ 12		$ 12
Number of Shares (in shares)		4,343,348		4,343,348
Investment, Unaffiliated Issuer [Member] | Secure Transfusion Services, Inc [Member] | Other Healthcare Sector [Member] | Term Loan, Prime Index, One [Member]
Cash Rate				13.25%
Margin				5.75%
Floor				9%
Ceiling				0%
ETP				4%
Maturity Date				Oct. 01, 2025
Principal Amount				$ 4,943
Investments at cost				4,943
Investments at fair value				$ 1,668
Investment, Unaffiliated Issuer [Member] | Secure Transfusion Services, Inc [Member] | Other Healthcare Sector [Member] | Term Loan, Prime Index Two [Member]
Cash Rate				13.25%
Margin				5.75%
Floor				9%
Ceiling				0%
ETP				4%
Maturity Date				Dec. 31, 2025
Principal Amount				$ 2,500
Investments at cost				2,467
Investments at fair value				832
Investment, Unaffiliated Issuer [Member] | Secure Transfusion Services, Inc [Member] | Other Healthcare Sector [Member] | Preferred Stock Warrants [Member]
Investments at cost				47
Investments at fair value				$ 0
Number of Shares (in shares)				77,690
Investment, Affiliated Issuer, Noncontrolled [Member]
Investments at cost		$ 39,666		$ 0
Investments at fair value		20,485	$ 906	0	$ 0	$ 0	$ 0
Investment, Affiliated Issuer, Noncontrolled [Member] | Debt Securities [Member]
Investments at cost		34,540
Investments at fair value		12,000
Investment, Affiliated Issuer, Noncontrolled [Member] | Warrant [Member]
Investments at cost		126
Investments at fair value		0
Investment, Affiliated Issuer, Noncontrolled [Member] | Life Science [Member] | Equity Securities [Member]
Investments at cost		5,000
Investments at fair value		$ 8,485
Number of Shares (in shares)
Investment, Affiliated Issuer, Noncontrolled [Member] | Evelo Biosciences, Inc. [Member] | Biotechnology Sector [Member] | Term Loan, Prime Index, One [Member]
Cash Rate		12.75%
Margin		4.25%
Floor		11%
Ceiling		0%
ETP		4.25%
Maturity Date		Jan. 01, 2028
Principal Amount		$ 7,778
Investments at cost		7,672
Investments at fair value		$ 2,666
Investment, Affiliated Issuer, Noncontrolled [Member] | Evelo Biosciences, Inc. [Member] | Biotechnology Sector [Member] | Term Loan, Prime Index Two [Member]
Cash Rate		12.75%
Margin		4.25%
Floor		11%
Ceiling		0%
ETP		4.25%
Maturity Date		Jan. 01, 2028
Principal Amount		$ 11,667
Investments at cost		11,509
Investments at fair value		3,997
Investment, Affiliated Issuer, Noncontrolled [Member] | Evelo Biosciences, Inc. [Member] | Biotechnology Sector [Member] | Common Stock [Member]
Investments at cost		5,000
Investments at fair value		$ 8,485
Number of Shares (in shares)		2,164,502
Investment, Affiliated Issuer, Noncontrolled [Member] | Evelo Biosciences, Inc. [Member] | Biotechnology Sector [Member] | Term Loan, Prime Index Three [Member]
Cash Rate		12.75%
Margin		4.25%
Floor		11%
Ceiling		0%
ETP		4.25%
Maturity Date		Jan. 01, 2028
Principal Amount		$ 4,681
Investments at cost		4,618
Investments at fair value		$ 1,604
Investment, Affiliated Issuer, Noncontrolled [Member] | Evelo Biosciences, Inc. [Member] | Biotechnology Sector [Member] | Term Loan, Prime Index, Four [Member]
Cash Rate		12.75%
Margin		4.25%
Floor		11%
Ceiling		0%
ETP		4.25%
Maturity Date		Jan. 01, 2028
Principal Amount		$ 4,667
Investments at cost		4,603
Investments at fair value		$ 1,597
Investment, Affiliated Issuer, Noncontrolled [Member] | Evelo Biosciences, Inc. [Member] | Biotechnology Sector [Member] | Term Loan, Prime Index, Five [Member]
Cash Rate		12.75%
Margin		4.25%
Floor		11%
Ceiling		0%
ETP		4.25%
Maturity Date		Jan. 01, 2028
Principal Amount		$ 3,111
Investments at cost		3,069
Investments at fair value		1,068
Investment, Affiliated Issuer, Noncontrolled [Member] | Evelo Biosciences, Inc. [Member] | Biotechnology Sector [Member] | Warrant [Member]
Investments at cost		126
Investments at fair value		$ 0
Number of Shares (in shares)		23,196
Investment, Affiliated Issuer, Noncontrolled [Member] | Evelo Biosciences, Inc. [Member] | Biotechnology Sector [Member] | Term Loan, Prime Index, Six [Member]
Cash Rate		12.75%
Margin		4.25%
Floor		11%
Ceiling		0%
ETP		4.25%
Maturity Date		Jan. 01, 2028
Principal Amount		$ 3,111
Investments at cost		3,069
Investments at fair value		1,068
Investment, Affiliated Issuer, Noncontrolled [Member] | Aulea Medical, Inc. [Member]
Investments at fair value		0	0	0
Investment, Affiliated Issuer, Noncontrolled [Member] | Aulea Medical, Inc. [Member] | Medical Device Sector [Member] | Common Stock [Member]
Investments at cost		0
Investments at fair value		$ 0
Number of Shares (in shares)		660,537
Investment, Affiliated Issuer, Noncontrolled [Member] | Cadrenal Therapeutics, Inc. [Member]
Investments at fair value	[1]	$ 0	906	0
Investment, Affiliated Issuer, Noncontrolled [Member] | Cadrenal Therapeutics, Inc. [Member] | Biotechnology Sector [Member] | Common Stock [Member]
Investments at cost		0
Investments at fair value		$ 408
Number of Shares (in shares)		600,000
Investment, Affiliated Issuer, Controlled [Member]
Investments at cost		$ 14,216		0
Investments at fair value		13,145	0	0	$ 0	$ 0	$ 0
Investment, Affiliated Issuer, Controlled [Member] | Biotechnology Sector [Member] | Other Investments [Member]
Investments at cost		6,154
Investments at fair value		6,154
Investment, Affiliated Issuer, Controlled [Member] | Consumer-related Technologies [Member] | Debt Securities [Member]
Investments at cost		5,251
Investments at fair value		4,439
Investment, Affiliated Issuer, Controlled [Member] | Technology Sector [Member] | Equity Securities [Member]
Investments at cost		2,811
Investments at fair value		$ 2,552
Investment, Affiliated Issuer, Controlled [Member] | Better Place Forests Co. [Member] | Consumer-related Technologies [Member] | Term Loan, Prime Index, One [Member]
Cash Rate		12.25%
Margin		3.75%
Floor		12%
Ceiling		0%
ETP		2.78%
Maturity Date		Aug. 01, 2029
Principal Amount		$ 3,604
Investments at cost		3,556
Investments at fair value		$ 3,006
Investment, Affiliated Issuer, Controlled [Member] | Better Place Forests Co. [Member] | Consumer-related Technologies [Member] | Term Loan, Prime Index Two [Member]
Cash Rate		12.25%
Margin		3.75%
Floor		12%
Ceiling		0%
ETP		2.78%
Maturity Date		Aug. 01, 2029
Principal Amount		$ 1,719
Investments at cost		1,695
Investments at fair value		1,433
Investment, Affiliated Issuer, Controlled [Member] | Better Place Forests Co. [Member] | Technology Sector [Member] | Preferred and Common Stock [Member]
Investments at cost		2,811
Investments at fair value		$ 2,552
Number of Shares (in shares)		2,551,596
Investment, Affiliated Issuer, Controlled [Member] | HIMV LLC [Member]
Investments at fair value		$ 6,154	$ 0	$ 0
Investment, Affiliated Issuer, Controlled [Member] | HIMV LLC [Member] | Biotechnology Sector [Member] | Other Investments [Member]
Investments at cost		6,154
Investments at fair value		$ 6,154
[1]As of September 30, 2023, the Company no longer owns 5% or more of the portfolio company.

Consolidated Schedule of Inve_5

Consolidated Schedule of Investments (Unaudited) - Investments (Details) (Parentheticals)	Sep. 30, 2023	Dec. 31, 2022
NAV %	210.40%	226.10%
Investment, Affiliated Issuer, Controlled [Member] | Debt Securities [Member]
NAV %	3.80%
Investment, Affiliated Issuer, Controlled [Member] | Debt Securities [Member] | Consumer-related Technologies [Member]
NAV %	1.30%
Investment, Affiliated Issuer, Controlled [Member] | Preferred and Common Stock [Member] | Technology Sector [Member]
NAV %	0.70%
Investment, Affiliated Issuer, Controlled [Member] | Other Investments [Member] | Biotechnology Sector [Member]
NAV %	1.80%
Investment, Affiliated Issuer, Noncontrolled [Member]
NAV %	5.90%
Investment, Affiliated Issuer, Noncontrolled [Member] | Debt Securities [Member] | Life Science [Member]
NAV %	3.50%
Investment, Affiliated Issuer, Noncontrolled [Member] | Equity Securities [Member] | Life Science [Member]
NAV %	2.40%
Investment, Affiliated Issuer, Noncontrolled [Member] | Warrant [Member] | Life Science [Member]
NAV %	0%
Investment, Unaffiliated Issuer [Member]
NAV %	200.70%	226.10%
Investment, Unaffiliated Issuer [Member] | Debt Securities [Member]
NAV %	191.40%	215.50%
Investment, Unaffiliated Issuer [Member] | Debt Securities [Member] | Life Science [Member]
NAV %	69.70%	99.70%
Investment, Unaffiliated Issuer [Member] | Debt Securities [Member] | Technology Sector [Member]
NAV %	80.50%	81.40%
Investment, Unaffiliated Issuer [Member] | Debt Securities [Member] | Other Sustainability Sector [Member]
NAV %	23.80%
Investment, Unaffiliated Issuer [Member] | Debt Securities [Member] | Sustainability Segment [Member]
NAV %		26.30%
Investment, Unaffiliated Issuer [Member] | Debt Securities [Member] | Healthcare Sector [Member]
NAV %	17.40%	8.10%
Investment, Unaffiliated Issuer [Member] | Equity Securities [Member]
NAV %	1.40%	0.80%
Investment, Unaffiliated Issuer [Member] | Warrant [Member]
NAV %	7.60%	9.40%
Investment, Unaffiliated Issuer [Member] | Warrant [Member] | Life Science [Member]
NAV %		3.10%
Investment, Unaffiliated Issuer [Member] | Warrant [Member] | Technology Sector [Member]
NAV %	4.70%	5.10%
Investment, Unaffiliated Issuer [Member] | Warrant [Member] | Healthcare Information and Services Segment [Member]
NAV %	0.60%
Investment, Unaffiliated Issuer [Member] | Warrant [Member] | Life Science Segment [Member]
NAV %	2%
Investment, Unaffiliated Issuer [Member] | Warrant [Member] | Sustainability Segment [Member]
NAV %	0.20%	0.60%
Investment, Unaffiliated Issuer [Member] | Warrant [Member] | Healthcare Sector [Member]
NAV %		0.60%
Investment, Unaffiliated Issuer [Member] | Other Long-Term Investments [Member]
NAV %		0.40%
Investment, Unaffiliated Issuer [Member] | Other Long-Term Investments [Member] | Life Science [Member]
NAV %	0.30%

Note 1 - Organization (Details

Note 1 - Organization (Details Textual) - Investment, Affiliated Issuer, Controlled [Member]	Sep. 30, 2023
HIMV LLC [Member] | Co-lender [Member]
Subsidiary, Ownership Percentage, Noncontrolling Owner	30%
HIMV LLC [Member] | Horizon Technology Finance Corporation [Member]
Investment Owned, Net Assets, Percentage	70%

Note 2 - Basis of Presentatio_2

Note 2 - Basis of Presentation and Significant Accounting Policies (Details Textual) - USD ($) $ / shares in Units, $ in Thousands			3 Months Ended		9 Months Ended		29 Months Ended
	Jun. 02, 2023	Mar. 14, 2022	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 22, 2023	Dec. 31, 2022	Apr. 28, 2022	Aug. 02, 2021
Investments, Nonaccrual, Interest Income			$ 0	$ 0	$ 0	$ 0
Interest Income, Operating, Paid in Kind			$ 3,900	$ 0	$ 6,088	$ 0
Investment, Nonaccrual, Income Not Received in Cash, Percent			5.10%	7%	4.90%	7.50%
Debt Issuance Costs, Net			$ 6,400		$ 6,400		$ 6,400		$ 7,100
Accumulated Amortization, Debt Issuance Costs			6,300		6,300		$ 6,300		4,800
Amortization of Debt Issuance Costs			$ 500	$ 400	$ 1,433	$ 1,142
Federal Excise Tax, Percent			4%		4%		4%
Investment Income, Operating, Tax Expense (Benefit)			$ 179	$ 100	$ 542	306
Open Tax Year					2022 2021 2020
Proceeds from Issuance of Common Stock					$ 65,031	$ 67,525
Stock Repurchase Program, Remaining Authorized Repurchase Amount										$ 5,000
Stock Repurchased During Period, Shares (in shares)			0	0	0	0	167,465
Stock Repurchased During Period, Per Share (in dollars per share)							$ 11.22
Stock Repurchased During Period, Value							$ 1,900
The 2021 Equity Distribution Agreement [Member]
Equity Sales Agreement, Maximum Value											$ 100,000
Equity Sales Agreement, Remaining Amount Available for Issuance								$ 0
Stock Issued During Period, Shares, New Issues (in shares)				1,523,519		2,641,920
Proceeds from Issuance of Common Stock				$ 19,000		$ 33,200
Payments of Stock Issuance Costs				$ 400		$ 600
The 2023 Equity Distribution Agreement [Member]
Equity Sales Agreement, Maximum Value								$ 150,000
Equity Sales Agreement, Remaining Amount Available for Issuance			$ 146,800		$ 146,800		146,800
The2023 Equity Distribution Agreement and the 2021 Equity Distribution Agreement [Member]
Stock Issued During Period, Shares, New Issues (in shares)			1,186,303		2,240,326
Proceeds from Issuance of Common Stock			$ 13,900		$ 26,100
Payments of Stock Issuance Costs			400		700
Public Offering [Member]
Stock Issued During Period, Shares, New Issues (in shares)	3,250,000	2,500,000
Proceeds from Issuance of Common Stock	$ 38,900	$ 34,300
Shares Issued, Price Per Share (in dollars per share)	$ 12.50	$ 14.35
Three Investments [Member]
Investments, Cost, Nonaccrual Status			43,600		43,600		43,600		20,900
Investments, Fair Value, Nonaccrual Status			$ 17,200		$ 17,200		$ 17,200		$ 8,300

Note 3 - Related Party Transa_2

Note 3 - Related Party Transactions (Details Textual) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022
Management Fee Payable	$ 1,080		$ 1,080		$ 1,065
Management Fee Expense	3,213	$ 2,788	9,621	$ 7,555
Incentive Fee Payable	0		0		1,392
Administrative Fees Expense	$ 441	412	1,249	1,147
Investment Management Agreement [Member]
Base Management Fee, Annual, Percent	2%
Base Management Fee, Annual, Percent, Gross Assets Exceeding $250 Million	1.60%
Management Fee Payable	$ 1,100		1,100		1,100
Management Fee Expense	$ 3,200	2,800	9,600	7,600
Incentive Fee to Pre-incentive Net Investment Income	20%
Pre-Incentive Fee Net Investment Income, Hurdle Rate	1.75%
Pre-Incentive Fee Net Investment Income, Hurdle Rate, Annualized	7%
Pre-Incentive Fee Net Investment Income, Catch-up, Percent	100%
Pre-Incentive Fee Net Investment Income, Maximum Rate to Trigger Catch-up	2.1875%
Pre-Incentive Fee Net Investment Income, Maximum Rate to Trigger Catch-up, Annualized	8.75%
Incentive Fee Expense	$ 0	2,800	3,100	6,400
Incentive Fee Cap and Deferral Mechanism Reduction to Expense	3,500		6,800
Incentive Fee Cap and Deferral Mechanism, Contingent Future Liability	7,800		7,800
Incentive Fee Payable	0		0		$ 1,400
Investment Management Agreement [Member] | December 31, 2025 Expiration [Member]
Incentive Fee Cap and Deferral Mechanism, Contingent Future Liability	1,000		1,000
Investment Management Agreement [Member] | March 31, 2026 Expiration [Member]
Incentive Fee Cap and Deferral Mechanism, Contingent Future Liability	200		200
Investment Management Agreement [Member] | June 30, 2026 Expiration [Member]
Incentive Fee Cap and Deferral Mechanism, Contingent Future Liability	3,100		3,100
Investment Management Agreement [Member] | September 30, 2026 Expiration [Member]
Incentive Fee Cap and Deferral Mechanism, Contingent Future Liability	3,500		3,500
Administration Agreement [Member]
Administrative Fees Expense	$ 400	$ 400	$ 1,200	$ 1,100

Note 4 - Investments - Investme

Note 4 - Investments - Investments (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Investments at cost	$ 754,814	$ 721,248
Investments at fair value	729,053	720,026
Biotechnology Sector [Member]
Investments at cost	158,953	193,372
Investments at fair value	139,935	195,006
Medical Device Sector [Member]
Investments at cost	140,172	132,803
Investments at fair value	139,039	135,960
Communications Sector [Member]
Investments at cost	21,057	22,892
Investments at fair value	24,317	26,176
Consumer-related Sector [Member]
Investments at cost	110,245	121,961
Investments at fair value	106,559	114,050
Data Storage Sector [Member]
Investments at cost	417	476
Investments at fair value	1,070	1,316
Internet and Media Sector [Member]
Investments at cost	329	329
Investments at fair value	1,615	1,159
Networking Sector [Member]
Investments at cost	6,671	11,831
Investments at fair value	6,558	11,710
Power Management Sector [Member]
Investments at cost	1,585	1,585
Investments at fair value	2,901	2,610
Semiconductor Sector [Member]
Investments at cost	56	56
Investments at fair value	0	0
Software Sector [Member]
Investments at cost	164,903	120,157
Investments at fair value	161,258	118,716
Energy Efficiency [Member]
Investments at cost	111	8
Investments at fair value	36	27
Other Sustainability Sector [Member]
Investments at cost	89,395	84,633
Investments at fair value	83,476	85,524
Diagnostics Sector [Member]
Investments at cost	9,971	9,851
Investments at fair value	9,939	9,858
Other Healthcare Sector [Member]
Investments at cost	102	7,559
Investments at fair value	1,379	3,870
Software, Healthcare Information and Service [Member]
Investments at cost	50,847	13,735
Investments at fair value	50,971	14,044
Debt [Member]
Investments at cost	716,655	701,074
Investments at fair value	679,838	686,458
Warrant [Member]
Investments at cost	15,783	14,790
Investments at fair value	26,189	29,712
Other Debt Obligations [Member]
Investments at cost	7,354	1,200
Investments at fair value	7,254	1,300
Equity Securities [Member]
Investments at cost	15,022	4,184
Investments at fair value	$ 15,772	$ 2,556

Note 5 - Transactions With Af_3

Note 5 - Transactions With Affiliated Companies (Details Textual)	Sep. 30, 2023
Cadrenal Therapeutics, Inc. [Member] | Investment, Unaffiliated Issuer [Member] | Percentage of Net Assets Previously Held [Member]
Investment Owned, Net Assets, Percentage	5%

Note 5 - Transactions With Af_4

Note 5 - Transactions With Affiliated Companies - Investments in Controlled Affiliated Companies (Details) - USD ($) $ in Thousands		3 Months Ended		9 Months Ended
		Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Investments, fair value				$ 720,026
Net unrealized appreciation (depreciation) on investments		$ (17,518)	$ 3,442	(24,448)	$ 1,169
Net realized gain (loss) on investments		(11,816)	(8,585)	(28,513)	(9,484)
Investments, fair value		729,053		729,053
Interest Income, Operating, Paid in Kind		3,900	0	6,088	0
Investments, fair value		(729,053)		(729,053)
Evelo Biosciences, Inc. [Member]
Investments, fair value		8,500		8,500
Investments, fair value		(8,500)		(8,500)
Investment, Affiliated Issuer, Noncontrolled [Member]
Investments, fair value		906	0	0	0
Purchases		0	0	0	0
Reductions		0	(30)	0	(30)
Transfers in/(out) at fair value		38,599	0	38,599	0
Discount accretion		35	0	35	0
Net unrealized appreciation (depreciation) on investments		(19,055)	0	(18,149)	0
Net realized gain (loss) on investments		0	30	0	30
Investments, fair value		20,485	0	20,485	0
Interest income		1,246	0	1,246	0
Transfers in/(out) at fair value		38,599	0	38,599	0
Investments, fair value		(20,485)	0	(20,485)	0
Investment, Affiliated Issuer, Noncontrolled [Member] | MVI (ABC) LLC fka StereoVision, Inc [Member]
Investments, fair value			0		0
Purchases			0		0
Reductions			(30)		(30)
Transfers in/(out) at fair value			0		0
Discount accretion			0		0
Net unrealized appreciation (depreciation) on investments			0		0
Net realized gain (loss) on investments			30		30
Investments, fair value			0		0
Interest income			0		0
Transfers in/(out) at fair value			0		0
Investments, fair value			0		0
Investment, Affiliated Issuer, Noncontrolled [Member] | Aulea Medical, Inc. [Member]
Investments, fair value		0		0
Purchases		0		0
Reductions		0		0
Transfers in/(out) at fair value		0		0
Discount accretion		0		0
Net unrealized appreciation (depreciation) on investments		0		0
Net realized gain (loss) on investments		0		0
Investments, fair value		0		0
Interest income		0		0
Transfers in/(out) at fair value		0		0
Investments, fair value		0		0
Investment, Affiliated Issuer, Noncontrolled [Member] | Cadrenal Therapeutics, Inc. [Member]
Investments, fair value	[1]	906		0
Purchases	[1]	0		0
Reductions	[1]	0		0
Transfers in/(out) at fair value	[1]	(906)		(906)
Discount accretion	[1]	0		0
Net unrealized appreciation (depreciation) on investments	[1]	0		906
Net realized gain (loss) on investments	[1]	0		0
Investments, fair value	[1]	0		0
Interest income	[1]	0		0
Transfers in/(out) at fair value	[1]	(906)		(906)
Investments, fair value	[1]	0		0
Investment, Affiliated Issuer, Noncontrolled [Member] | Evelo Biosciences, Inc. [Member] | Investment One [Member]
Investments, fair value		0		0
Purchases		0		0
Reductions		0		0
Transfers in/(out) at fair value		7,665		7,665
Discount accretion		8		8
Net unrealized appreciation (depreciation) on investments		(5,007)		(5,007)
Net realized gain (loss) on investments		0		0
Investments, fair value		2,666		2,666
Interest income		277		277
Transfers in/(out) at fair value		7,665		7,665
Investments, fair value		(2,666)		(2,666)
Investment, Affiliated Issuer, Noncontrolled [Member] | Evelo Biosciences, Inc. [Member] | Investment Two [Member]
Investments, fair value		0		0
Purchases		0		0
Reductions		0		0
Transfers in/(out) at fair value		11,496		11,496
Discount accretion		11		11
Net unrealized appreciation (depreciation) on investments		(7,510)		(7,510)
Net realized gain (loss) on investments		0		0
Investments, fair value		3,997		3,997
Interest income		415		415
Transfers in/(out) at fair value		11,496		11,496
Investments, fair value		(3,997)		(3,997)
Investment, Affiliated Issuer, Noncontrolled [Member] | Evelo Biosciences, Inc. [Member] | Investment Three [Member]
Investments, fair value		0		0
Purchases		0		0
Reductions		0		0
Transfers in/(out) at fair value		4,612		4,612
Discount accretion		5		5
Net unrealized appreciation (depreciation) on investments		(3,013)		(3,013)
Net realized gain (loss) on investments		0		0
Investments, fair value		1,604		1,604
Interest income		166		166
Transfers in/(out) at fair value		4,612		4,612
Investments, fair value		(1,604)		(1,604)
Investment, Affiliated Issuer, Noncontrolled [Member] | Evelo Biosciences, Inc. [Member] | Investment Four [Member]
Investments, fair value		0		0
Purchases		0		0
Reductions		0		0
Transfers in/(out) at fair value		4,598		4,598
Discount accretion		3		3
Net unrealized appreciation (depreciation) on investments		(3,004)		(3,004)
Net realized gain (loss) on investments		0		0
Investments, fair value		1,597		1,597
Interest income		163		163
Transfers in/(out) at fair value		4,598		4,598
Investments, fair value		(1,597)		(1,597)
Investment, Affiliated Issuer, Noncontrolled [Member] | Evelo Biosciences, Inc. [Member] | Investment Five [Member]
Investments, fair value		0		0
Purchases		0		0
Reductions		0		0
Transfers in/(out) at fair value		3,067		3,067
Discount accretion		4		4
Net unrealized appreciation (depreciation) on investments		(2,003)		(2,003)
Net realized gain (loss) on investments		0		0
Investments, fair value		1,068		1,068
Interest income		114		114
Transfers in/(out) at fair value		3,067		3,067
Investments, fair value		(1,068)		(1,068)
Investment, Affiliated Issuer, Noncontrolled [Member] | Evelo Biosciences, Inc. [Member] | Investment Six [Member]
Investments, fair value		0		0
Purchases		0		0
Reductions		0		0
Transfers in/(out) at fair value		3,067		3,067
Discount accretion		4		4
Net unrealized appreciation (depreciation) on investments		(2,003)		(2,003)
Net realized gain (loss) on investments		0		0
Investments, fair value		1,068		1,068
Interest income		111		111
Transfers in/(out) at fair value		3,067		3,067
Investments, fair value		(1,068)		(1,068)
Investment, Affiliated Issuer, Noncontrolled [Member] | Evelo Biosciences, Inc. [Member] | Investment Seven [Member]
Investments, fair value		0		0
Purchases		0		0
Reductions		0		0
Transfers in/(out) at fair value		5,000		5,000
Discount accretion		0		0
Net unrealized appreciation (depreciation) on investments		3,485		3,485
Net realized gain (loss) on investments		0		0
Investments, fair value		8,485		8,485
Interest income		0		0
Transfers in/(out) at fair value		5,000		5,000
Investments, fair value		(8,485)		(8,485)
Investment, Affiliated Issuer, Controlled [Member]
Investments, fair value		0	0	0	0
Purchases		809	0	809	0
Reductions		0	(50)	0	(300)
Transfers in/(out) at fair value		10,818	0	10,818	0
Discount accretion		3	0	3	0
Net unrealized appreciation (depreciation) on investments		1,357	0	1,357	1,450
Net realized gain (loss) on investments		0	50	0	(1,150)
Investments, fair value		13,145	0	13,145	0
Interest income		8	0	8	0
Interest Income, Operating, Paid in Kind		158	0	158	0
Transfers in/(out) at fair value		10,818	0	10,818	0
Investments, fair value		(13,145)	0	(13,145)	0
Investment, Affiliated Issuer, Controlled [Member] | Investment [Member]
Interest income		166		166
Investment, Affiliated Issuer, Controlled [Member] | Better Place Forests Co. [Member] | Investment One [Member]
Investments, fair value		0		0
Purchases		59		59
Reductions		0		0
Transfers in/(out) at fair value		1,759		1,759
Discount accretion		2		2
Net unrealized appreciation (depreciation) on investments		1,080		1,080
Net realized gain (loss) on investments		0		0
Investments, fair value		3,005		3,005
Interest income		111		111
Interest Income, Operating, Paid in Kind		105		105
Transfers in/(out) at fair value		1,759		1,759
Investments, fair value		(3,005)		(3,005)
Investment, Affiliated Issuer, Controlled [Member] | Better Place Forests Co. [Member] | Investment Two [Member]
Investments, fair value		0		0
Purchases		0		0
Reductions		0		0
Transfers in/(out) at fair value		844		844
Discount accretion		1		1
Net unrealized appreciation (depreciation) on investments		536		536
Net realized gain (loss) on investments		0		0
Investments, fair value		1,434		1,434
Interest income		55		55
Interest Income, Operating, Paid in Kind		53		53
Transfers in/(out) at fair value		844		844
Investments, fair value		(1,434)		(1,434)
Investment, Affiliated Issuer, Controlled [Member] | Better Place Forests Co. [Member] | Investment Three [Member]
Investments, fair value		0		0
Purchases		0		0
Reductions		0		0
Transfers in/(out) at fair value		2,061		2,061
Discount accretion		0		0
Net unrealized appreciation (depreciation) on investments		0		0
Net realized gain (loss) on investments		0		0
Investments, fair value		2,061		2,061
Interest income		0		0
Interest Income, Operating, Paid in Kind		0		0
Transfers in/(out) at fair value		2,061		2,061
Investments, fair value		(2,061)		(2,061)
Investment, Affiliated Issuer, Controlled [Member] | Better Place Forests Co. [Member] | Investment Four [Member]
Investments, fair value		0		0
Purchases		750		750
Reductions		0		0
Transfers in/(out) at fair value		0		0
Discount accretion		0		0
Net unrealized appreciation (depreciation) on investments		(259)		(259)
Net realized gain (loss) on investments		0		0
Investments, fair value		491		491
Interest income		0		0
Interest Income, Operating, Paid in Kind		0		0
Transfers in/(out) at fair value		0		0
Investments, fair value		(491)		(491)
Investment, Affiliated Issuer, Controlled [Member] | HESP LLC [Member]
Investments, fair value			0		0
Purchases			0		0
Reductions			(50)		(300)
Transfers in/(out) at fair value			0		0
Discount accretion			0		0
Net unrealized appreciation (depreciation) on investments			0		1,450
Net realized gain (loss) on investments			50		(1,150)
Investments, fair value			0		0
Interest income			0		0
Transfers in/(out) at fair value			0		0
Investments, fair value			$ 0		$ 0
Investment, Affiliated Issuer, Controlled [Member] | HIMV LLC [Member]
Investments, fair value		0		0
Purchases		0		0
Reductions		0		0
Transfers in/(out) at fair value		6,154		6,154
Discount accretion		0		0
Net unrealized appreciation (depreciation) on investments		0		0
Net realized gain (loss) on investments		0		0
Investments, fair value		6,154		6,154
Interest income		0		0
Interest Income, Operating, Paid in Kind		0		0
Transfers in/(out) at fair value		6,154		6,154
Investments, fair value		$ (6,154)		$ (6,154)
[1]As of September 30, 2023, the Company no longer owns 5% or more of the portfolio company.

Note 6 - Fair Value (Details Te

Note 6 - Fair Value (Details Textual) $ / shares in Units, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023 USD ($) $ / shares	Sep. 30, 2022 USD ($)	Sep. 30, 2023 USD ($) $ / shares	Sep. 30, 2022 USD ($)	Jun. 30, 2022
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers, Net	$ (5,000)	$ (1,117)	$ (5,111)	$ (1,117)
Unrealized Gain (Loss) on Investments	(17,518)	3,442	(24,448)	1,169
Warrant [Member]
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers, Net	0	(1,117)	0	(1,117)
Equity Securities [Member]
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers, Net	0	0	(111)	0
Fair Value, Inputs, Level 1 [Member] | Debt Securities [Member]
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers out of Level 3	$ 5,000
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers, Net			5,000
Fair Value, Inputs, Level 1 [Member] | Warrant [Member]
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers out of Level 3		1,100		1,100
Fair Value, Inputs, Level 1 [Member] | Equity Securities [Member]
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers out of Level 3			100
Fair Value, Inputs, Level 3 [Member] | Debt Securities [Member]
Unrealized Gain (Loss) on Investments			(33,600)	(3,500)
Fair Value, Inputs, Level 3 [Member] | Warrant [Member]
Unrealized Gain (Loss) on Investments			(2,100)	1,200
Fair Value, Inputs, Level 3 [Member] | Equity Securities [Member]
Unrealized Gain (Loss) on Investments			$ (1,600)	(400)
Fair Value, Inputs, Level 2 [Member] | Warrant [Member]
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers out of Level 3		$ 40		$ 40
The 2026 Notes [Member]
Debt Instrument, Share Price (in dollars per share) | $ / shares	$ 23.60		$ 23.60
The 2026 Notes [Member] | Fair Value, Inputs, Level 1 [Member]
Debt Instrument, Fair Value Disclosure	$ 54,300		$ 54,300
The 2027 Notes [Member]
Debt Instrument, Share Price (in dollars per share) | $ / shares	$ 24.18		$ 24.18
The 2027 Notes [Member] | Fair Value, Inputs, Level 1 [Member]
Debt Instrument, Fair Value Disclosure	$ 55,600		$ 55,600
Asset-backed Notes 2019 [Member] | Fair Value, Inputs, Level 3 [Member]
Debt Instrument, Fair Value Disclosure	18,700		18,700
Asset-backed Notes 2022 [Member] | Fair Value, Inputs, Level 3 [Member]
Debt Instrument, Fair Value Disclosure	$ 100,000		$ 100,000
Measurement Input, Hypothetical Market Yields [Member]
Debt Instrument, Measurement Input					0.25

Note 6 - Fair Value - Assets at

Note 6 - Fair Value - Assets at Fair Value on a Recurring Basis (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Fair Value, Recurring [Member]
Investments, fair value	$ 729,053	$ 720,026
Fair Value, Recurring [Member] | Debt [Member]
Investments, fair value	679,838	686,458
Fair Value, Recurring [Member] | Warrant [Member]
Investments, fair value	26,189	29,712
Fair Value, Recurring [Member] | Other Investments [Member]
Investments, fair value	7,254	1,300
Fair Value, Recurring [Member] | Equity Securities [Member]
Investments, fair value	15,772	2,556
Fair Value, Inputs, Level 1 [Member] | Fair Value, Recurring [Member]
Investments, fair value	8,962	140
Fair Value, Inputs, Level 1 [Member] | Fair Value, Recurring [Member] | Debt [Member]
Investments, fair value	0	0
Fair Value, Inputs, Level 1 [Member] | Fair Value, Recurring [Member] | Warrant [Member]
Investments, fair value	0	0
Fair Value, Inputs, Level 1 [Member] | Fair Value, Recurring [Member] | Other Investments [Member]
Investments, fair value	0	0
Fair Value, Inputs, Level 1 [Member] | Fair Value, Recurring [Member] | Equity Securities [Member]
Investments, fair value	8,962	140
Fair Value, Inputs, Level 2 [Member] | Fair Value, Recurring [Member]
Investments, fair value	956	3,567
Fair Value, Inputs, Level 2 [Member] | Fair Value, Recurring [Member] | Debt [Member]
Investments, fair value	0	0
Fair Value, Inputs, Level 2 [Member] | Fair Value, Recurring [Member] | Warrant [Member]
Investments, fair value	956	3,567
Fair Value, Inputs, Level 2 [Member] | Fair Value, Recurring [Member] | Other Investments [Member]
Investments, fair value	0	0
Fair Value, Inputs, Level 2 [Member] | Fair Value, Recurring [Member] | Equity Securities [Member]
Investments, fair value	0	0
Fair Value, Inputs, Level 3 [Member]
Investments, fair value	719,135	716,319
Fair Value, Inputs, Level 3 [Member] | Fair Value, Recurring [Member]
Investments, fair value	719,135	716,319
Fair Value, Inputs, Level 3 [Member] | Fair Value, Recurring [Member] | Debt [Member]
Investments, fair value	679,838	686,458
Fair Value, Inputs, Level 3 [Member] | Fair Value, Recurring [Member] | Warrant [Member]
Investments, fair value	25,233	26,145
Fair Value, Inputs, Level 3 [Member] | Fair Value, Recurring [Member] | Other Investments [Member]
Investments, fair value	7,254	1,300
Fair Value, Inputs, Level 3 [Member] | Fair Value, Recurring [Member] | Equity Securities [Member]
Investments, fair value	$ 6,810	$ 2,416

Note 6 - Fair Value - Significa

Note 6 - Fair Value - Significant Level 3 Fair Value Measurement Inputs (Details) - Fair Value, Inputs, Level 3 [Member] $ in Thousands		Sep. 30, 2023 USD ($)	Dec. 31, 2022 USD ($)
Investments, fair value		$ 719,135	$ 716,319
Investments, measurement input	[1]	0.83
Minimum [Member]
Investments, measurement input		0.30
Maximum [Member]
Investments, measurement input		1
Debt [Member] | Valuation Technique, Discounted Cash Flow [Member]
Investments, fair value		$ 607,193	$ 669,617
Debt [Member] | Valuation Technique, Discounted Cash Flow [Member] | Minimum [Member] | Hypothetical Market Yield [Member]
Investments, measurement input		0.11	0.03
Debt [Member] | Valuation Technique, Discounted Cash Flow [Member] | Maximum [Member] | Hypothetical Market Yield [Member]
Investments, measurement input		0.20	0.22
Debt [Member] | Valuation Technique, Discounted Cash Flow [Member] | Weighted Average [Member] | Hypothetical Market Yield [Member]
Investments, measurement input	[1]	0.14	0.14
Debt [Member] | Multiple Probability Weighted Cash Flow Model [Member]
Investments, fair value		$ 72,645	$ 16,545
Debt [Member] | Multiple Probability Weighted Cash Flow Model [Member] | Minimum [Member] | Probability Weighting [Member]
Investments, measurement input		0.20	0.10
Debt [Member] | Multiple Probability Weighted Cash Flow Model [Member] | Maximum [Member] | Probability Weighting [Member]
Investments, measurement input		1	0.75
Debt [Member] | Multiple Probability Weighted Cash Flow Model [Member] | Weighted Average [Member] | Probability Weighting [Member]
Investments, measurement input	[1]	0.50	0.31
Debt [Member] | Black-scholes Valuation Model [Member]
Investments, fair value			$ 26,145
Debt [Member] | Black-scholes Valuation Model [Member] | Measurement Input, Price Volatility [Member]
Investments, measurement input			0.28
Debt [Member] | Black-scholes Valuation Model [Member] | Measurement Input, Discount for Lack of Marketability [Member]
Investments, measurement input			0.20
Debt [Member] | Black-scholes Valuation Model [Member] | Minimum [Member] | Measurement Input, Share Price [Member]
Investments, measurement input			0
Debt [Member] | Black-scholes Valuation Model [Member] | Minimum [Member] | Estimated Time to Exit [Member]
Investments, measurement input			1
Debt [Member] | Black-scholes Valuation Model [Member] | Maximum [Member] | Measurement Input, Share Price [Member]
Investments, measurement input			1.89
Debt [Member] | Black-scholes Valuation Model [Member] | Maximum [Member] | Estimated Time to Exit [Member]
Investments, measurement input			5
Debt [Member] | Black-scholes Valuation Model [Member] | Weighted Average [Member] | Measurement Input, Share Price [Member]
Investments, measurement input	[1]		58.52
Debt [Member] | Black-scholes Valuation Model [Member] | Weighted Average [Member] | Measurement Input, Price Volatility [Member]
Investments, measurement input	[1]		0.28
Debt [Member] | Black-scholes Valuation Model [Member] | Weighted Average [Member] | Measurement Input, Discount for Lack of Marketability [Member]
Investments, measurement input	[1]		0.20
Debt [Member] | Black-scholes Valuation Model [Member] | Weighted Average [Member] | Estimated Time to Exit [Member]
Investments, measurement input	[1]		3
Debt [Member] | Convertible Note Analysis [Member]
Investments, fair value			$ 296
Debt [Member] | Convertible Note Analysis [Member] | Measurement Input, Share Price [Member]
Investments, measurement input			168.93
Debt [Member] | Convertible Note Analysis [Member] | Weighted Average [Member] | Measurement Input, Share Price [Member]
Investments, measurement input	[1]		168.93
Warrant [Member] | Black-scholes Valuation Model [Member]
Investments, fair value		$ 25,171
Warrant [Member] | Black-scholes Valuation Model [Member] | Measurement Input, Price Volatility [Member]
Investments, measurement input		0.28
Warrant [Member] | Black-scholes Valuation Model [Member] | Measurement Input, Discount for Lack of Marketability [Member]
Investments, measurement input		0.20
Warrant [Member] | Black-scholes Valuation Model [Member] | Minimum [Member] | Measurement Input, Share Price [Member]
Investments, measurement input		0
Warrant [Member] | Black-scholes Valuation Model [Member] | Minimum [Member] | Measurement Input, Discount for Lack of Marketability [Member]
Investments, measurement input	[1]	0.20
Warrant [Member] | Black-scholes Valuation Model [Member] | Minimum [Member] | Estimated Time to Exit [Member]
Investments, measurement input		1
Warrant [Member] | Black-scholes Valuation Model [Member] | Maximum [Member] | Measurement Input, Share Price [Member]
Investments, measurement input		1,899
Warrant [Member] | Black-scholes Valuation Model [Member] | Maximum [Member] | Estimated Time to Exit [Member]
Investments, measurement input		5
Warrant [Member] | Black-scholes Valuation Model [Member] | Weighted Average [Member] | Measurement Input, Share Price [Member]
Investments, measurement input	[1]	58.11
Warrant [Member] | Black-scholes Valuation Model [Member] | Weighted Average [Member] | Measurement Input, Price Volatility [Member]
Investments, measurement input	[1]	0.28
Warrant [Member] | Black-scholes Valuation Model [Member] | Weighted Average [Member] | Estimated Time to Exit [Member]
Investments, measurement input	[1]	3
Warrant [Member] | Expected Proceeds [Member]
Investments, fair value		$ 62
Warrant [Member] | Expected Proceeds [Member] | Measurement Input, Share Price [Member]
Investments, measurement input		0.25
Warrant [Member] | Expected Proceeds [Member] | Weighted Average [Member] | Measurement Input, Share Price [Member]
Investments, measurement input	[1]	0.25
Other Investments [Member] | Multiple Probability Weighted Cash Flow Model [Member]
Investments, fair value		$ 7,254	$ 1,300
Other Investments [Member] | Multiple Probability Weighted Cash Flow Model [Member] | Probability Weighting [Member]
Investments, measurement input			1
Other Investments [Member] | Multiple Probability Weighted Cash Flow Model [Member] | Measurement Input, Discount Rate [Member]
Investments, measurement input		0.25	0.25
Other Investments [Member] | Multiple Probability Weighted Cash Flow Model [Member] | Weighted Average [Member] | Probability Weighting [Member]
Investments, measurement input	[1]		1
Other Investments [Member] | Multiple Probability Weighted Cash Flow Model [Member] | Weighted Average [Member] | Measurement Input, Discount Rate [Member]
Investments, measurement input	[1]	0.25	0.25
Equity Securities [Member] | Last Equity Financing [Member]
Investments, fair value		$ 6,810	$ 2,416
Equity Securities [Member] | Last Equity Financing [Member] | Minimum [Member] | Measurement Input, Share Price [Member]
Investments, measurement input		0.03
Equity Securities [Member] | Last Equity Financing [Member] | Maximum [Member] | Measurement Input, Share Price [Member]
Investments, measurement input		215.03
Equity Securities [Member] | Last Equity Financing [Member] | Weighted Average [Member] | Measurement Input, Share Price [Member]
Investments, measurement input	[1]	18.30	26.93
[1]Weighted average is calculated by multiplying (a) the unobservable input for each investment in the investment type by (b) (1) the fair value of the related investment in the investment type divided by (2) the total fair value of the investment type.

Note 6 - Fair Value - Reconcili

Note 6 - Fair Value - Reconciliation of Level 3 Assets Measured on a Recurring Basis (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Balance	$ 713,244	$ 577,380	$ 716,319	$ 457,557
Purchase of investments	66,935	94,627	154,488	348,347
Warrants received and classified as Level 3	1,294	964	2,039	2,441
Principal payments received on investments	(25,726)	26,960	(90,222)	114,433
Payment-in-kind interest on investments	3,934		6,088
Proceeds from sale of investments	(2,557)	6,126	(11,063)	49,552
Net realized (loss) gain on investments	(11,552)	(8,195)	(28,198)	(9,094)
Unrealized (depreciation) appreciation included in earnings	(20,722)	4,227	(26,384)	2,720
Transfer out of Level 3	(5,000)	(1,117)	(5,111)	(1,117)
Transfer out of debt investments	0	0	0	0
Other	(715)	(541)	1,179	(2,610)
Balance	719,135	634,259	719,135	634,259
Principal payments received on investments	25,726	(26,960)	90,222	(114,433)
Proceeds from sale of investments	2,557	(6,126)	11,063	(49,552)
Debt [Member]
Balance	683,309	551,560	686,458	437,317
Purchase of investments	66,185	94,627	153,728	348,097
Warrants received and classified as Level 3	0	0	0	0
Principal payments received on investments	(25,726)	26,929	(90,222)	114,120
Payment-in-kind interest on investments	3,934		6,088
Proceeds from sale of investments	(2,528)	6,088	(9,564)	49,088
Net realized (loss) gain on investments	(11,440)	(8,492)	(29,105)	(8,492)
Unrealized (depreciation) appreciation included in earnings	(18,877)	8,095	(21,325)	1,128
Transfer out of Level 3	(5,000)	0	(5,000)	0
Transfer out of debt investments	(9,304)	(3,200)	(12,399)	(3,200)
Other	(715)	(541)	1,179	(2,610)
Balance	679,838	609,032	679,838	609,032
Principal payments received on investments	25,726	(26,929)	90,222	(114,120)
Proceeds from sale of investments	2,528	(6,088)	9,564	(49,088)
Warrant [Member]
Balance	24,376	25,167	26,145	19,837
Purchase of investments	0	0	0	0
Warrants received and classified as Level 3	1,294	964	1,950	2,441
Principal payments received on investments	0	0	0	0
Payment-in-kind interest on investments	0		0
Proceeds from sale of investments	(23)	38	(1,493)	464
Net realized (loss) gain on investments	(118)	266	1,028	535
Unrealized (depreciation) appreciation included in earnings	(296)	(3,348)	(2,392)	662
Transfer out of Level 3	0	(1,117)	0	(1,117)
Transfer out of debt investments	0	0	(5)	0
Other	0	0	0	0
Balance	25,233	21,894	25,233	21,894
Principal payments received on investments	0	0	0	0
Proceeds from sale of investments	23	(38)	1,493	(464)
Equity Securities [Member]
Balance	4,259	453	2,416	203
Purchase of investments	750	0	760	250
Warrants received and classified as Level 3	0	0	89	0
Principal payments received on investments	0	0	0	0
Payment-in-kind interest on investments	0		0
Proceeds from sale of investments	(6)	0	(6)	0
Net realized (loss) gain on investments	6	0	(121)	0
Unrealized (depreciation) appreciation included in earnings	(1,349)	(420)	(2,467)	(420)
Transfer out of Level 3	0	0	(111)	0
Transfer out of debt investments	3,150	2,000	6,250	2,000
Other	0	0	0	0
Balance	6,810	2,033	6,810	2,033
Principal payments received on investments	0	0	0	0
Proceeds from sale of investments	6	0	6	0
Other Investments [Member]
Balance	1,300	200	1,300	200
Purchase of investments	0	0	0	0
Warrants received and classified as Level 3	0	0	0	0
Principal payments received on investments	0	31	0	313
Payment-in-kind interest on investments	0		0
Proceeds from sale of investments	0	0	0	0
Net realized (loss) gain on investments	0	31	0	(1,137)
Unrealized (depreciation) appreciation included in earnings	(200)	(100)	(200)	1,350
Transfer out of Level 3	0	0	0	0
Transfer out of debt investments	6,154	1,200	6,154	1,200
Other	0	0	0	0
Balance	7,254	1,300	7,254	1,300
Principal payments received on investments	0	(31)	0	(313)
Proceeds from sale of investments	$ 0	$ 0	$ 0	$ 0

Note 7 - Borrowings (Details Te

Note 7 - Borrowings (Details Textual) - USD ($) $ / shares in Units, $ in Thousands				3 Months Ended		9 Months Ended
	May 24, 2023	Feb. 25, 2022	Apr. 21, 2020	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Jun. 29, 2023	Dec. 31, 2022	Nov. 09, 2022	Jun. 15, 2022	Mar. 30, 2021	Aug. 13, 2019
Asset Coverage to Borrowings, Ratio, Percent						179%
Restricted Investments				$ 2,838		$ 2,838			$ 2,788
Long-Term Debt, Gross				439,696		439,696			439,323
Debt Instrument, Face Amount				$ 633,696		$ 633,696			582,573
Key Facility [Member]
Line of Credit Facility, Maximum Borrowing Capacity, Accordian Feature								$ 150,000
Line of Credit Facility, Maximum Borrowing Capacity								$ 300,000
Line of Credit Facility, Advance Rate of Eligible Debt Investments								60%
Long-Term Debt, Weighted Average Interest Rate, over Time				8.68%	5.60%	8.34%	4.75%
Line of Credit Facility, Unused Capacity, Commitment Fee Percentage				0.50%
Line of Credit Facility, Current Borrowing Capacity				$ 125,000		$ 125,000			120,000
Line of Credit Facility, Remaining Borrowing Capacity				38,300		38,300			40,200
Long-Term Debt, Gross				25,000		25,000			5,000
Debt Instrument, Face Amount				$ 150,000		$ 150,000			$ 125,000
Key Facility [Member] | Prime Rate [Member]
Debt Instrument, Basis Spread on Variable Rate				0.25%
Debt Instrument, Variable Rate				8.50%		8.50%			7.50%
NYL Facility [Member]
Line of Credit Facility, Maximum Borrowing Capacity	$ 250,000		$ 100,000
Line of Credit Facility, Current Borrowing Capacity				$ 69,000		$ 69,000			$ 23,200
Line of Credit Facility, Remaining Borrowing Capacity				5,100		5,100			23,200
Line of Credit Facility, Maximum Borrowing Capacity, Accordion Feature			$ 200,000
Line of Credit Facility, Advance Rate			67%
Line of Credit Facility, Change in Maximum Borrowing Capacity	$ 50,000	$ 100,000
Debt Instrument, Interest Rate, Stated Percentage	4.60%
Long-Term Line of Credit				$ 181,000		$ 181,000			$ 176,800
Line of Credit Facility, Interest Rate at Period End				5.85%		5.85%			5.57%
Restricted Investments				$ 1,300		$ 1,300			$ 1,000
Long-Term Debt, Gross				181,000		181,000			176,750
Debt Instrument, Face Amount				250,000		250,000			200,000
NYL Facility [Member] | USD Mid-market Swap Rate [Member]
Debt Instrument, Basis Spread on Variable Rate		3%
NYL Facility [Member] | Three Year I Curve [Member]
Debt Instrument, Basis Spread on Variable Rate	3.50%
Asset-backed Notes 2019 [Member]
Debt Instrument, Interest Rate, Stated Percentage													4.21%
Restricted Investments				400		400			600
Long-Term Debt, Gross				18,696		18,696			42,573
Debt Instrument, Face Amount				18,696		18,696			42,573				$ 160,000
Asset-backed Notes 2022 [Member]
Debt Instrument, Interest Rate, Stated Percentage										7.56%
Restricted Investments				1,200		1,200
Long-Term Debt, Gross				100,000		100,000			100,000
Debt Instrument, Face Amount				100,000		100,000			100,000	$ 157,800
The 2026 Notes [Member]
Debt Instrument, Interest Rate, Stated Percentage												4.875%
Long-Term Debt, Gross				57,500		57,500			57,500
Debt Instrument, Face Amount				57,500		57,500			57,500			$ 57,500
The 2026 Notes Underwriter Option [Member]
Debt Instrument, Face Amount												$ 7,500
Debt Instrument, Convertible, Conversion Price (in dollars per share)												$ 25
The 2027 Notes [Member]
Debt Instrument, Interest Rate, Stated Percentage											6.25%
Long-Term Debt, Gross				57,500		57,500			57,500
Debt Instrument, Face Amount				$ 57,500		$ 57,500			$ 57,500		$ 50,000
The 2027 Notes Underwriter Option [Member]
Debt Instrument, Face Amount											$ 7,500
Debt Instrument, Convertible, Conversion Price (in dollars per share)											$ 25
Minimum [Member]
Asset Coverage to Borrowings, Ratio, Percent						150%
Minimum [Member] | Key Facility [Member] | Prime Rate [Member]
Debt Instrument, Basis Spread on Variable Rate				4.25%
Minimum [Member] | NYL Facility [Member] | USD Mid-market Swap Rate [Member]
Debt Instrument, Basis Spread on Variable Rate			3.55%
Maximum [Member] | NYL Facility [Member] | USD Mid-market Swap Rate [Member]
Debt Instrument, Basis Spread on Variable Rate			5.15%

Note 7 - Borrowings - Borrowing

Note 7 - Borrowings - Borrowings (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022	Nov. 09, 2022	Jun. 15, 2022	Mar. 30, 2021	Aug. 13, 2019
Total commitment	$ 633,696	$ 582,573
Balance outstanding	439,696	439,323
Unused commitment	194,000	143,250
Unamortized debt issuance costs attributable to term borrowings	(4,196)	(5,245)
Total borrowings outstanding, net	435,500	434,078
Key Facility [Member]
Total commitment	150,000	125,000
Balance outstanding	25,000	5,000
Unused commitment	125,000	120,000
NYL Facility [Member]
Total commitment	250,000	200,000
Balance outstanding	181,000	176,750
Unused commitment	69,000	23,250
Asset-backed Notes 2019 [Member]
Total commitment	18,696	42,573				$ 160,000
Balance outstanding	18,696	42,573
Unused commitment	0	0
Asset-backed Notes 2022 [Member]
Total commitment	100,000	100,000	$ 157,800
Balance outstanding	100,000	100,000
Unused commitment	0	0
The 2027 Notes [Member]
Total commitment	57,500	57,500		$ 50,000
Balance outstanding	57,500	57,500
Unused commitment	0	0
The 2026 Notes [Member]
Total commitment	57,500	57,500			$ 57,500
Balance outstanding	57,500	57,500
Unused commitment	$ 0	$ 0

Note 8 - Financial Instrument_3

Note 8 - Financial Instruments With Off-balance-sheet Risk (Details Textual) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Other Commitment	$ 181,800
Fair Value Disclosure, off-Balance-Sheet Risks, Amount, Liability	2,036	$ 1,761
Commitments to Extend Credit [Member]
Other Commitment	$ 190,000

Note 8 - Financial Instrument_4

Note 8 - Financial Instruments With Off-balance-sheet Risk - Unfunded Commitments (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Unfunded commitments, principal balance	$ 181,750	$ 190,000
Fair value of unfunded commitment liability	2,036	1,761
BrightInsight, Inc. [Member]
Unfunded commitments, principal balance	18,250	21,000
Fair value of unfunded commitment liability	241	278
Britecore Holdings, Inc. [Member]
Unfunded commitments, principal balance	5,000	5,000
Fair value of unfunded commitment liability	72	66
Candesant Biomedical Corporation [Member]
Unfunded commitments, principal balance	10,000	0
Fair value of unfunded commitment liability	151	0
Castle Creek Biosciences [Member]
Unfunded commitments, principal balance	4,000	4,000
Fair value of unfunded commitment liability	72	72
Divergent Technologies, Inc. [Member]
Unfunded commitments, principal balance	11,250	22,500
Fair value of unfunded commitment liability	118	236
Elligo Healthcare Research, Inc. [Member]
Unfunded commitments, principal balance	15,000	0
Fair value of unfunded commitment liability	194	0
Engage3, LLC [Member]
Unfunded commitments, principal balance	0	8,000
Fair value of unfunded commitment liability	0	40
Groundspeed Analytics, Inc. [Member]
Unfunded commitments, principal balance	0	15,000
Fair value of unfunded commitment liability	0	150
Hound Labs, Inc. [Member]
Unfunded commitments, principal balance	0	7,500
Fair value of unfunded commitment liability	0	88
KSQ Therapeutics, Inc. [Member]
Unfunded commitments, principal balance	0	10,000
Fair value of unfunded commitment liability	0	100
Lytics, Inc. [Member]
Unfunded commitments, principal balance	4,000	5,000
Fair value of unfunded commitment liability	52	65
Mirantis, Inc [Member]
Unfunded commitments, principal balance	15,000	0
Fair value of unfunded commitment liability	136	0
Native Microbials, Inc. [Member]
Unfunded commitments, principal balance	0	7,500
Fair value of unfunded commitment liability	0	72
Noodle Partners, Inc. [Member]
Unfunded commitments, principal balance	5,000	0
Fair value of unfunded commitment liability	61	0
Optoro, Inc. [Member]
Unfunded commitments, principal balance	6,250	15,000
Fair value of unfunded commitment liability	0	38
PDS Biotechnology Corporation [Member]
Unfunded commitments, principal balance	0	10,000
Fair value of unfunded commitment liability	0	158
Robin Healthcare, Inc. [Member]
Unfunded commitments, principal balance	0	10,000
Fair value of unfunded commitment liability	0	100
SafelyYou, Inc [Member]
Unfunded commitments, principal balance	20,000	0
Fair value of unfunded commitment liability	270	0
Scientia Vascular, Inc. [Member]
Unfunded commitments, principal balance	5,000	10,000
Fair value of unfunded commitment liability	55	110
Slingshot Aerospace, Inc. [Member]
Unfunded commitments, principal balance	0	5,000
Fair value of unfunded commitment liability	0	64
Sonex Health, Inc. [Member]
Unfunded commitments, principal balance	15,000	0
Fair value of unfunded commitment liability	176	0
Supply Network Visibility Holdings, LLC [Member]
Unfunded commitments, principal balance	10,000	0
Fair value of unfunded commitment liability	35	0
Swift Health Systems Inc. [Member]
Unfunded commitments, principal balance	11,500	25,500
Fair value of unfunded commitment liability	0	105
Tallac Therapeutics, Inc [Member]
Unfunded commitments, principal balance	10,000	0
Fair value of unfunded commitment liability	229	0
Temperpack Technologies, Inc [Member]
Unfunded commitments, principal balance	6,500	9,000
Fair value of unfunded commitment liability	14	19
Viken Detection Corporation [Member]
Unfunded commitments, principal balance	10,000	0
Fair value of unfunded commitment liability	$ 160	$ 0

Note 9 - Concentrations of Cr_2

Note 9 - Concentrations of Credit Risk (Details Textual) - Debt Investments [Member] - Five Largest Debt Investments [Member]	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022
Investment Concentration Risk [Member] | Reported Value Measurement [Member]
Concentration Risk, Percentage			23%		23%
Investment Concentration Risk [Member] | Estimate of Fair Value Measurement [Member]
Concentration Risk, Percentage			22%		23%
Investment Income Concentration Risk [Member] | Reported Value Measurement [Member]
Concentration Risk, Percentage	24%	18%	23%
Investment Income Concentration Risk [Member] | Estimate of Fair Value Measurement [Member]
Concentration Risk, Percentage			21%	18%
Interest Income [Member] | Reported Value Measurement [Member]
Concentration Risk, Percentage				18%
Interest Income [Member] | Estimate of Fair Value Measurement [Member]
Concentration Risk, Percentage	22%	18%

Note 10 - Distributions (Detail

Note 10 - Distributions (Details Textual) - $ / shares	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Common Stock, Dividends, Per Share, Cash Paid (in dollars per share)	$ 0.33
Earnings Per Share, Basic (in dollars per share)	0.53	$ 0.43	$ 1.54	$ 1.06
Earnings Per Share, Basic, Undistributed (in dollars per share)	$ 1.23

Note 10 - Distributions - Distr

Note 10 - Distributions - Distribution Activity (Details) - USD ($) $ / shares in Units, $ in Thousands		3 Months Ended		9 Months Ended		12 Months Ended
	Oct. 27, 2023	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022
Distributions declared per share (in dollars per share)		$ 0.33	$ 0.30	$ 0.99	$ 0.90	$ 1.28
Dividends, cash				$ 22,954		$ 32,659
Dividends, shares (in shares)				60,190		61,859
Dividends, stock				$ 742		$ 754
February 15, 2024 Dividend [Member] | Forecast [Member]
Distributions declared per share (in dollars per share)	$ 0.11
November 16, 2023 Dividend [Member] | Forecast [Member]
Distributions declared per share (in dollars per share)	0.05
January 17, 2024 Dividend [Member] | Forecast [Member]
Distributions declared per share (in dollars per share)	0.11
First 7/28/2023 Dividend [Member]
Record date				Nov. 17, 2023
Payment date				Dec. 15, 2023
Distributions declared per share (in dollars per share)				$ 0.11
Dividends, cash				$ 0
Dividends, shares (in shares)				0
Dividends, stock				$ 0
December 18, 2023 Dividend [Member] | Forecast [Member]
Distributions declared per share (in dollars per share)	$ 0.11
Second 7/28/2023 Dividend [Member]
Record date				Oct. 18, 2023
Payment date				Nov. 11, 2023
Distributions declared per share (in dollars per share)				$ 0.11
Dividends, cash				$ 0
Dividends, shares (in shares)				0
Dividends, stock				$ 0
Third 7/28/2023 Dividend [Member]
Record date				Sep. 19, 2023
Payment date				Oct. 16, 2023
Distributions declared per share (in dollars per share)				$ 0.11
Dividends, cash				$ 3,445
Dividends, shares (in shares)				15,067
Dividends, stock				$ 184
First 4/28/2023 Dividend [Member]
Record date				Aug. 17, 2023
Payment date				Sep. 15, 2023
Distributions declared per share (in dollars per share)				$ 0.11
Dividends, cash				$ 3,458
Dividends, shares (in shares)				8,665
Dividends, stock				$ 106
Second 4/28/2023 [Member]
Record date				Jul. 18, 2023
Payment date				Aug. 15, 2023
Distributions declared per share (in dollars per share)				$ 0.11
Dividends, cash				$ 3,427
Dividends, shares (in shares)				8,307
Dividends, stock				$ 105
Third 4/28/2023 Dividend [Member]
Record date				Jun. 16, 2023
Payment date				Jul. 14, 2023
Distributions declared per share (in dollars per share)				$ 0.11
Dividends, cash				$ 3,434
Dividends, shares (in shares)				7,424
Dividends, stock				$ 96
First 2/23/2023 Dividend [Member]
Record date				May 18, 2023
Payment date				Jun. 14, 2023
Distributions declared per share (in dollars per share)				$ 0.11
Dividends, cash				$ 3,087
Dividends, shares (in shares)				7,128
Dividends, stock				$ 86
Second 2/23/2023 Dividend [Member]
Record date				Apr. 18, 2023
Payment date				May 16, 2023
Distributions declared per share (in dollars per share)				$ 0.11
Dividends, cash				$ 3,068
Dividends, shares (in shares)				6,705
Dividends, stock				$ 84
Third 2/23/2023 Dividend [Member]
Record date				Mar. 17, 2023
Payment date				Apr. 14, 2023
Distributions declared per share (in dollars per share)				$ 0.11
Dividends, cash				$ 3,035
Dividends, shares (in shares)				6,894
Dividends, stock				$ 81
First 10/28/2022 Dividend [Member]
Record date						Feb. 17, 2023
Payment date						Mar. 15, 2023
Distributions declared per share (in dollars per share)						$ 0.11
Dividends, cash						$ 3,040
Dividends, shares (in shares)						6,764
Dividends, stock						$ 75
Second 10/28/2022 Dividend [Member]
Record date						Jan. 18, 2023
Payment date						Feb. 15, 2023
Distributions declared per share (in dollars per share)						$ 0.11
Dividends, cash						$ 3,021
Dividends, shares (in shares)						5,754
Dividends, stock						$ 74
Third 10/28/2022 Dividend [Member]
Record date						Dec. 19, 2022
Payment date						Jan. 13, 2023
Distributions declared per share (in dollars per share)						$ 0.11
Dividends, cash						$ 2,978
Dividends, shares (in shares)						5,618
Dividends, stock						$ 69
Fourth 10/28/2022 Dividend [Member]
Record date						Nov. 17, 2022
Payment date						Dec. 15, 2022
Distributions declared per share (in dollars per share)						$ 0.05
Dividends, cash						$ 1,319
Dividends, shares (in shares)						2,171
Dividends, stock						$ 27
First 7/29/2022 Dividend [Member]
Record date						Nov. 17, 2022
Payment date						Dec. 15, 2022
Distributions declared per share (in dollars per share)						$ 0.10
Dividends, cash						$ 2,638
Dividends, shares (in shares)						4,341
Dividends, stock						$ 57
Second 7/29/2022 Dividend [Member]
Record date						Oct. 18, 2022
Payment date						Nov. 15, 2022
Distributions declared per share (in dollars per share)						$ 0.10
Dividends, cash						$ 2,580
Dividends, shares (in shares)						4,621
Dividends, stock						$ 60
Third 7/29/2022 Dividend [Member]
Record date						Sep. 19, 2022
Payment date						Oct. 14, 2022
Distributions declared per share (in dollars per share)						$ 0.10
Dividends, cash						$ 2,558
Dividends, shares (in shares)						7,703
Dividends, stock						$ 81
First 4/29/22 Dividend [Member]
Record date						Aug. 18, 2022
Payment date						Sep. 15, 2022
Distributions declared per share (in dollars per share)						$ 0.10
Dividends, cash						$ 2,528
Dividends, shares (in shares)						4,925
Dividends, stock						$ 60
Second 4/29/2022 Dividend [Member]
Record date						Jul. 19, 2022
Payment date						Aug. 16, 2022
Distributions declared per share (in dollars per share)						$ 0.10
Dividends, cash						$ 2,484
Dividends, shares (in shares)						3,939
Dividends, stock						$ 55
Third 4/29/2022 Dividend [Member]
Record date						Jun. 17, 2022
Payment date						Jul. 15, 2022
Distributions declared per share (in dollars per share)						$ 0.10
Dividends, cash						$ 2,434
Dividends, shares (in shares)						4,286
Dividends, stock						$ 51
First 2/25/2022 Dividend [Member]
Record date						May 18, 2022
Payment date						Jun. 15, 2022
Distributions declared per share (in dollars per share)						$ 0.10
Dividends, cash						$ 2,378
Dividends, shares (in shares)						4,428
Dividends, stock						$ 50
Second 2/25/2022 Dividend [Member]
Record date						Apr. 19, 2022
Payment date						May 16, 2022
Distributions declared per share (in dollars per share)						$ 0.10
Dividends, cash						$ 2,349
Dividends, shares (in shares)						4,088
Dividends, stock						$ 49
Third 2/25/2022 Dividend [Member]
Record date						Mar. 18, 2022
Payment date						Apr. 14, 2022
Distributions declared per share (in dollars per share)						$ 0.10
Dividends, cash						$ 2,352
Dividends, shares (in shares)						3,221
Dividends, stock						$ 46

Note 11 - Financial Highlight_2

Note 11 - Financial Highlights - Financial Highlights (Details) - USD ($) $ / shares in Units, $ in Thousands		3 Months Ended		9 Months Ended
		Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022
Net asset value at beginning of period (in dollars per share)				$ 11.47	$ 11.56
Net investment income (in dollars per share)				1.54	1.06
Realized loss (in dollars per share)				(0.95)	(0.40)
Unrealized (depreciation) appreciation on investments (in dollars per share)				(0.81)	0.05
Net increase in net assets resulting from operations (in dollars per share)		$ (0.37)	$ 0.23	(0.22)	0.71
Distributions declared (in dollars per share)	[1]			(0.99)	(0.90)
From net investment income (in dollars per share)				(0.99)	(0.90)
From net realized gain on investments (in dollars per share)		0	0	0	0
Return of capital (in dollars per share)				0	0
Other (in dollars per share)	[2]			0.15	0.29
Net asset value at end of period (in dollars per share)		10.41	11.66	10.41	11.66
Per share market value, beginning of period (in dollars per share)				11.60	15.92
Per share market value, end of period (in dollars per share)		$ 11.88	$ 10.01	$ 11.88	$ 10.01
Total return based on a market value	[3]			10.90%	(31.50%)
Shares outstanding at end of period (in shares)		33,306,958	26,393,773	33,306,958	26,393,773	27,753,373
Expenses without incentive value	[4]			14%	11.40%
Incentive fees	[4]			1.20%	3%
Net expenses	[4]			15.20%	14.40%
Net investment income with incentive fees	[4]			18.50%	12.10%
Net assets at the end of the period		$ 346,575	$ 307,687	$ 346,575	$ 307,687	$ 318,448
Average net asset value		$ 335,531	$ 280,904	$ 335,531	$ 280,904
Average debt per share (in dollars per share)				$ 14.29	$ 13.32
Portfolio turnover ratio	[5]			10%	14.90%
[1]Distributions are determined based on taxable income calculated in accordance with income tax regulations, which may differ from amounts determined under GAAP due to (i) changes in unrealized appreciation and depreciation, (ii) temporary and permanent differences in income and expense recognition, and (iii) the amount of spillover income carried over from a given tax year for distribution in the following tax year. The final determination of taxable income for each tax year, as well as the tax attributes for distributions in such tax year, will be made after the close of the tax year.[2]Includes the impact of the different share amounts as a result of calculating per share data based on the weighted average basic shares outstanding during the period and certain per share data based on the shares outstanding as of a period end or transaction date. The issuance of common stock on a per share basis reflects the incremental net asset value changes as a result of the issuance of common stock in the Company’s continuous public offering and pursuant to the Company’s distribution reinvestment plan. The issuance of common stock at an offering price, net of sales commissions and dealer manager fees, that is greater than the net asset value per share results in an increase in net asset value per share.[3]The total return equals the change in the ending market value over the beginning of period price per share plus distributions paid per share during the period, divided by the beginning price.[4]Annualized.[5]Calculated by dividing the lesser of purchases or the sum of (1) principal prepayments and (2) maturities by the monthly average debt investment balance.

Note 12 - Subsequent Events (De

Note 12 - Subsequent Events (Details Textual) - USD ($) $ in Thousands	Oct. 30, 2023	Sep. 30, 2023	Dec. 31, 2022
Investment Owned, Fair Value		$ 729,053	$ 720,026
Evelo Biosciences, Inc. [Member]
Investment Owned, Fair Value		$ 8,500
Subsequent Event [Member] | Evelo Biosciences, Inc. [Member]
Investment Owned, Fair Value	$ 1,100